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Protease inhibitors are thought to be the major antiretroviral drugs involved in various 
metabolic disorders in HIV-positive patients. The primary side-effect induced by 
protease inhibitors is insulin resistance. However, the mechanistic basis of this 
insulin resistance remains largely unknown. Thus, this study was undertaken to 
understand the molecular basis of insulin resistance induced by protease inhibitors in 
Chinese hamster ovary cells transfected with high levels of human insulin receptor 
(CHO-IR cells) and in differentiated 3T3-L1 murine adipocytes. 
 
The most pronounced effect of insulin resistance induced by protease inhibitors is 
inhibition of insulin-stimulated glucose uptake (the final outcome in the insulin 
signalling pathway). This effect on glucose uptake may result from inhibition at a 
proximal level, i.e. insulin-stimulated tyrosine phosphorylation of the insulin receptor 
β-subunit and insulin receptor substrate 1 (IRS-1). CHO-IR cells and 3T3-L1 
adipocytes were treated with the protease inhibitors saquinavir and indinavir, 
followed by insulin stimulation. Since saquinavir may be toxic to these cells, indinavir 
was used in further analysis. 
 
It was found for the first time that indinavir significantly inhibited insulin-stimulated 
tyrosine phosphorylation of the insulin receptor β-subunit and IRS-1. Indinavir also 
significantly increased serine 307 phosphorylation of IRS-1 in both cell lines. The 
effects of indinavir were reduced when CHO-IR cells were pre-treated with sodium 
salicylate. This result suggests that protease inhibitors inhibit insulin receptor tyrosine 
phosphorylation indirectly, via the nuclear factor kappa B (NFκB) pathway. The NFκB 
pathway works as a secondary process involving a regulator of tyrosine 
phosphorylation, specifically the level of phosphorylation of IRS-1 at serine 307. The 
findings also showed that other phosphotyrosine regulatory proteins investigated in 
the insulin signalling pathway were not altered and not involved in insulin resistance 
induced by protease inhibitors. 
 
Metabolomic analysis was performed on free fatty acids (FFAs), amino acids and 
organic acids in 3T3-L1 adipocytes treated with indinavir. Free fatty acid analysis 
indicated that the levels of FFAs were not significantly decreased in the treated cell 
culture supernatants versus the basal medium. Concomitantly, the level of FFA was 
higher (i.e. had accumulated) in the treated versus the untreated cell culture 













level of FFA is known to induce insulin resistance. FFA may also play a role in 
inducing insulin resistance via the NFκB pathway, as observed above. Alterations 
recorded in the levels of amino acids and organic acids may be a secondary effect of 
insulin insensitivity induced by a high level of FFA. For example, insulin-induced 
hydroxylysine synthesis in cells pre-treated with indinavir. 
 
A colourimetric assay was established to measure lipoprotein lipase (LPL) activity in 
supernatants of 3T3-L1 adipocytes after exposure to protease inhibitors. The assay 
revealed that protease inhibitors significantly decreased LPL activity in the cells and 
the inhibition profile differed among different drugs.  
 
Taken together, the results of this study suggest that treatment with HIV protease 
inhibitors inhibits LPL activity and increases the level of FFA. The high level of FFA 
stimulates the NFκB pathway, which then increases serine 307 phosphorylation of 
IRS-1. The level of FFA also decreased insulin-stimulated tyrosine phosphorylation of 
IRS-1 and insulin receptor β-subunit, inducing insulin resistance. Low levels of 
hydroxylysine and succinate, and high levels of aspartate, butanoic acid acid 3-
(trimethylsiloxy)-ethylester and isovalerate, were probably secondary effects found to 































CHAPTER 1: GENERAL INTRODUCTION 
1.1 Introduction  
 
Twenty-seven years after the association between acquired immune deficiency 
syndrome (AIDS) and the human immunodeficiency virus (HIV) was first reported, 
HIV infection remains a major global challenge, especially in the southern part of 
sub-Saharan Africa. In South Africa, six million people were infected and more than 




Figure 1.1: A global view of HIV infection in 2007 
[http://data.unaids.org/pub/GlobalReport/2008/GR08_2007_HIVPrevWallMap_GR08_en.jpg] 
 
Currently, the most potent treatment for AIDS is highly active antiretroviral therapy 
(HAART). This therapy uses a combination of three or more antiretroviral drugs. 
These drugs are inhibitors derived from five classes, namely entry inhibitors, 
nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleotide 
reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, and protease 
inhibitors. This treatment may extend the lifespan of HIV-infected patients by 
suppressing HIV viral load, increasing CD4+ T-cell1 count2, and reducing 
                                                            
1 T-cells or T-helper cells are a subgroup of lymphocytes; a T-cell is a type of white cell which functions 













opportunistic infections associated with AIDS (Hammer et al., 1997; Piacenti, 2006). 
Unfortunately, in addition to improving patient prognosis, these drugs also result in 
metabolic abnormalities; in particular, insulin resistance accompanied by 
hyperglycaemia and lipodystrophy3 (Bernasconi, 1999; Esser et al., 2007). 
Consequently, patients are also at high risk of developing premature cardiovascular 
morbidity and type 2 diabetes mellitus (Bozkurt, 2004; Florescu and Kotler, 2007; 
Friedl et al., 2000; Stein, 2007).  
A substantial number of clinical and epidemiological studies have shown that 
protease inhibitors play a major role in inducing metabolic disorders in HAART-
treated patients (Bernasconi, 1999; Carr, 2000; Hui, 2003). It appears that all 
protease inhibitor compounds induce insulin resistance and lipid abnormalities to 
various degrees (Young et al., 2005), but the mechanisms of these serious side-
effects are largely unknown. In one study, it was found that protease inhibitors 
impaired insulin-regulated metabolism in adipose tissue to the extent of inducing 
metabolic disorders (Gougeon et al., 2004).  
However, a systematic molecular evaluation of the effects of these drugs on 
metabolism in fully-differentiated adipocytes has not yet been performed. Only a few 
studies have reported alterations in insulin signalling and insulin-regulated 
metabolism caused by protease inhibitors at the cellular level (Ben-Romano et al., 
2006; Rudich et al., 2005). It is important to understand the mechanistic basis for 
these side-effects, as their incidence is likely to increase as the rollout of antiretroviral 
drugs continues. For this reason, this study was undertaken to further understand the 
molecular basis of insulin resistance induced by protease inhibitors in a cell culture 
system. 
1.2 Human immunodeficiency virus 
 
HIV, particularly HIV-1, is the causative agent of AIDS in HIV-positive patients. This 
virus is a member of the retrovirus family (Gallo and Reitz, 1985). At present, HAART 
is the only treatment available for AIDS. In order to understand the mechanisms of 
action of these antiretroviral drugs, it is essential to know and understand the 
structure of HIV and its replication cycle (Temesgen et al., 2006). 
 
                                                                                                                                                                          
2 This figure may be used to detect HIV infection, as HIV targets cells that express CD4+ T-cells and 
reduces the circulating levels of the cells. 













1.2.1 HIV morphology 
HIV is an enveloped virus that contains a single infectious strand of viral genomic 
ribonucleic acid (RNA), with some cellular factors and enzymes at its core. The 
enzymes required for HIV replication are reverse transcriptase, integrase, protease, 
Vpu, Vif, Vpr and Nef. An HIV virion has a spherical morphology of 100-120 nm 
diameter, and is surrounded by a lipid bilayer membrane with glycoprotein 120 
(gp120). This is anchored to the viral envelope by glycoprotein 41 (gp41) molecules 
(Sierra et al., 2005; Turner and Summers, 1999) (Figure 1.2).  
 
 
Figure 1.2: HIV structure [www.vircolab.com/.../hiv_virus.gif] 
 
1.2.2 HIV life-cycle and pathogenesis 
 
The initial step in the HIV replication cycle (Figure 1.3) is the interaction between the 
envelope proteins of the virus, HIV gp 120, and specific host-cell surface receptors 
such as CD4 receptors, with the presence of co-receptors such as chemokine co-
receptor 5 (CCR5)4 or CXC chemokine co-receptor 4 (CXCR4)5.  
                                                            
4 CCR5 is expressed on dendritic cells, macrophages and T-lymphocyte cells.  


























Figure 1.3: HIV-1 replication cycle (Turner and Summers, 1999) 
 
Binding of the HIV to a co-receptor causes conformational changes in the envelope 
proteins. This leads to the fusion of the viral envelope and the host cytoplasmic 
membrane, creating a pore through which the viral capsid contents enter the cell. 
Within the cell, the viral reverse transcriptase enzyme catalyses the conversion of 
one single-stranded viral RNA into a double-stranded complementary viral 
deoxyribonucleic acid (DNA). The viral DNA enters the nucleus and integrates with 
the chromosomal DNA of the host cell, via integrase. 
 
The integration between viral DNA and chromosomal DNA induces the HIV 
replication process. The CD4+ T-lymphocyte cells produce strands of viral Gag (p55) 
and Gag-Pol (p160) polyproteins. New HIV virions are produced when a protease, 
aspartyl endopeptidase, cleaves viral Gag (p55) and Gag-Pol (p160) polyprotein 
strands. These virions are able to grow to become mature virions and infect other 
healthy human host cells within 1.5 days (Sierra et al., 2005; Turner and Summers, 
1999). 
 
1.3 Highly active antiretroviral therapy 
 
Although HIV was identified in 1983, the use of HAART to treat HIV-positive patients 
was only introduced in 1996 (Weiss, 2008). This therapy is a combination of three or 






























1.3.1 HAART treatment 
 
HAART acts to alter and impair the HIV life-cycle. This results in a reduction of the 
HIV viral load and an increase in CD4+ T-cell counts, and consequently a decrease in 
opportunistic infections associated with AIDS (Hammer et al., 1997; Piacenti, 2006).  
At the early stage of the HIV life-cycle, entry inhibitors (number 1 in Figure 1.4) block 
the binding of HIV gp 120 to human host CD4 receptors, and prevent the fusion of 
the viral envelope to the plasma membrane. NRTIs (number 2 in Figure 1.4) are 
designed to inhibit reverse transcriptase through competition with the natural 
substrate to decrease the synthesis of viral DNA. The function of NNRTIs (number 2 
in Figure 1.4) is to block enzyme activity by binding the natural substrate directly. 
This causes a conformational change, and disrupts the catalytic site of the enzyme. 
Integrase inhibitors (number 3 in Figure 1.4) prevent integration of double-stranded 




1. Abacir Ziagen GlaxoSmithKline 
2. Didanosine Videx Bristol-Myers 
Squibb 
3. Lamivudine Epivir GlaxoSmithKline 
4. Stavudine Zerit Bristol-Myers 
Squibb 
5. Zidovudine Retrovir GlaxoSmithKline 




1. Efavirenz Sustiva Bristol-Myers 
Squibb 
2. Nevirapine Viramune Boehringer 
Ingelheim 
Protease inhibitors 
1. Indinavir Crixivan Merck 
2. Ritonavir Norvir Abbott 
Laboratories 
3. Saquinavir Invirase Roche 














complementary viral DNA into the cell genome. In the final stages of the HIV life-
cycle, protease inhibitors (number 6 in Figure 1.4) prevent HIV protease from 




Figure 1.4: HAART targets in the HIV life-cycle 
 [www.gladstone.ucsf.edu/.../section.php?id=1707] 
 
1.3.2 Effects of HAART 
 
Following the introduction of HAART as a treatment for AIDS in 1996, HIV-associated 
morbidity and mortality have decreased significantly (Palella et al., 1998; Quinn, 
2008). Unfortunately, though HAART lengthened the lifespan of HIV-positive 
patients, more than 60 % of patients treated using HAART developed various 
metabolic disorders, such as insulin resistance accompanied by lipodystrophy and 
atherosclerosis (Monier and Wilcox, 2004). Protease inhibitors play the major role in 
causing these adverse effects (Barbaro and Barbarini, 2006; Bernasconi, 1999; Carr, 
2000; Hui, 2003). 
1.4 Protease inhibitors 
 
The management of AIDS underwent a dramatic change in 1996, when HIV-positive 
patients were first introduced to saquinavir, the first protease inhibitor (Palella et al., 













aspartyl endopeptidase, an enzyme required for normal processing of the Gag and 
Gag-Pol HIV proteins (Flexner, 1998).  
Protease inhibitors bind to the HIV protease active site which contains two flap 
domains, two core domains and a terminal domain. The domains accommodate the 
ligand binding as an induced fit mechanism (Rose et al., 1998).  The protease 
inhibitor binding prevents interaction of the enzyme with its substrate. The substrate 
contains a recognition motif i.e. a polypeptide between phenylalanine, or tyrosine, 
and proline. The lack of cleavage produces immature virions (Figure 1.5) (Temesgen 
et al., 2006). This cleavage, specifically N-terminal of proline, is considered to be rare 
in mammals. Therefore, inhibition of the cleavage does not impact significantly on the 
mammalian host, as mammalian proteases do not display such cleavage preferences 
(Schmidtke et al., 1999). 
Protease inhibitors are active against clinical isolates of HIV-1 in vitro with an IC50 
ranging from 2 to 60 nM. Simultaneously, they are inactive or weakly active (IC50 > 10 
000 nM) against the human aspartyl proteases, renin and pepsin (Flexner, 1998). 
It has emerged that all protease inhibitors play a critical role in inducing various side-











































Figure 1.5: Protease inhibitors bind to the HIV protease active site to produce a non-infectious 






































Clinical studies have demonstrated that both long-term and short-term protease 
inhibitor therapies are strongly associated with the development of metabolic 
abnormalities such as insulin resistance and lipodystrophy (Monier and Wilcox, 2004; 
Moyle, 2007). In addition, the incidence of insulin resistance in HIV-positive patients 
is significantly higher in protease-inhibitor-treated patients than in patients treated 
with NRTIs or NNRTIs (Woerle et al., 2003), even when one considers related factors 
such as demography and virology (Palella et al., 1998). Furthermore, protease 
inhibitors have been shown to induce insulin resistance in seronegative patients and 
in animal models (Hruz et al., 2002; Lee et al., 2007; Noor et al., 2001; Noor et al., 
Protease inhibitors Major side-effects 
1. Amprenavir Gastrointestinal, severe rash, hyperglycaemia, 
hypertriglyceridaemia and hypercholesterolaemia  
2. Atazanavir Indirect hyperbilirubinaemia, rash, gastrointestinal 
3. Darunavir Diarrhoea, nausea, hyperlipidaemia 
4. Fosamprenavir Rash, gastrointestinal, hyperglycaemia, hyperlipidaemia, 
headache, hepatotoxicity 
5. Indinavir Nephrolithiasis, hyperbilirubinaemia, gastrointestinal, insulin 
resistance, hyperglycaemia, hyperlipidaemia, hepatoxicity 
6. Kaletra 
(lopinavir/ritonavir) 
Gastrointestinal (particularly diarrhoea), hyperlipidaemia 
(especially hypertriglyceridaemia), elevated transaminases, 
hyperglycaemia, hepatotoxicity 
7. Nelfinavir Gastrointestinal (particularly diarrhoea), hyperglycaemia, 
hyperlipidaemia, hepatotoxicity 
8. Ritonavir Gastrointestinal, paresthesia, taste perversion, 
hyperlipidaemia, hyperglycaemia, hepatotoxicity 
9. Saquinavir Gastrointestinal, hepatotoxicity, hyperglycaemia 
10. Tipranavir Hepatotoxicity, rash, hyperlipidaemia (especially 













2002), implying a clear link between protease inhibitor use and insulin resistance 
(Ismail et al., 2009).  
With the rollout of these drugs and the increased longevity of patients, the side-
effects have become more apparent. Currently, in South Africa, NRTIs (stavudine, 
lamivudine, zidovudine and didanosine), NNRTIs (efavirenz and nevirapine) and 
protease inhibitors (lopinavir/ritonavir) are used to treat AIDS; and the side-effects of 
protease inhibitors have also been observed in this country (Filippini et al., 2006; 
Wouters et al., 2009).  
1.5 Insulin resistance  
 
The primary metabolic disorder induced by protease inhibitors is insulin resistance 
(Carr et al., 1998). This occurs when normal insulin levels are inadequate to 
stimulate glucose uptake in the insulin signalling pathway in insulin-sensitive tissues 
such as liver, skeletal muscle and adipose tissue. Insulin resistance frequently 
manifests as dyslipidaemia (hypertriglyceridaemia) and lipodystrophy (Ismail et al., 
2009). 
1.5.1 The insulin signalling pathway 
At a physiological level, signalling through the insulin receptor pathway is critical for 
the regulation of blood glucose levels by insulin (Youngren, 2007). In the post-
prandial phase, the pancreas releases insulin into the bloodstream in response to 
glucose. Insulin then binds to its heterotetrameric (2 α- and 2 β-subunits) receptor, 
which is a ligand-activated tyrosine kinase.  
This binding of insulin leads to autophosphorylation of the receptor β-subunit on 
tyrosine residues, which then activates the intrinsic tyrosine kinase domain and leads 
to tyrosine phosphorylation of its substrate, insulin receptor substrate 1 (IRS-1). 
Following autophosphorylation of the kinase domain, some regulatory proteins in the 
insulin signalling pathway – such as Src homology 2B (SH2B), and adapter proteins 
with a pleckstrin homology domain and an SH2 domain (APS) – bind to 
phosphorylated tyrosines on the kinase domain and lead to further activation of 
phosphorylation of the insulin receptor and IRS-1 (Ahmed and Pillay, 2001). The 
tyrosine-phosphorylated IRS-1 binds to the SH2 domain of phosphoinositide 3-kinase 
(PI3-K) with high specificity and affinity, leading to the activation of this enzyme and 
the conversion of phosphatidylinositol 4,5-biphosphate (PIP2) into 













The bound PIP3 causes translocation of both the PIP3-dependent protein kinase 
(PDK) and protein kinase B (PKB), aka Akt. This allows the PDK to phosphorylate 
and then activate PKB/Akt. The activation of PKB/Akt is necessary for the final steps 
leading to glucose transport, and results in the migration of glucose transporter 4 
(GLUT4) from the cytoplasm to the cell membrane, to facilitate the uptake of 















IR = insulin receptor   PH = Pleckstrin homology  
IRS-1 = insulin receptor substrate-1 PI3-K = phosphoinositide 3-kinase 
Y = tyrosine residue  PIP2 = phosphatidylinositol 4,5-biphosphate 
S = serine residue  PIP3 = phosphatidylinositol 3,4,5-triphosphate 
pY = phosphorylated tyrosine  PDK = PIP3-dependent protein kinase 
SH2 = Src homology 2 domain  PKB = protein kinase B 
PTB = phosphotyrosine binding GLUT4 = glucose transporter 4 
 
 Figure 1.6: Insulin signalling pathway (Ismail et al., 2009) 
After the blood glucose has reached the normal level (approximately 5-6.6 mmol/l), 
the insulin signalling pathway is deactivated by phosphotyrosine regulatory proteins. 
There are several known phosphotyrosine regulatory proteins in the insulin signalling 
pathway that act as inhibitors, such as serine 307 phosphorylated IRS-1; protein 
tyrosine phosphatase 1B (PTP1B); and suppressor of cytokine signaling-1 and -3 
(SOCS-1 and -3) (Aguirre et al., 2002; Ueki et al., 2004; Youngren, 2007; Zhang et 
al., 2002). There is a possibility that protease inhibitors may also activate these 





















































1.5.2 The mechanism of insulin resistance 
The primary metabolic disorder induced by protease inhibitors is insulin resistance. 
This is also the primary metabolic disorder in type 2 diabetes, obesity, the metabolic 
syndrome and atherosclerotic cardiovascular disease (Meyer et al., 2002; Nolan et 
al., 1994; Savage et al., 2005). The most pronounced effect of insulin resistance is 
the inhibition of glucose uptake, the major outcome of the activation of the insulin 
signalling pathway (Murata et al., 2002; Rudich et al., 2005).  
This effect on glucose uptake may result from inhibition at a proximal level. However, 
in the context of insulin resistance induced by protease inhibitors, there are relatively 
few studies that have examined proximal steps in the insulin signalling cascade. This 
includes insulin binding to the insulin receptor β-subunit, and activation of the intrinsic 
tyrosine kinase activity and subsequent tyrosine phosphorylation of the substrate, 
where direct or indirect protease inhibitor-induced inhibition may occur. Thus, an 
understanding of the effects of protease inhibitors on these proximal steps in the 
insulin signalling pathway may shed new light on the molecular basis of insulin 
resistance induced by antiretroviral drugs. In addition, other mechanisms such as 
activation of inflammatory pathways and mitochondrial dysfunction, as observed in 
type 2 diabetes and obesity, may also be involved in the insulin resistance induced 
by protease inhibitors.  
1.5.2.1 Insulin receptor 
The insulin signalling pathway is initiated by the activation of the insulin receptor, i.e. 
tyrosine kinase activity after binding with insulin. The insulin receptor, a receptor 
tyrosine kinase, plays an important role in the insulin regulation of glucose transport 
and oxidation, as well as in glycogen, lipid and protein synthesis. The insulin receptor 
is usually expressed at a very high level in insulin-sensitive tissues such as skeletal 
muscle, liver and adipose tissue (Youngren, 2007). Autophosphorylation of insulin 
receptor tyrosine residues stimulates the intrinsic catalytic activity of tyrosine kinase. 
Phosphorylation of the receptor results in the recruitment of IRS-1. This substrate 
initiates a cascade of cellular phosphorylation reactions that regulate protein 
interactions in the insulin signalling pathway to stimulate GLUT4 translocation and 
glucose uptake (Youngren, 2007).  
In type 2 diabetes, tyrosine phosphorylation of the insulin receptor β-subunit is 
reduced in vivo, resulting in the inhibition of glucose uptake (Meyer et al., 2002; 













diabetes (Arner et al., 1987; Caro et al., 1987; Nolan et al., 1994), and obesity with 
insulin resistance and polycystic ovary syndrome (Dunaif et al., 1995). However, 
tyrosine phosphorylation of the insulin receptor β-subunit (in the context of insulin 
resistance induced by protease inhibitors) has not been investigated in depth. A few 
studies have shown that some protease inhibitors decreased tyrosine 
phosphorylation of IRS-1, e.g. in HepG2 hepatoma cells exposed to 100 µM indinavir 
for 48 h (Schutt et al., 2000), and in 3T3-L1 preadipocytes exposed to 10 µM ritonavir 
for 11 days (Cammalleri and Germinario, 2003). The findings from these studies 
show that protease inhibitors may also affect tyrosine phosphorylation of the insulin 
receptor β-subunit as a primary site of insulin resistance in HIV-positive patients, 
similar to the findings in type 2 diabetes patients. 
In order to understand the effect of protease inhibitors on tyrosine phosphorylation of 
the insulin receptor β-subunit and IRS-1, a number of phosphotyrosine regulatory 
proteins also require further study. Previous work has revealed several 
phosphotyrosine regulatory proteins now known to be involved in the modulation of 
tyrosine phosphorylation of the insulin receptor β-subunit and of IRS-1, such as 
SH2B, APS, IRS-1 phosphorylated on serine 307 (phosphoIRS-1 Ser 307), PTP1B, 
and SOCS-1 and -3 (Aguirre et al., 2002; Ueki et al., 2004; Youngren, 2007; Zhang 
et al., 2002). 
1.5.2.2 SH2B and APS 
SH2B (aka SH2B1) is an adapter protein involved in the signalling pathways 
mediated by insulin tyrosine kinase and the Janus kinase (Kotani et al., 1998). 
Deletion of the adapter protein gene in mice results in severe obesity, infertility, and 
leptin and insulin resistance (Maures et al., 2007). This protein has also been shown 
to regulate the tyrosine phosphorylation state of the insulin receptor (Ahmed and 
Pillay, 2001).  
Another adapter protein, APS (aka SH2B2) has a similar role to the SH2B1 protein in 
delaying the dephosphorylation of the insulin receptor kinase, and IRS-1 and -2, in 
the insulin signalling pathway (Ahmed and Pillay, 2001; Ahmed and Pillay, 2003). 
However, APS binds the insulin receptor with a higher affinity than SH2B (Ahmed 
and Pillay, 2001; Ahmed and Pillay, 2003). The role of these adapter proteins has not 














1.5.2.3 Phosphorylation of serine 307 on IRS-1 
Serine phosphorylation of IRS-1 (serine 307 in rat or serine 312 in human) is known 
to inhibit tyrosine phosphorylation of the insulin receptor β-subunit (Aguirre et al., 
2002). This increase in serine phosphorylation in induced by means of several 
mechanisms (Figure 1.7), viz. elevation of circulating levels of several adipose-
derived cytokines such as TNF-α (section 1.5.2.6) and metabolites (e.g. free fatty 
acids (FFAs)) (section 1.5.2.9), and activation of IκB kinase (IKK) (section 1.5.2.7), 
Jun kinase (JNK) (section 1.5.2.8), protein kinase Cs (PKCs) (section 1.5.2.10) and 
mammalian target of rapamycin (mTOR) (section 1.5.2.11) (Aguirre et al., 2002; Lee 
et al., 2009). The increased serine 307 phosphorylation of IRS-1, decreased tyrosine 
phosphorylation of IRS-1 and then reduced activation of PI3-K leads to an inhibition 
of translocation of GLUT4 from the cytoplasm to the cell membrane. This reduces 
glucose uptake and results in insulin resistance in adipocytes, hepatocytes and 
skeletal muscle cells (Figure 1.7).  
1.5.2.4 PTP1B 
Protein tyrosine phosphatase 1 B (PTP1B), a tyrosine phosphatase negatively 
regulates insulin signalling by binding to the tyrosine phosphorylated proteins, insulin 
receptor β-subunit and IRS-1 (Figure 1.7), and catalysing tyrosine dephosphorylation 
(Cheng et al., 2002; Zhang et al., 2002). Mice lacking functional PTP1B exhibit 
increased sensitivity toward insulin, and are resistant to obesity (Zhang et al., 2002). 
However, the effect of protease inhibitors on PTP1B expression in vivo and in vitro 















Figure 1.7: Pathways implicated in insulin resistance in adipocytes, hepatocytes and skeletal 
muscle cells (Vodenik et al., 2009). Adipo = adipocytes, FFA = free fatty acid, TNF-α = tumour 
necrosis factor alpha, IKK = IκB kinase, JNK = Jun kinase, mTOR = mammalian target of rapamycin, 
PKC = protein kinase C, ERK = extracellular-signal regulated kinase, IR = insulin receptor, IRS = insulin 
receptor substrate, Tyr = tyrosine, +p = phosphorylation, PTP1B = protein tyrosine phosphatase 1 B, 
SOCS-1/3 = suppressor of cytokine signaling-1 and -3, PI3-K = phosphoinositide 3-kinase  and GLUT4 
= glucose transporter 4. 
 
1.5.2.5 SOCS-1 and -3 
SOCS-1 and -3 are adapter proteins that bind to the insulin receptor β-subunit or 
IRS-1 or IRS-2 to inhibit downstream signalling (Figure 1.7) (Emanuelli et al., 2000). 
The expression of these proteins can be induced by tumour necrosis factor alpha 
(TNF-α) (Emanuelli et al., 2001). Increased SOCS-1 and -3 expression has been 
reported to induce insulin resistance involved in obesity (Ueki et al., 2004; Youngren, 
2007). In addition, knockout of SOCS expression in adipocytes prevented much of 
the impaired tyrosine phosphorylation of IRS-1 or IRS-2 induced by TNF-α 
(Youngren, 2007). Therefore, studies of SOCS-1 and -3 expressions in protease 
inhibitor-induced insulin resistance in cells may provide information regarding the 
molecular basis of this side-effect. 
1.5.2.6 TNF-α 
TNF-α is a multifunctional cytokine secreted largely by adipocytes (Hotamisligil et al., 
1993). This cytokine is involved in inflammation, apoptosis, cytotoxicity, the 
production of other cytokines, such as interleukin 1 (IL-1) and interleukin 6 (IL-6), and 













of TNF-α correlates negatively with the level of adiponectin (Lee et al., 2009). 
Adiponectin is another adipocytokine secreted by adipocytes. This protein hormone 
promotes insulin sensitivity by modulating  a number of metabolic processes in 
adipose tissue and the whole body including decreasing blood glucose levels and 
stimulating fatty acid catabolism (Lee et al., 2009).  Thus, a high level of adiponectin 
acting through endocrine mechanisms is able to increase insulin sensitivity (Guogeon 
et al., 2004). In contrast, plasma adiponectin was found to be low in insulin 
resistance induced by protease inhibitors, type 2 diabetes and obesity, in vivo and in 
vitro (Kadowaki et al., 2006; Kern et al., 2003).  
Mice lacking TNF-α or TNF-α receptors show improved insulin sensitivity in both 
dietary and genetic models of obesity (Lee et al., 2009). Therefore, an understanding 
of the function of TNF-α may provide a therapeutic target for insulin resistance and 
type 2 diabetes. However, the signalling cascades regulated by TNF-α are complex 
and involve many pathways, including the activation of various serine kinases and 
transcription factors (White, 2002). 
TNF-α activates the transcription factor of the IκB kinase β (IKKβ), the nuclear factor 
kappa B (NFκB) pathway, and increases phosphorylation of serine 307 on IRS-1 in 
the liver of obese Zucker rats (Cai et al., 2005). This activation then induces insulin 
insensitivity in both the liver and in skeletal muscle (Figure 1.7) (Cai et al., 2005). In a 
subsequent study, rats with high-fat-diet-induced insulin resistance do not develop 
the insulin resistance when IKKβ was lacking in the liver (Arkan et al., 2005).  
Interestingly, high doses of salicylate have been shown to reverse obesity- and diet-
induced insulin resistance in Zucker rats through disruption of IKKβ (Yuan et al., 
2001). Adipose tissue biopsies from lipodystrophic HIV-positive patients undergoing 
treatment with protease inhibitors and NRTIs, showed an increased expression of 
TNF-α (Vigouroux et al., 2003). However, IKKβ expression and the NFκB pathway 
induced by TNF-α have not been investigated in insulin resistance induced by 
protease inhibitors in HIV-positive patients. 
1.5.2.7 The NFκB pathway 
It has been shown that IKKβ and the NFκB pathway become a target for TNF-α and 
SOCS-1/3 induced insulin resistance (Yuan et al., 2001). IKKβ is a serine kinase that 
regulates the activation of NFκB, a crucial activator of genes involved in inflammation 
and immunity. Prior to activation, NFκB is bound to the inhibitor κB (IκB). The 













conjugation of IκB with ubiquitin and the subsequent degradation of IκB protein in the 
proteasome, leading to the nuclear translocation of NFκB (Tergaonkar, 2006). 
Activation of IKKβ also induces serine 307 phosphorylation of IRS-1, as IRS-1 is a 
substrate of IKKβ. This phosphorylation blocks interactions with the insulin receptor 
β-subunit, decreases tyrosine phosphorylation, and inhibits insulin action in cells 
(Figure 1.7) (Aguirre et al., 2002; Gao et al., 2003). 
1.5.2.8 JNK-1 
Jun kinase 1 (JNK-1) is another inflammatory serine kinase involved in insulin 
resistance via phosphorylation of serine 307 on IRS-1 (Lee et al., 2009; Perseghin et 
al., 2003). TNF-α and FFAs have been found to activate JNK-1 (Figure 1.7) (Lee et 
al., 2009). In both dietary and genetic (ob/ob) mice models of obesity, there was a 
significant increase in total JNK activity in liver, adipose tissue and skeletal muscle 
(Hirosumi et al., 2002). JNK-1 knockout mice show an increase in insulin sensitivity 
implying a role of JNK-1 in modulating insulin sensitivity (Hirosumi et al., 2002). 
Therefore, JNK-1 could potentially also be involved in the insulin resistance induced 
by protease inhibitors.  
1.5.2.9 Free fatty acids (FFAs) 
Increased lipolysis with decreased suppression of FFA levels by insulin suggests a 
state of insulin resistance at the adipose tissue level (Rudich et al., 2005). In addition, 
increased plasma FFA concentrations are also associated with obesity and type 2 
diabetes (Lee et al., 2009). Prolonged treatment of adipocytes in vitro with TNF-α 
stimulates lipolysis – and thereby increases circulating FFA levels, promoting insulin 
resistance (Gougeon et al., 2004).  
In addition, patients receiving treatment with protease inhibitors and who have insulin 
resistance and lipodystrophy show elevated TNF-α levels, and increased lipolysis 
and FFA flux (Lenhard et al., 2000; Meininger et al., 2002; Rudich et al., 2005). 
Moreover, it was found that the level of FFA was reduced by acipimox, a potent 
inhibitor of lipolysis, and insulin sensitivity was significantly increased in 
lipodystrophic HIV-positive patients under treatment with protease inhibitors and 
NRTIs (Hadigan et al., 2003). These findings show that TNF-α stimulates lipolysis, 
increases FFA levels and induces insulin resistance. It is interesting that salicylate 
has also been found to block lipolytic actions of TNF-α and increase insulin sensitivity 













IRS-1 has been suggested as a molecular target of FFAs in the development of 
insulin resistance (Gao et al., 2004). Increased FFA concentrations led to 
phosphorylation of serine 307 directly on IRS-1, thus reducing the ability of the IRS-1 
to activate PI3-K and GLUT4, and inducing insulin resistance (Gao et al., 2004; Lee 
et al., 2009; Meininger et al., 2002). Moreover, increased FFA levels play a similar 
role to TNF-α in activating inflammatory pathways such as IKKβ and JNK-1 (Figure 
1.7), thereby inhibiting insulin signalling in rodents (Lee et al., 2009).  
In addition to TNF-α, protease inhibitors were found to increase lipolysis via the 
inhibition of the activity of the insulin-regulated enzyme, lipoprotein lipase (LPL), to 
increase the level of FFA (Ranganathan and Kern, 2002). Alteration of LPL activity 
affects lipid metabolism, and induces metabolic disorders such as chylomicronaemia, 
atherosclerosis, cancer and lipodystrophy associated with insulin resistance, as well 
as diabetes mellitus. Triglyceride-rich lipoproteins such as chylomicrons and very low 
density lipoproteins are not stored in adipocytes without the LPL enzyme, which 
leads to hypertriglyceridaemia, lipodystrophy and increased coronary artery disease 
(Mead et al., 2002) 
1.5.2.10 PKCs 
FFAs may also induce insulin resistance through the overexpression of protein 
kinase C (PKC) isoforms. This overexpression of PKCs may stimulate IKKβ to 
increase serine 307 phosphorylation of IRS-1 or PKCs may phosphorylate IRS-1 
directly, and decrease tyrosine phosphorylation of IRS-1, thus inducing insulin 
resistance (Figure 1.7) (Perseghin et al., 2003). PKC isoforms are divided into 
classical (cPKC-α, -βI, -βII and -γ), novel (nPKC-δ, -ε, -ζ and –ε) and atypical (aPKC-
δ and –λ) forms. nPKCs are known to play a role in insulin signalling (Bhattacharya et 
al., 2007).  
Overexpression of PKC-δ due to stimulation with 12-O-tetradecanoyl 13-phorbol 
acetate (TPA), an activator of PKC, may induce insulin resistance in cultured 
myotubes and skeletal muscle cells (Bhattacharya et al., 2007; Waraich et al., 2008). 
This may occur via stimulation of serine phosphorylation of the insulin receptor, and 
reduction of tyrosine phosphorylation of the insulin receptor (Bhattacharya et al., 
2007; Waraich et al., 2008). In addition, overexpression of PKC-ε in the skeletal 
muscle of diabetic animals and humans has also been reported to induce insulin 
resistance (Ikeda et al., 2001; Itani et al., 2002). The high levels of FFAs stimulate 
the PKC-ε to induce insulin resistance through PDK1-independent phosphorylation, 













details of the precise mechanism causing PKC to inhibit the gene transcription are 
still unclear.  
In a recent study, increased FFA concentrations have also been shown to activate 
PKC-ζ in the skeletal muscle of rats with fat-induced insulin resistance. 
Subsequently, the activated PKC-ζ was found to increase serine 307 
phosphorylation, decrease tyrosine phosphorylation of IRS-1 and induce insulin 
resistance in the rats (Lee et al., 2009). In contrast, PKC-ζ-deficient mice are 
protected from fat-induced insulin resistance (Kim et al., 2004). A few studies have 
also reported that the knock-out of PKC-α in mice and the inhibition of PKC-ε in rats 
enhanced insulin signalling (Kim et al., 2004; Leitges et al., 2002; Samuel et al., 
2007). An evaluation of the role of PKCs in the insulin resistance induced by 
protease inhibitors may provide interesting findings.  
1.5.2.11 mTOR 
mTOR, a conserved serine/threonine kinase, plays a key role in the regulation of 
cellular response to nutrients (Vodenik et al., 2009). For this reason, it was 
suggested that mTOR is also involved in obesity and insulin resistance (Figure 1.7) 
(Um et al., 2006). In a model of nutrient overload presenting as obesity, constitutive 
and sustained activation of the mTORC1 (an mTOR complex) pathway led to insulin 
resistance (Um et al., 2006). mTORC1 was found to increase serine phosphorylation 
of IRS-1 on serine 632 in mice and serine 636 in humans; and it appears the effect 
was abrogated by sirolimus, the mTOR inhibitor (Um et al., 2006).  
1.5.2.12 PAI-1 
Recently, there has been growing evidence linking plasminogen activator inhibitor 1 
(PAI-1) with obesity and insulin resistance (Lee et al., 2009). PAI-1 is a key 
regulatory protein of tissue fibrinolysis, cell migration, angiogenesis and tissue 
remodelling, and is mainly synthesised in adipose tissue (Lijnen, 2005). It has been 
found that PAI-1 can be induced by TNF-α and PKCs (Pandey et al., 2005). PKCs 
and TNF-α may induce PAI-1 mRNA by increasing the rate of transcription of the 
PAI-1 gene. The dramatic increase in PAI-1 results in insulin resistance (Pandey et 
al., 2005). Interestingly, the absence or inhibition of PAI-1 through genetic alteration 
in adipocytes was found to protect against insulin resistance, by promoting glucose 
uptake and adipocyte differentiation via increased peroxisome proliferator-activated 













PAI-1 in insulin resistance induced by protease inhibitors in HIV-positive patients has 
investigated as yet. 
1.5.2.13 Oxidative stress 
Oxidative stress – or chronic and/or increased production of reactive molecules such 
as reactive oxygen species (ROS) and reactive nitrogen species (RNS) – has also 
been associated with insulin resistance, type 2 diabetes, cardiovascular disease and 
cancer (Figure 1.8) (Evans et al., 2005). High levels of FFAs, inflammatory cytokines, 
hyperinsulinaemia and hyperglycaemia have been reported to induce oxidative 
stress, which later triggers the activation of the stress-sensitive serine/threonine 
kinase signalling pathway such as TNF-α, JNK, IKKβ, PKCs and mTOR. This stress-
sensitive serine/threonine kinase increases phosphorylation of IRS-1 on serine 307 
and induces insulin resistance (Evans et al., 2005). In animal models and patients 
with diabetes, treatment with the antioxidant α-lipoic acid or salicylate has been 
reported to improve insulin sensitivity (Evans et al., 2005; Fenkci et al., 2003). 
1.5.2.14 Pre-lamin A 
Lamin A is a nuclear laminar protein and is ubiquitously expressed in differentiated 
tissues (Capanni et al., 2005). However, the physiological function of lamin A is still 
unclear. Biogenesis of lamin A from pre-lamin A requires the ZMPST24 enzyme. The 
inhibition of ZMPST24 leads to the blockade of lamin A processing and the 
accumulation of pre-lamin A. Recently, pre-lamin A was found to be involved in 
lipodystrophy associated with insulin resistance in HIV-positive patients treated with 
protease inhibitors (Goulbourne and Vaux, 2010). Similar effects have also been 
observed in inherited lipodystrophy such as the Dunning-type familial partial 
lipodystrophy (FPDL) (Capanni et al., 2005). In the adipose tissue from these 
patients, the accumulated pre-lamin A was found to cause a reduction in the amount 
of the DNA-bound adipocyte transcription factor sterol regulatory element binding 
protein 1 (SREBP-1) and consequently a reduction of PPARγ expression. This 
resulted in an impairment of pre-adipocyte differentiation and induced lipodystrophy 
associated with insulin resistance (Maraldi et al., 2007). Interestingly, the treatment 
with the PPARγ ligand troglitazone (a thiazolidinedione) was found to improve 
adipocyte differentiation in these patients (Maraldi et al., 2007). These findings 
suggest that pre-lamin A is a possible therapeutic target in lipodystrophy associated 















Figure 1.8: The role of serine kinase activation in oxidative stress-induced insulin resistance 
(Evans et al., 2005) 
 
1.5.2.15 Mitochondrial dysfunction and endoplasmic reticulum stress response 
In addition to insulin signalling and inflammatory pathways, severe mitochondrial 
dysfunction has been known to cause type 2 diabetes (van den Ouweland et al., 
1992). The mitochondrion is a membrane-enclosed organelle which plays an 
important role in cellular metabolism, via the Krebs cycle (van den Ouweland et al., 
1992). 
Mitochondrial dysfunction is known to elevate several kinase activities such as PKC 
and JNK. PKC and JNK are capable of increasing serine phosphorylation of IRS-1 
and inducing insulin resistance (Lim et al., 2009). Using a magnetic resonance 
spectroscopy (MRS) approach, it was found that mitochondrial function was reduced 
in healthy lean insulin-resistant offspring of parents with type 2 diabetes. This finding 
was attributed to reductions in mitochondrial density (Morino et al., 2006).  
Endoplasmic reticulum (ER) stress response (aka the unfolded protein response, 
UPR) has also been found to induce type 2 diabetes (Lim et al., 2009). ER stress 
response is triggered by the accumulation of unfolded proteins in the ER lumen (Lim 













Mitochondria and the ER are able to interact with each other both physically and 
functionally, and form an endomembrane network known as a mitochondria-
associated ER membrane (MAM). In type 2 diabetes, mitochondrial dysfunction was 
found to induce ER stress response and form a MAM. The MAM then coordinated 
the increased levels of gluconeogenic enzyme, as observed in many insulin 
resistance states, through p38 mitogen-activated protein kinase (MAPK) and JNK, in 
a Ca2+-dependent manner (Lim et al., 2009).  
1.5.2.16 Adiponectin 
Adiponection is also secreted by adipocytes, in addition to TNF-α (Lee et al., 2009). 
This adipokine contains a collagenous domain with four lysine residues (68, 71, 80 
and 104) which are hydroxylated to hydroxylysine. The hydroxylysines are 
subsequently glycosylated to modulate the insulin sensitivity of cells (Fonseca-Alaniz 
et al., 2007; Wang et al., 2002).  
Adiponectin exists as multiple isoforms, such as trimeric low molecular weight 
(LMW), albumin-binding LMW (Alb-LMW), hexameric middle molecular weight 
(MMW) and high molecular weight (HMW) forms (Hara et al., 2006). The biologically 
active form of adiponectin is the HMW form, and its ratio to total adiponectin is 
closely correlated with insulin sensitivity (Hara et al., 2006). A high level of 
adiponectin in vivo acting via endocrine mechanisms is able to increase insulin 
sensitivity and known as an insulin sensitising hormone (Guogeon et al., 2004). This 
is probably by acting through AMP kinase to increase fatty acid oxidation. In contrast, 
a low level of adiponectin is associated with several diseases, such as insulin 
resistance, type 2 diabetes, obesity and lipodystrophy (Kadowaki et al., 2006; Kern et 
al., 2003). Adiponectin also plays a major role to modulate a number of metabolic 
processes such as glucose regulation, fatty acid catabolism in adipose tissue, anti-
atherosclerotic and anti-inflammatory actions in human and animal (Lee et al., 2009). 
Adiponection production is upregulated during adipogenesis which is enhanced by 
PPARγ (Guogeon et al., 2004). 
HIV protease inhibitors have also been known to decrease the secretion of 
adiponectin in inducing insulin resistance and lipodystrophy (Jones et al., 2008). 
These findings show that adiponectin may play a leading role as a biomarker, in 
particular in insulin resistance induced by protease inhibitors. However, further study 
of adiponectin, in particular synthesis of hydroxylysine in type 2 diabetes, obesity and 













1.5.3 Review of insulin resistance induced by protease inhibitors 
The mechanism of insulin resistance is complex, and is the result of many factors. In 
the context of insulin resistance induced by protease inhibitors, the molecular basis is 
largely unknown. An understanding of the general mechanism of insulin resistance 
may provide ideas for investigating the possible pathway of insulin resistance 
induced by the antiretroviral drugs.  
Briefly, the effects of protease inhibitors on the insulin signalling pathway have been 
reviewed in several types of cell lines and appear to occur via three major 
mechanisms (Ismail et al., 2009). The drugs impair either the distal steps, or the 
proximal steps in the insulin signalling pathway; or they involve other factors such as 
oxidative stress, adapter proteins and adiponectin (Table 1.3) (Ismail et al., 2009). 
1.5.3.1 Protease inhibitors impair the distal steps in the insulin signalling 
pathway 
An early study of insulin resistance induced by protease inhibitors demonstrated that 
the drug inhibits GLUT4 uptake in vitro (Murata et al., 2000). GLUT4 is the major 
transporter responsible for insulin-stimulated glucose disposal into adipose tissue, 
cardiac and skeletal muscle, and plays a critical role in whole-body glucose 
homeostasis (Mueckler, 2001). In this particular study, it was reported that 3T3-L1 
adipocytes treated with indinavir, a protease inhibitor, at 100 μM for 4 h decreased 
GLUT4 uptake (Murata et al., 2000). However, there was no evidence for any effects 
from protease inhibitors on early insulin signalling events, such as insulin receptor β-
subunit and IRS-1 tyrosine phosphorylation (Hertel et al., 2004; Murata et al., 2000; 
Murata et al., 2002). Similar effects on glucose uptake were reported in rats and in 
HIV-negative patients treated with protease inhibitors (Hruz et al., 2002; Lee et al., 



















Table 1.3: Summary of the effects of protease inhibitors in the insulin signalling pathway (Ismail 




References Drug concentration 
used in the 
experiments 
Experimental model Observations 





(Murata et al., 
2000) 
Indinavir (100 µM) for 4 
h 
3T3-L1 adipocytes Decreased glucose uptake 
 
 
(Rudich et al., 
2001) 
Nelfinavir (10 µM) for 
18 h 
3T3-L1 adipocytes Impaired GLUT4 translocation 
and glucose uptake by 
inhibiting stimulation of PKB 
serine 473 phosphorylation 
(Ben-Romano et 
al., 2004) and 
(Rudich et al., 
2005) 
Nelfinavir (30 µM) for 
18 h 
3T3-L1 adipocytes Inhibited recruitment and 
activation of PI3-K, impaired 
GLUT4 translocation and 
glucose uptake 
 
(Kachko et al., 
2009) 
Nelfinavir (30 µM) for 
18 h 
3T3-L1 adipocytes 
used a GLUT4-GFP 
chimeric construct 
Interfered with the sensing of 








(Schutt et al., 
2000) 













Decreased insulin receptor 
expression and tyrosine 
phosphorylation of IRS-1 
(Djedaini et al., 
2009) 
Lopinavir (10 µg/ml) for 
48 h 
Human adipocytes Decreased tyrosine 






Nelfinavir (30 µM) for 
18 h 
3T3-L1 adipocytes Induced oxidative stress 
(Lagathu et al., 
2007) 
Indinavir, amprenavir, 
lopinavir, ritonavir (10 
µmol/l), atazanavir (4 
µmol/l), nelfinavir (5 
µmol/l) for 24 and 48 h 
Human adipocytes 
and macrophages 
Induced oxidative stress and 
altered chemokines, cytokines 
or adiponectin production 
(Carper et al., 
2008) 
Indinavir (20 µM) for 7 
weeks 
Rats Increased SOCS-1, TNF-α 
and SREBP-1 expression 




ritonavir and saquinavir 
Human adipose 
tissue biopsies 




However, in a subsequent study, prolonged treatment (18 h) of 3T3-L1 adipocytes 
with another protease inhibitor, nelfinavir, at plasma concentrations (10 μM), 
impaired both GLUT4 translocation and glucose uptake (Rudich et al., 2001). 
Nelfinavir appeared to induce insulin resistance by inhibiting the stimulation of 
PKB/Akt serine 473 phosphorylation without any effect on the tyrosine 
phosphorylation of IRS-1. Nelfinavir also decreased expression of the lipolysis 
regulator, perilipin (Rudich et al., 2001). The ability of nelfinavir to impair PKB/Akt 
activation, GLUT4 translocation and glucose uptake was confirmed in a subsequent 












Nelfinavir concentration at 30 µM induced insulin resistance in 3T3-L1 adipocytes by 
inhibiting recruitment and activation of PI3-K, leading to impaired GLUT4 
translocation and thus preventing insulin-stimulated glucose uptake (Ben-Romano et 
al., 2004; Rudich et al., 2005). These effects were not accompanied by changes in 
insulin receptor expression or insulin receptor tyrosine phosphorylation. A 
subsequent study using a similar model maintained that PKB/Akt activation was 
affected after insulin-stimulated generation of PIP3, leading to impaired GLUT4 
translocation (Kachko et al., 2009).  
It has also been proposed that nelfinavir induces oxidative stress (Ben-Romano et 
al., 2006; Chandra et al., 2009). Oxidative stress induces insulin resistance by 
activating serine kinase, leading to serine phosphorylation of IRS-1, and also by 
disrupting the subcellular distribution of PI3-K (i.e. decreased membrane 
localisation). This in turn would lead to decreased tyrosine phosphorylation of IRS-1 
and consequently reduced PKB/Akt activation, and hence decreased GLUT4 
translocation. 
1.5.3.2 Protease inhibitors impair the proximal steps in the insulin signalling 
pathway 
On the other hand, a previous study proposed that indinavir interfered with the very 
early steps of the insulin signalling cascade in HepG2 hepatoma cells, (Schutt et al., 
2000). The drug inhibited phosphorylation of IRS-1, activation of PI3-K and 
phosphorylation of PKB/Akt, without affecting the insulin binding. Ritonavir at 10 µM 
decreased insulin receptor numbers in 3T3-L1 pre-adipocytes without any effect on 
binding affinity. This was accompanied by decreased IRS-1 tyrosine phosphorylation 
in response to insulin (Cammalleri and Germinario, 2003). A more recent study 
suggested that lopinavir, a protease inhibitor, inhibited IRS-1 phosphorylation in 
human adipocytes and resulted in a concentration-dependent decrease in glucose 
uptake (Djedaini et al., 2009). It was suggested that lopinavir decreased the 
phosphorylation of IRS-1 directly since there was no effect observed on the 
phosphorylation of the insulin receptor β-subunit. 
1.5.3.3 Protease inhibitors induce insulin resistance via other factors: oxidative 
stress, adapter proteins and adipokines  
As indicated above (section 1.5.3.1), some of the protease inhibitors may increase 
oxidative stress (Ben-Romano et al., 2006; Chandra et al., 2009). Protease inhibitors 













and macrophages (Lagathu et al., 2007). The induction of oxidative stress is known 
to cause insulin resistance. Changes in the expression of regulatory proteins in the 
insulin signalling pathway could also potentially explain the effects of protease 
inhibitors. SOCS-1 and -3 are examples of known inducers of insulin resistance. 
These proteins bind to the insulin receptor β-subunit following activation, and impair 
the ability of the insulin receptor β-subunit to phosphorylate downstream substrates.  
It has also been shown that the expression of SOCS-1 was increased in indinavir-
treated rats (Carper et al., 2008). In this study, chronic protease inhibitor exposure 
induced SOCS-1 expression in muscle, liver and adipose tissue. This was associated 
with an increase in the expression of TNF-α and the downstream target SREBP-1, 
along with decreased expression of IRS-2. IRS-2 is another major substrate that 
mediates insulin action in the insulin signalling pathway (Carper et al., 2008).  
In relation to IRS-1, TNF-α induces the activation of several serine kinases (JNK and 
IKK) leading to increased serine 307 phosphorylation of IRS-1. Increasing the serine 
phosphorylation converts it into an inhibitory protein of the insulin receptor, leading to 
insulin resistance. Therefore, in summary, TNF-α can induce insulin resistance by 
affecting IRS-1 function directly or by inducing the expression of SOCS-1. 
Protease inhibitors have also been found to alter adipose tissue gene expression in 
vivo (Chaparro et al., 2005). The mRNA expression levels of the CCAAT/enhancer-
binding protein α, leptin, and adiponectin of HIV-positive patients treated with 
protease inhibitors have been found to be significantly lower than the levels 
measured in protease-inhibitor-naive patients (Chaparro et al., 2005). Since 
adiponectin levels are important in the whole body response to insulin such as 
glucose regulation and fatty acid catabolism, a lowering of adiponectin would affect 
glucose homeostasis adversely and oppose the actions of insulin. 
Briefly, the differences in the protease inhibitor effects observed in the different 
studies may be attributed to the different protease inhibitor drugs used in the studies, 
and to differences in experimental design. Some studies report that protease 
inhibitors induce different effects on different cell lines (Ben-Romano et al., 2003; 
Kovsan et al., 2009). Additionally, several protease inhibitors demonstrate different 
results in vitro and in vivo (Noor et al., 2006). However, the most consistent 
phenomenon observed has been the effect on glucose uptake, the most obvious 













Whether these phenomena arise primarily from effects on early steps in the insulin 
signalling pathway or otherwise is not entirely clear. Recent studies (Djedaini et al., 
2009; Kachko et al., 2009) support the idea that protease inhibitors affect a more 
proximal level of the insulin signalling pathway, in particular tyrosine phosphorylation 
of the insulin receptor and its substrate, IRS-1. This leads to the inhibition of 
downstream insulin signalling events; in particular, extracellular glucose uptake by 
GLUT4, similar to insulin resistance in type 2 diabetes and obesity (Meyer et al., 
2002; Nolan et al., 1994). 
1.6 Objectives 
 
The general mechanism of insulin resistance in type 2 diabetes and obesity (section 
1.5.2) has been extensively studied. The study of the insulin resistance induced by 
protease inhibitors is still in its infancy, and the information available does not 
precisely allude to the mechanisms of insulin resistance because the studies have 
been performed using different models and have produced divergent findings.  
Therefore, this study was undertaken to clarify the molecular basis of the insulin 
resistance induced by protease inhibitors using several cell culture models. 
The objectives were therefore to: 
1. Analyse the effects of protease inhibitors on the insulin signalling pathway of cells 
transfected with the insulin receptor, and in 3T3-L1 adipocytes. Of particular 
interest were the proximal steps of the insulin signalling cascade, and the 
associated regulatory proteins.  
 
2. Analyse the effects of protease inhibitors on metabolic pathways in 3T3-L1 
adipocytes, by analysing metabolites in the cell culture medium, particularly 
amino acids, organic acids and free fatty acids. 
 
3. Analyse and compare the effects of protease inhibitors on lipoprotein lipase 
activity, an important step in the insulin-activated anabolic functions of 
adipocytes. This would be achieved by establishing a rapid method for analysing 
















CHAPTER 2: GENERAL MATERIALS AND METHODS 
2.1 Methods 
This study was designed to investigate the molecular basis of insulin resistance 
induced by protease inhibitors in vitro, using a cell culture system. The full study is 
summarised by the flowchart in Figure 2.1. 
The study of insulin signalling was performed using two cell lines: CHO-IR cells 
(Ahmed and Pillay, 2001) and differentiated 3T3-L1 murine adipocytes (Wilcox et al., 
2004). The CHO-IR cell line is a useful cell culture model for the study of insulin 
signalling; the cells are easy to culture as they have a short doubling time, making 
the planning of experiments relatively simple. They also have high levels of insulin 
receptor protein expression, allowing sensitive detection of changes in signalling 
proteins involved in the insulin receptor signalling pathway. 
This study also used 3T3-L1 adipocytes, as these cells are a well-known model for 
studying the insulin signalling pathway and lipid metabolism in vitro (Glenn et al., 
1992). The cells have a similar morphology and physiology to human adipocytes 
(Glenn et al., 1992), and also express additional substrates that are not present in 
CHO-IR cells, such as the APS and the GLUT4 transporter (Ahn et al., 2004).  
The cells were serum-starved and then stimulated with insulin, both in the presence 
and absence of protease inhibitors saquinavir and indinavir. The cells were serum-
starved to obtain the highest impact of insulin stimulation in the cells and to provide a 
high level of phosphorylation of the insulin receptor β-subunit. It is also used to 
reduce the basal level of phosphorylation induced by growth factors present in serum 
such that a higher level of stimulation is facilitated. The level of insulin stimulation 
was compared with that of the basal unstimulated cells (the control). The cell lysates 
were then subjected to immunoblotting with the appropriate antibodies. The CHO-IR 
cells were also pre-treated with sodium salicylate (known to reduce blood glucose), 
prior to treatment with the protease inhibitor (indinavir). The results were analysed 
using realtime imaging (ChemiImager).  
In addition, the cell culture supernatants of 3T3-L1 adipocytes treated with protease 






































Treat with protease 
inhibitors 
 





Quantify protein intensity using 
Chemilmager 
LPL analysis Metabolomics 
Figure 2.1: Flowchart of study to understand molecular basis of insulin resistance induced by protease 








Molecular basis of insulin 


















2.1.1 Preparation of culture medium and maintenance of cell lines 
 
The CHO-IR cells were cultured in Ham’s F12 mixture culture medium in 75 cm2 
flasks, and incubated at 37 °C in a 5 % CO2 incubator. The medium was 
supplemented with 10 % FCS, 2 mM L-glutamine, 1 % of 100 x antibiotic/antimycotic 
(combination of penicillin, streptomycin and amphotericin), 0.5 % gentamicin and 400 
µg/ml G418-sulphate solution. Ham’s F12 medium was used as a base medium for 
the CHO-IR cells as the cells require L-proline, which is supplied by the medium. 
FCS has a high level of insulin growth factor (IGF) to stimulate the growth of cells. L-
glutamine is an essential amino acid for supporting the growth of cells, and is an 
alternative energy source for rapidly dividing cells and cells that use glucose 
inefficiently. Antibiotic/antimycotic solution is effective against the most common 
forms of cell culture contamination, including gram-positive and gram-negative 
bacteria, yeast and fungi. Gentamicin was used to prevent contamination of the 
mycoplasma in the cell culture medium. As mentioned earlier in this chapter, CHO-IR 
cells are transfected cells with insulin receptor. The transfected insulin receptor is on 
a plasmid that contains the G418 resistance gene. G418 is an antibiotic to ensure 
that only transfected cells are present in a flask while any cells that lose the plasmid 
will die. 
Within 3-4 days, after the cells had reached semi-confluence, they were split for 
subculture in the following way: the culture medium was drained and the cells were 
rinsed, first with sterile phosphate buffered saline (PBS) (10 ml) and then with 1x 
trypsin-ethylenedinitrilotetraacetic acid (Trypsin-EDTA) (2 ml) solution. The flask was 
incubated at 37 °C for 2 min to allow the release of the cells from the flask. The 
trypsin reaction was terminated with 5 ml of culture medium, and 1 ml of the culture 
medium was then transferred to a new flask containing the fresh culture medium (20 
ml). 
The 3T3-L1 pre-adipocyte fibroblasts were cultured in four different culture media 
(named Medium 1, 2, 3 and 4) in 75 cm2 flasks, and incubated at 37 °C in a 10 % 
CO2 incubator during the process of maintenance culture and the induction of 
differentiation.  
The 3T3-L1 pre-adipocytes were initially cultured in Medium 1 (Dulbecco’s modified 
Eagle’s medium (DMEM) with 10 % newborn calf serum (NCS), 2 mM L-glutamine, 1 













growth. DMEM was used as a base medium. NCS has a low level of IGF, which 
allows cells to grow as fibroblasts and prevents them from differentiating. After the 
cells had grown to 60-70 % confluence, they were split into a new flask, in order to 
maintain the fibroblasts for other experiments. 
For the differentiation procedure, the pre-adipocytes were grown to confluence in 
Medium 1. Subsequently, the cells were induced to differentiate by placing them for 
two days in Medium 2 (DMEM with 10 % FCS, 2 mM L-glutamine, 1 % of 100 x 
antibiotic/antimycotic, 0.1 % gentamicin, 0.25 µM dexamethasone and 0.5 mM 3-
isobutyl-1-methyl-xanthine (IBMX) and 166 nM insulin). FCS has a high level of IGF, 
which stimulates the differentiation of pre-adipocytes to adipocytes. Dexamethasone 
and IBMX were used to induce differentiation of 3T3-L1 pre-adipocytes through the 
activation of transcription factors, the CCAAT/echancer-binding proteins (C/EBPs) 
and the PPARγ. Insulin was added to the culture medium to facilitate the 
differentiation procedure in the cells. The differentiation of cells was continued for two 
days in Medium 3 (DMEM with 10 % FCS, 2 mM L- glutamine, 1 % of 100 x 
antibiotic/antimycotic, 0.1 % gentamicin and 166 nM insulin). The 3T3-L1 adipocytes 
were then cultured in Medium 4, which was prepared as for Medium 3, but without 
insulin to maintain the adipocyte differentiation. 
Stocks of frozen CHO-IR cells and 3T3-L1 pre-adipocytes were routinely prepared for 
storage in liquid nitrogen. The freezing medium for CHO-IR cells was prepared using 
20 % dimethyl sulfoxide (DMSO) in FCS solution. The freezing medium for 3T3-L1 
adipocytes was prepared using 20 % DMSO in NCS solution. Following trypsinisation 
and suspension in culture medium, the cells were mixed in a cryotube, with a ratio of 
1:1 to the freezing medium. The tube was then placed in an isopropanol cryo-
freezing container at -80 °C. Isopropanol was added to the container to freeze the 
cells gradually in the liquid nitrogen. Isopropanol facilitated the temperature in the 
container to drop about 1°C per minute.  
 
Cells were thawed by placing the cryotubes in 37 °C in an incubator for 
approximately 2 min, or until thawed. The cells/freezing medium solution was then 
added to 5 ml of the culture medium (i.e. Ham’s F12 mixture culture medium, or 
Medium 1) in a 25 cm2 flask, and resuspended. The culture medium was changed 
after 12 h, grown as above, and split into a 75 cm2 flask when the cells were in a 














2.1.2 Serum starvation procedure 
1 x 105 cells/ml of CHO-IR cells were plated into 6-well plates until they were in a 
state of semi-confluence. In parallel, 3T3-L1 pre-adipocyte fibroblasts were 
subcultured in 3.5 cm dishes and then grown to full confluence, after which 
differentiation was induced (Mehra et al., 2007). Both CHO-IR cells and differentiated 
3T3-L1 adipocytes were serum-starved for 16 h in a serum-free medium (2 mM L-
glutamine, 1 % of 100 x antibiotic/antimycotic and 0.1 % gentamicin in DMEM). The 
cells were incubated at 37 ºC in an incubator, with 10 % CO2.  
Prior to aspirating the serum-free medium from the cells, the cells were stimulated 
with 10-100 ng/ml (1.7-17 nM) insulin for 5 min. The serum-free medium from the 
CHO-IR cells was discarded, and the medium from 3T3-L1 adipocytes was stored at 
-80 ºC for the subsequent analysis. 
2.1.3 Preparation of cell lysates 
After serum-starvation for 16 h, followed by insulin stimulation for 5 min, the serum-
free medium was discarded. The 6-well plates were put on ice. Subsequently, 100 µl 
lysis buffer (consisting of 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), pH 7.5, 1 % phenoxylpolyethoxyethanol (NP40), 10 % glycerol, 50 mM 
sodium chloride (NaCl), protease inhibitor and phosphatase inhibitor) was added 
evenly to the plates, which were left on ice for 10 min.  Protease and phosphatase 
inhibitors were added to the lysis buffer to protect proteins of the cells against 
dephosphorylation. Specifically, protease inhibitor inhibits a broad spectrum of 
serine, cysteine, metalloproteases and calpains, while phosphatase inhibitor inhibits 
a broad spectrum of phosphatases such as acid, alkaline, serine/threonine and 
tyrosine protein phosphatase.  
The cells were scraped with a scraper and transferred into a micro-centrifuge tube. 
They were then centrifuged at 4 °C and 10 000 rpm for 10 min. 60 µl of the cells were 
mixed with 15 µl of 5 x Laemmli buffer (25 nM Tris, pH 6.8, 2 % SDS, 0.002 % 
bromophenol blue, 10 % glycerol and 5 % 2-mercaptoethanol) prior to boiling at 100 
ºC for 5 min, and brief spinning to settle all the evaporation from the lid of the micro-















The experiment was repeated using cells treated with 0-100 µM protease inhibitors 
indinavir and saquinavir, left for 16 h in a serum-free medium followed by insulin 
stimulation. 
2.1.4 Measurement of protein concentration 
A Bradford protein assay was performed to measure the protein concentration of cell 
lysate (Bradford, 1976). This method is a colourimetric protein assay based on an 
absorbance shift in the dye Coomassie when bound to arginine and hydrophobic 
amino acid residues present in the protein. The colour of the dye is blue, and it has 
an absorption spectrum maximum of 595 nm. The increase in absorbance at 595 nm 
is proportional to the amount of bound dye, and thus to the amount (i.e. 
concentration) of protein present in the sample. 
The concentrated dye reagent of Bio-Rad protein assay was added to dH2O with 
ratio 1:5, to measure protein concentration in a sample. The reagent was then filtered 
using filter paper (110 mm diameter) prior to use. 
Bovine serum albumin (BSA) (1 mg/ml) was prepared as a stock in dH2O to generate 
a standard curve. The standard curve was designed with 5, 10 and 15 μl of BSA was 
added into the reagent to give final concentrations 5, 10 and 15 µg/ml. 5 µl of cell 
lysate was mixed with the reagent in another cuvette. The absorbance of the mixture 
in the cuvette was measured at 595 nm, with the reagent as a blank. 
2.1.5 Preparation of protease inhibitors 
5 mM indinavir and saquinavir, 1.2 mM tipranavir and 0.2 mM darunavir were 
prepared as a stock in dimethyl sulphoxide (DMSO) (final concentration 0.01 %) 
(Martin et al., 2009; Vernochet et al., 2005). DMSO was used as a solvent because 
the drugs are not water-soluble and furthermore, DMSO has minimal effects on the 
cells, in terms of the parameters under investigation (Martin et al., 2009; Vernochet et 
al., 2005). 
2.1.6 Statistical analysis 
Data are expressed as the mean ± S.E.M. of at least triplicate experiments. 
Statistical comparisons were made using Student’s t-test or factorial-ANOVA using 














CHAPTER 3: THE EFFECT OF HIV PROTEASE INHIBITORS ON THE INSULIN 
SIGNALLING PATHWAY 
3.1 Introduction  
More than 60 % of HIV-positive patients treated with protease inhibitors suffer from 
various metabolic disorders; in particular, insulin resistance, which is associated with 
lipodystrophy, type 2 diabetes mellitus and cardiovascular disease (Barbaro, 2002; 
Esser et al., 2007; Florescu and Kotler, 2007; Stein, 2007).  
Previous studies (Ismail et al., 2009) have suggested that the manifestation of insulin 
resistance due to treatment using protease inhibitors is likely to be a result of 
dysregulation of several cellular factors, specifically in the early steps in the pathway 
of insulin receptor signalling, in addition to alterations in GLUT4 transporter function.  
In order to clarify the role of protease inhibitors in insulin resistance, the protease 
inhibitors saquinavir and indinavir were used in the present study. These drugs were 
obtained more readily than other protease inhibitors. Thus, the drugs were chosen for 
the study. CHO-IR cells and differentiated murine 3T3-L1 adipocytes were treated 
with various drug concentrations (0-100 µM) of saquinavir and indinavir for 16 h, 
followed by insulin stimulation (10-100 ng/ml) (1.7-17 nM).  
CHO-IR cells were also pre-treated with a high dose of sodium salicylate (5 mM) for 
1 h prior to indinavir treatment. These cells were selected as they have a short 
doubling time and a high level of insulin receptor expression than 3T3-L1 adipocytes. 
Sodium salicylate is known to reduce fasting blood glucose in diabetic patients (Yuan 
et al., 2001). The mechanism by which salicylates reduce blood glucose is well-
understood (i.e. via IKKβ in the NFκB pathway) (Yuan et al., 2001). This may 
potentially explain the molecular basis of insulin resistance induced by protease 
inhibitors. Although sodium salicylate has been superseded by other oral 
hypoglycaemics such as metformin (Yuan et al., 2001), there has been a recent 
resurgence of interest in the use of salicylates as hypoglycaemic agents because of 
the role of IKKβ in mediating insulin resistance (Fleischman et al., 2008; Koska et al., 
2009). In view of the above, the effects of sodium salicylate were also evaluated. 
As mentioned previously, the precise mechanism by which protease inhibitors induce 
insulin resistance is not clear (Ismail et al., 2009). Therefore, the main objective of 













induce insulin resistance in CHO-IR cells and 3T3-L1 adipocytes, by the analysis of 
signalling proteins in the insulin signalling cascade. 
3.2 Methods 
3.2.1 Preparation of acrylamide gels for sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
An SDS polyacrylamide gel (8 cm x 7.3 cm) was prepared as a composite of two 
gels, following a standard protocol. The upper gel was a 4 % stacking gel (0.126 M 
Tris, pH 6.8, 4 % acrylamide/bis (19:1), 0.1 % SDS, 0.05 % ammonium persulphate 
(APS) and 0.1 % N, N, N’, N’,-tetramethylethylenediamine (TEMED)) and the lower 
gel was a 7.5 % resolving gel (0.375 M Tris, pH 8.8, 7.5 % acrylamide/bis (19:1), 0.1 
% SDS, 0.05 % APS and 0.05 % TEMED) (Figure 3.1). The stacking gel contained 







Figure 3.1: Acrylamide gel for SDS-PAGE 
3.2.2 Electrophoresis  
Cell lysates (20 µl) (from section 2.2.3) and a marker (Precision Plus Protein Dual 
Colour Standard, Bio-Rad) (5 µl) were loaded into the wells of the gel. The gel was 
placed in a tank (Bio-Rad Mini Protean II apparatus) with a running buffer (0.025 M 
Tris, 0.192 M glycine and 0.1 % SDS). Electrophoresis was performed at 150 V and 


















3.2.3 Protein transfer 
Following electrophoresis, the acrylamide gel was placed in a nitrocellulose 
membrane-filter paper transfer sandwich. The transfer sandwich was prepared as 
shown in Figure 3.2, and placed in a tank with a transfer buffer (0.025 M Tris, 0.192 
M glycine and 20 % methanol), and an ice box and a bar stirrer to facilitate the 










Figure 3.2: Transfer sandwich 
 
3.2.4 Immunoblotting 
The membrane was stained with 0.1 % Ponceau S in 5 % acetic acid, to confirm 
successful and even transfer of proteins to the membrane. The membrane was 
destained with deionised water and incubated in a blocking solution (3 % BSA or 5 % 
skimmed milk solution (Marvel) in Tris buffered saline (0.05 M Tris, 0.150 M NaCl, pH 
7.4)) + 0.1% Tween 20 (TBST) for 1 h at room temperature (18-25 °C). The 
membrane was then incubated with a specific primary antibody (Table 3.2), and 
washed with 20 ml TBST for 15 min, 4 times.  
The membrane was then incubated with a horseradish peroxidase (HRP)-labelled 
secondary antibody (Table 3.2) to detect the primary antibody bound to the protein of 
interest. It was rinsed once with TBST and then twice more with deionised water (20 
ml). The membrane was then soaked in chemiluminescent reagent (Pierce) (4 ml) for 
1 min, and excess reagent was drained using tissue paper. The membrane was 
covered with transparent plastic and exposed to X-ray film (Agfa) for a few sec to 1 h 
to capture a visual signal from the secondary antibody. The film was developed in 
developer (Ilford, Cheshire) for 1 min, washed with tap water, fixed with fixer (Ilford, 
Cheshire) for 1 min, washed again with tap water and then air-dried.



























PY20 = phosphotyrosine, IR = insulin receptor, PTP1B = protein tyrosine phosphatase 1 B, SOCS-1 = suppressor of cytokines signalling 1, SOCS-3 = suppressor of cytokines signalling 3, SH2B = 
Src homology 2 B, IRS-1 = insulin receptor substrate 1, pIRS-1 (S307) = phosphoIRS-1 at serine 307, APS = adapter protein with a pleckstrin homology domain and an SH2 domain. 
Primary antibody Concentration 
(antibody : blocking 
solution) 











1) Mouse anti-PY20  
(1 mg/ml) 
 
1:2000 16 h (overnight) for 
3T3-L1 adipocyte 
cell lysate and 1 h 
for CHO-IR cell 
lysate 
4 °C for 16 h 
incubation and 
18-25 °C (room 
temperature) for 







1 h 18-25 °C 
3% BSA 
2) IR β-subunit rabbit  








1: 1000 5% Milk solution 
3) PTP1B rabbit 




16 h 4 °C 
Goat anti- rabbit 
(400 µg/ml) 
4)SOCS-1 rabbit 





polyclonal IgG (200 
µg/ml) 
 
6) SH2B rabbit polyclonal 
IgG (crude serum) 
(Kotani et al., 1998) 
 1 h 18-25 °C 
7) Actin goat polyclonal 
IgG (200 µg/ml) 
 
Mouse anti- goat 
(1 mg/ml) 
8) Total IRS-1 rabbit 
polyclonal IgG (200 
µg/ml) 
 
16 h 4 °C 5% BSA Goat anti- rabbit (400 µg/ml) 
9) pIRS-1 (S307) rabbit 
polyclonal IgG (200 
µg/ml) 
 
10) APS (200 µg/ml) 













3.2.5 Stripping of membranes 
The membrane was stripped with a stripping solution (0.063 M Tris, pH 6.8, 2 % SDS 
and 0.1 M 2-mercaptoethanol) for 30 min at 50 ºC, incubated in a blocking solution 
once more and then reprobed with a different primary antibody (Table 3.2) as 
indicated in Section 3.2.4. 
3.2.6 Treatment with sodium salicylate 
50 mM sodium salicylate was prepared freshly in 1 M Tris, pH 7.4 (Yuan et al., 2001). 
CHO-IR cells were pre-treated with sodium salicylate (0.5-5 mM) at 37 ºC for 1 h 
prior to treatment with indinavir (100 µM) for 16 h. The cell lysates were prepared as 
described in section 2.2.3. 
3.2.7 Quantification of chemiluminescence  
The membrane was analysed using a realtime imager, ChemiImager (Fluorchem 
5500 Programme, Alpha Innotech Corporation, CA, USA) to quantify the 
chemiluminescent intensity.  
3.3 Results  
3.3.1 Pilot studies using different protease inhibitors in a range of 
concentrations 
Initially, saquinavir was used to examine the effects of protease inhibitors in the 
insulin receptor signalling pathway in CHO-IR cells and 3T3-L1 adipocytes. The cells 
were pre-treated with saquinavir (20-50 µM) for 16 h followed by insulin stimulation 
(100 ng/ml) (17 nM) for 5 min. Saquinavir inhibited tyrosine phosphorylation of the 
insulin receptor β-subunit in both cell lines (Figure 3.3(a) and (b)). Saquinavir also 
decreased the expression levels of total insulin receptor β-subunit and actin (Figure 


















 (a)      (b) 
 
Figure 3.3: Effects of saquinavir on insulin-stimulated tyrosine phosphorylation in (a) CHO-IR 
cells and (b) 3T3-L1 adipocytes. CHO-IR cells and 3T3-L1 adipocytes were treated with different 
concentrations of saquinavir for 16 h followed by insulin stimulation. The cells were then lysed and the 
lysates subjected to immunoblotting with anti-phosphotyrosine PY20 antibody (upper panels). The blots 
were then stripped and reprobed with anti-IR β-subunit and anti-actin (lower panels). Bound antibodies 
were made visible by chemiluminescence. Chemiluminescence was quantified by realtime imaging. The 
band intensity of the proteins from one experiment was normalised to the band intensity of total IR 
protein. The discontinuity in saquinavir concentrations in Figure 3.3(b) was inadvertent. pIR (PY20) = 
tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit. 
 
CHO-IR cells (Figure 3.4) and 3T3-L1 adipocytes (Figure 3.5) were pre-treated with 
indinavir (10-50 µM) for 16 h followed by insulin stimulation (10 ng/ml) (1.7 nM) for 5 
min. In CHO-IR cells, 50 µM indinavir inhibited tyrosine phosphorylation of the insulin 
receptor β-subunit without showing any effects on the expression levels of total 
insulin receptor β-subunit and actin (Figure 3.4). No inhibition of tyrosine 
phosphorylation on the insulin receptor β-subunit was observed in CHO-IR cells 
treated with 10-40 µM indinavir (Figure 3.4). 
 
 
Figure 3.4: Effects of indinavir on insulin-stimulated tyrosine phosphorylation in CHO-IR cells. 
CHO-IR cells were treated with different concentrations of indinavir for 16 h followed by insulin 
stimulation. The cells were then lysed and the lysates subjected to immunoblotting with anti-
phosphotyrosine PY20 antibody (upper panels). The blots were then stripped and reprobed with anti-IR 
β-subunit and anti-actin (lower panels). Bound antibodies were visualised by chemiluminescence. 
Chemiluminescence was quantified by realtime imaging. The band intensity of the proteins from one 
experiment was normalised to the band intensity of total IR protein. pIR (PY20) = tyrosine 
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In 3T3-L1 adipocytes, 50 µM indinavir significantly inhibited tyrosine phosphorylation 
of the insulin receptor β-subunit (p = 0.003) without having any effect on the 
expression levels of total insulin receptor β-subunit and actin (Figure 3.5).  
 
Figure 3.5: Effects of indinavir on insulin-stimulated tyrosine phosphorylation in 3T3-L1 
adipocytes. 3T3-L1 adipocytes were treated with different concentrations of indinavir for 16 h followed 
by insulin stimulation. The cells were then lysed and the lysates subjected to immunoblotting with anti-
phosphotyrosine PY20 antibody (upper panel). The blots were then stripped and reprobed with anti-IR 
β-subunit and anti-actin (lower panels). Bound antibodies were visualised by chemiluminescence. 
Chemiluminescence was quantified by realtime imaging. The band intensity of the proteins from six 
independent experiments for 3T3-L1 adipocytes was normalised to the band intensity of total IR protein. 
Data are shown as the mean ± S.E.M. (n=6). pIR (PY20) = tyrosine phosphorylation of IR, tIRβ = total 
insulin receptor β-subunit, *p < 0.05 versus cells stimulated with insulin without indinavir treatment, 
using Student’s t-test. 
 
3.3.2 Effect of protease inhibitors on tyrosine phosphorylation of insulin 
receptor β-subunit and IRS-1 
Based on the previous results, indinavir was then used to study the molecular basis 
of the effects of protease inhibitors on the insulin signalling pathway in both cell lines. 
CHO-IR cells and 3T3-L1 adipocytes were pre-treated with indinavir for 16 h prior to 
stimulation with a submaximal insulin concentration (10 ng/ml) (1.7 nM) for 5 min. In 
CHO-IR cells, samples pre-treated with indinavir and stimulated with insulin showed 
a significant decrease in tyrosine phosphorylation of the insulin receptor β-subunit (p 
= 0.02) (Figure 3.6(a)) and in the phosphorylation of IRS-1 (p = 0.0002) (Figure 
3.6(b)). In 3T3-L1 adipocytes under the same conditions, there was a significant 
decrease in tyrosine phosphorylation of the insulin receptor β-subunit (p = 0.003) 
(Figure 3.7(a)) and IRS-1 (p = 0.0002) (Figure 3.7(b)), compared to cells stimulated 
with insulin only. Based on chemiluminescence results and statistical analysis, 
indinavir itself did not increase basal pIR (3T3-L1 adipocytes) and pIRS (CHO-IR 
cells)  
The expression levels of total insulin receptor β-subunit and IRS-1 were also 
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changes in protein expression. There were no significant differences in expression 
levels of insulin receptor β-subunit and IRS-1 among the samples, indicating that the 
decreased signal observed (Figures 3.6 and 3.7) was due to a decrease in tyrosine 
phosphorylation rather than a decrease in total protein levels. In addition, the 
expression level of actin was examined as a loading control for cellular protein. 
(a)      (b) 
 
Figure 3.6: Effects of indinavir on insulin-stimulated tyrosine phosphorylation in CHO-IR cells. 
CHO-IR cells were treated with indinavir (50 µM) for 16 h, followed by insulin stimulation. The cells were 
then lysed and the lysates subjected to immunoblotting with anti-phosphotyrosine PY20 antibody (upper 
panels). The blots were then stripped and reprobed with anti-IR β-subunit, anti-IRS-1 and anti-actin 
(lower panels). Bound antibodies were visualised by chemiluminescence. Chemiluminescence was 
quantified by realtime imaging. The band intensity of the proteins from three independent experiments 
was normalised to the band intensity of total IR or IRS protein. Data are shown as the mean ± S.E.M. 
(n=3). pIR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit, pIRS-1 
(PY20) = tyrosine phosphorylation of IRS-1 and tIRS-1 = total IRS-1, *p < 0.05 versus cells with insulin 
stimulation only, using Student’s t-test (Lord test). 
 
 
(a)       (b) 
 
Figure 3.7: Effects of indinavir on insulin-stimulated tyrosine phosphorylation in 3T3-L1 
adipocytes. 3T3-L1 adipocytes were treated with different concentrations of indinavir for 16 h, followed 
by insulin stimulation. The cells were then lysed and the lysates subjected to immunoblotting with anti-
phosphotyrosine PY20 antibody (upper panels). The blots were then stripped and reprobed with anti-IR 
β-subunit, anti-IRS-1 and anti-actin (lower panels). Bound antibodies were visualised by 
chemiluminescence. Chemiluminescence was quantified by realtime imaging. The band intensity of the 
proteins from six independent experiments was normalised to the band intensity of total IR or IRS 
protein. Data are shown as the mean ± S.E.M. (n=6). pIR PY20 = tyrosine phosphorylation of IR, tIRβ = 
total insulin receptor β-subunit, pIRS-1 (PY20) = tyrosine phosphorylation of IRS-1 and tIRS-1 = total 
IRS-1, *p < 0.05 versus cells with insulin stimulation only, using Student’s t-test. Figure 3.7(a) has been 
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Based on these results, two possible hypotheses may be formulated: 
1. the drug inhibits the insulin receptor kinase directly, or  
2. the drug effects are indirect, and involve a regulator of tyrosine phosphorylation. 
In order to test these hypotheses, the blots were stripped and reprobed with 
antibodies against regulatory proteins of insulin receptor signalling, such as serine 
307 phosphorylated IRS-1, PTP1B, SOCS-1 and -3, SH2B and APS.  
3.3.3 Effect of protease inhibitors on regulatory proteins in the insulin 
signalling pathway 
There was a significant increase in the level of phosphorylated serine 307 on IRS-1 
in both cell lines, CHO-IR cells (p = 0.001) (Figure 3.8(a)) and 3T3-L1 adipocytes (p 
= 0.004) (Figure 3.8(b)), treated with indinavir and then stimulated with insulin, 
compared to cells stimulated with insulin alone. These results were not accompanied 
by a change in the level of total IRS-1 (Figures 3.8(a) and 3.8(b)). 
(a)      (b) 
 
Figure 3.8: Effects of indinavir on serine 307 phosphorylation of IRS-1 in the insulin signalling 
pathway in (a) CHO-IR cells and (b) 3T3-L1 adipocytes. CHO-IR cells and 3T3-L1 adipocytes were 
treated with different concentrations of indinavir for 16 h, followed by insulin stimulation. The cells were 
then lysed and the lysates subjected to immunoblotting with an antibody against pS307 (upper panels). 
The blots were then stripped and reprobed with anti-IRS or anti-actin (lower panels). Bound antibodies 
were visualised by chemiluminescence. Chemiluminescence was quantified by realtime imaging. The 
band intensity of the proteins from three independent experiments was normalised to the band intensity 
of total IRS protein. Data are shown as the mean ± S.E.M. (n=3). pS307 = phosphorylated serine at 
residue 307, tIRS-1 = total IRS-1, *p < 0.05 versus cells with insulin stimulation only, using Student’s t-
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The expression levels of PTP1B, SOCS-1 and -3, and SH2B in CHO-IR cells after 
pre-treatment with indinavir were not significantly different (Figure 3.9(a, b, c, d)).  
 (a)      (b) 
 
(c)       (d) 
 
Figure 3.9: Effects of indinavir on regulatory proteins in the insulin signalling pathway in CHO-IR 
cells. CHO-IR cells were treated with indinavir (50 µM) for 16 h followed by insulin stimulation. The cells 
were then lysed and the lysates subjected to immunoblotting with antibodies against: (a) PTP1B (b) 
SOCS-1 (c) SOCS-3 (d) SH2B (upper panels). The blots were then stripped and reprobed with anti-actin 
(lower panels). Bound antibodies were visualised by chemiluminescence. Chemiluminescence was 
quantified by realtime imaging. The band intensity of the proteins from five independent experiments 
was normalised to the band intensity of actin. Data are shown as the mean ± S.E.M. (n=5). PTP1B = 
protein tyrosine phosphatase 1 B, SOCS-1 = suppressor of cytokines signalling 1, SOCS-3 = 
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In 3T3-L1 adipocytes, pre-treatment with indinavir did not significantly alter the 
expression levels of PTP1B, SOCS-1 and -3, SH2B1 and APS (Figure 3.10(a, b, c, d, 
e)).  
(a)        (b) 
 
 
(c)      (d) 
 
 
e)      
 
 
Figure 3.10: Effects of indinavir on regulatory proteins in the insulin signalling pathway in 3T3-L1 
adipocytes. 3T3-L1 adipocytes were treated with different concentrations of indinavir for 16 h, followed 
by insulin stimulation. The cells were then lysed and the lysates subjected to immunoblotting with 
antibodies against: (a) PTP1B (b) SOCS-1 (c) SOCS-3 (d) SH2B (e) APS (upper panels). The blots 
were then stripped and reprobed with anti-actin (lower panels). Bound antibodies were visualised by 
chemiluminescence. Chemiluminescence was quantified by realtime imaging. The band intensity of the 
proteins from three to six independent experiments was normalised to the band intensity of actin. Data 
are shown as the mean ± S.E.M. (n=3 to 6). PTP1B = protein tyrosine phosphatase 1 B, SOCS-1 = 
suppressor of cytokines signalling 1, SOCS-3 = suppressor of cytokines signalling 3, SH2B = Src 
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3.3.4 Effect of protease inhibitors after pre-treatment with sodium salicylate  
 
CHO-IR cells were used to examine the effects of sodium salicylate on indinavir 
treatment, as the cells have a high level of insulin receptor expression, which 
facilitates more sensitive detection of changes in signalling proteins than is the case 
with 3T3-L1 adipocytes. 
Cells pre-treated with sodium salicylate prior to treatment with indinavir showed a 
significant increase in insulin-stimulated tyrosine phosphorylation of the insulin 
receptor β-subunit (p = 0.002) (Figure 3.11(a)) when compared to cells treated with 
indinavir and insulin only. In fact, insulin-stimulated tyrosine phosphorylation was 
restored to the levels seen in the presence of insulin only, without indinavir. This 
indicates that sodium salicylate blocked the effects of indinavir to inhibit tyrosine 
phoshorylation of the insulin receptor β-subunit.  
A slight, but statistically insignificant, increase in insulin-stimulated tyrosine 
phosphorylation of IRS-1 was also observed after salicylate treatment, when 
compared to cells treated with indinavir and insulin alone (Figure 3.11(b)). Sodium 
salicylate also decreased phosphorylation of IRS-1 at serine 307 twofold, although 
this was not statistically significant compared to cells treated with indinavir followed 
by insulin (Figure 3.11(c)).These results suggest that sodium salicylate treatment 
abrogated the effects of indinavir to inhibit tyrosine phosphorylation of the insulin 
receptor β-subunit and IRS-1 in parallel with a decrease in phosphorylation of IRS-1 






























Figure 3.11: Effects of indinavir in the insulin signalling pathway of CHO-IR cells after pre-
treatment with sodium salicylate. CHO-IR cells were pre-treated with sodium salicylate (5 mM) for 1 h 
prior to treatment with indinavir (100 µM) for 16 h. The cells were stimulated with insulin for 5 min. The 
cells were then lysed and the lysates subjected to immunoblotting with antibodies against: (a) and (b) 
anti-phosphotyrosine PY20 antibody and (c) pS307 (upper panels). The blots were then stripped and 
reprobed with anti-IR, anti-IRS-1 and anti-actin (lower panels). Bound antibodies were visualised by 
chemiluminescence. Chemiluminescence was quantified by realtime imaging. The band intensity of the 
proteins from three independent experiments was normalised to the band intensity of total IR or IRS-1 
protein. Data are shown as the mean ± S.E.M. (n=3). pIR PY20 = tyrosine phosphorylation of IR, pIRS-1 
PY20 = tyrosine phosphorylation of IRS-1, tIRβ = total insulin receptor β-subunit, pS307 = 
phosphorylated serine at residue 307 of IRS-1, tIRS-1 = total IRS-1, *p< 0.05 versus cells treated with 
indinavir and stimulated with insulin, using factorial-ANOVA. 
 
3.4 Discussion 
The effects of antiretroviral protease inhibitors have been examined in numerous 
studies (for a review, see Ismail et al., 2009, and Chapter 1 of this study). The 
majority of studies have focused largely on downstream events in the insulin 
signalling pathway. Protease inhibitors, including saquinavir and indinavir, were 
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cytoplasm to the cell surface (Ben-Romano et al., 2003; Murata et al., 2002; Noor et 
al., 2002; Ranganathan and Kern, 2002). However, the underlying mechanism of this 
process has not yet been explained, and it is possible that these effects on glucose 
uptake may have resulted from inhibition at a proximal level. Few studies have 
examined proximal steps in the insulin signalling cascade. Areas still to be 
investigated include insulin binding to the receptor, and activation of intrinsic tyrosine 
kinase activity; and the subsequent tyrosine phosphorylation of substrate, where 
direct or indirect drug-induced inhibition may occur.  
In this study, for the first time, CHO-IR cells were used to analyse the effects of 
protease inhibitors on the insulin receptor β-subunit phosphorylation and tyrosine 
kinase activation. Saquinavir inhibited tyrosine phosphorylation of the insulin receptor 
β-subunit in CHO-IR cells and 3T3-L1 adipocytes. The drug also decreased the 
expression levels of insulin receptor β-subunit and actin in both cell lines. It is 
possible that saquinavir is toxic at 20 µM concentration. In addition, using an inverted 
microscope, the cells observed did not show normal growth at this concentration. The 
finding of saquinavir toxicity is supported by a previous study using a cell proliferation 
assay to monitor cell viability of human fibroblasts, 3T3-L1 fibroblasts, L6 myoblasts 
and myotubes (Germinario and Colby-Germinario, 2003). However, indinavir was not 
toxic to the cells at the same concentration (Germinario and Colby-Germinario, 
2003). Thus, indinavir was used to study the effects of protease inhibitors in the 
insulin signalling pathway in cell lines in the present study. 
The results of this study reveal that CHO-IR cells treated with indinavir (50 µM) for 
16 h, followed by insulin stimulation, inhibited tyrosine phosphorylation of the insulin 
receptor β-subunit and IRS-1. These are early events following the binding of insulin 
to the insulin receptor. The same effect was observed in 3T3-L1 adipocytes. In a 
prior study using HepG2 hepatoma cells, it was reported that indinavir (100 µM) 
treatment for 48 h decreased tyrosine phosphorylation of the IRS-1 protein, but not 
phosphorylation of the insulin receptor itself (Schutt et al., 2000). The effects of 
indinavir may differ in different cell lines, depending on the experimental model and 
the duration of the exposure (Ben-Romano et al., 2003; Kovsan et al., 2009; Noor et 
al., 2006).  
The indinavir concentration used in this study was higher than previously reported 
plasma concentrations (11 µM) (Lin, 1999). A prior study reported that indinavir 
accumulates in adipose tissue (Vernochet et al., 2005). Therefore, in vivo, drug 












levels, which may be higher than the circulating plasma levels (Ranganathan and 
Kern, 2002). The effects of indinavir observed in the present study are unlikely to be 
due to cellular toxicity, as the drug inhibited tyrosine phosphorylation of the insulin 
receptor β-subunit without decreasing the expression levels of insulin receptor β-
subunit and actin in CHO-IR cells and 3T3-L1 adipocytes. This finding is supported 
by an early study, using a cell viability test, which showed that indinavir was not toxic 
to a number of cells, even at concentrations of 100 µM (Germinario and Colby-
Germinario, 2003). Therefore, the range of indinavir used in the present study was 0-
100 µM. 
In a cellular context, ex vivo, the effects of indinavir may only be apparent at 
submaximal insulin concentrations, which are more typical of physiological circulating 
insulin concentrations. For this reason, a submaximal concentration of 10 ng/ml (1.7 
nM) insulin has been used to stimulate the cells, even though the maximal activation 
of the insulin receptor tyrosine phosphorylation is observed at levels approximately 
tenfold higher than 10 ng/ml, i.e. 100 ng/ml (17 nM). Therefore, even though the 
maximal activation of insulin receptor tyrosine phosphorylation is observed at much 
higher levels of insulin in CHO-IR cells, the effects of insulin used at pharmacological 
concentrations in a cell line that overexpresses insulin receptors at such a high level 
may mask the inhibitory effects of indinavir. 
The inhibition of tyrosine phosphorylation of the insulin receptor kinase and its 
substrate, IRS-1, implies that indinavir interacts at a very proximal step in the insulin 
signalling pathway. There are two possible mechanisms that may explain this. The 
drug may act directly to inhibit the insulin receptor kinase, or the drug may affect 
other proteins that regulate intrinsic tyrosine kinase activity. In order to address this 
hypothesis, the blots were stripped and reprobed with antibodies against regulatory 
proteins of insulin receptor signalling, such as serine 307 phosphorylated IRS-1, 
PTP1B, SOCS-1 and -3, SH2B and APS.  
The protein expression of PTP1B in CHO-IR cells and 3T3-L1 adipocytes after pre-
treatment with indinavir was not significantly different compared to control. PTP1B, a 
tyrosine phosphatase, may negatively regulate insulin signalling by binding to the 
tyrosine phosphorylated proteins, insulin receptor β-subunit and IRS-1 (Cheng et al., 
2002) and catalysing dephosphorylation. However, the effect of protease inhibitors 
on PTP1B expression in vivo and in vitro has not been investigated. In this study, it 













The protein expression of SOCS-1 and -3 in CHO-IR cells and 3T3-L1 adipocytes 
was again not significantly different after treatment with indinavir compared to control. 
SOCS-1 and -3 are adapter proteins that bind to the insulin receptor β-subunit or 
IRS-1 or IRS-2 to inhibit downstream signalling. Increased SOCS-1 and -3 
expression has been reported to be increased after treatment with indinavir and this 
could induce insulin resistance by preventing tyrosine phosphorylation and 
subsequent activation of IRS-1 and -2 proteins (Carper et al., 2008). In addition, it 
has been reported that SOCS-1 and -3 negatively regulate the insulin signalling 
pathway, without modifying the insulin receptor tyrosine kinase activity (Emanuelli et 
al., 2001).  
Furthermore, SOCS-1 and -3 expression can be induced by TNF-α (Emanuelli et al., 
2001). TNF-α induces insulin resistance (Lee et al., 2009). However, this cytokine is 
released from immune cells and adipose tissue, and not from CHO-IR cells. Thus, 
there was no change in SOCS-1 and -3 protein expression in CHO-IR cells following 
treatment with indinavir. Similarly, the protein expression of SOCS-1 and -3 was not 
significantly altered in 3T3-L1 adipocytes treated with indinavir. Thus, the results of 
this study indicate that in CHO-IR cells and 3T3-L1 adipocytes, these proteins are not 
involved in decreasing phosphorylation of the insulin receptor β-subunit. 
SH2B (aka SH2B1) is an adapter protein involved in the signalling pathway mediated 
by insulin tyrosine kinases and Janus kinase. Deletion of the adapter protein gene in 
mice results in severe obesity, infertility, and leptin and insulin resistance (Maures et 
al., 2007). This protein has also been shown to regulate the tyrosine phosphorylation 
state of the insulin receptor (Ahmed and Pillay, 2001). However, the expression of 
SH2B in CHO-IR cells and 3T3-L1 adipocytes was not significantly altered after 
treatment with indinavir.  
The adapter protein, APS (aka SH2B2) has similar roles to SH2B protein in that both 
proteins delay dephosphorylation of the insulin receptor kinase and IRS-1 and -2 in 
the insulin signalling pathway (Ahmed and Pillay, 2001; Ahmed and Pillay, 2003). 
However, APS binds the insulin receptor with a higher affinity than SH2B (Ahmed 
and Pillay, 2001; Ahmed and Pillay, 2003). CHO-IR cells lack endogenous APS 
protein (Ahmed et al., 2000). Thus, in this study, only 3T3-L1 adipocytes were used 
to analyse this protein (Ahn et al., 2004). The protein expression of APS in 3T3-L1 













Indinavir treatment resulted in a significant increase in phosphorylation of IRS-1 at 
serine 307 in both CHO-IR cells and 3T3-L1 adipocytes. Serine phosphorylation of 
IRS-1 is known to inhibit phosphorylation of the insulin receptor. Indinavir may induce 
pro-inflammatory cytokines such as TNF-α or unknown cytokines in the cells, which 
activate IKKβ. IKKβ is a serine kinase that regulates the activation of NFκB, a critical 
activator of genes involved in inflammation and immunity. Prior to activation, NFκB is 
bound to the inhibitor κB (IκB). The activated IKKβ phosphorylates the NFκB-IκB 
complex, which stimulates conjugation of IκB with ubiquitin and the subsequent 
degradation of IκB protein in the proteasome, leading to the nuclear translocation of 
NFκB (Tergaonkar, 2006). Activation of IKKβ also induces serine phosphorylation of 
IRS-1, as IRS-1 is a substrate of IKKβ. This phosphorylation blocks interactions with 
the insulin receptor β-subunit, decreases tyrosine phosphorylation, and inhibits 
insulin action in the cells (Aguirre et al., 2002; Gao et al., 2003). 
High doses of salicylate (4 to 10 g per day), including sodium salicylate and aspirin, 
are known to reduce blood glucose concentrations in diabetic patients via inhibition of 
NFκB and its upstream activator IKKβ (Yuan et al., 2001). In this study, sodium 
salicylate was used for the first time in the context of cells treated with protease 
inhibitors. In CHO-IR cells treated with protease inhibitors, the present findings 
revealed that salicylate inhibits the effects of indinavir on insulin receptor tyrosine 
phosphorylation, even at 100 µM concentration of indinavir, which was the 
concentration used to obtain the maximal effect of the drug on insulin receptor 
tyrosine phosphorylation. A significant increase of insulin-stimulated tyrosine 
phosphorylation of insulin receptor β-subunit in cells pre-treated with sodium 
salicylate (prior to treatment with protease inhibitor) was observed, and this is 
consistent with the known effects of sodium salicylate on the activation of IKKβ. 
Sodium salicylate also increased tyrosine phosphorylation of IRS-1 slightly, and 
decreased serine phosphorylation of IRS-1 twofold. This was associated with a 
decreased inhibition of tyrosine phosphorylation in response to indinavir i.e. a 
blockade of the effects of indinavir. Based on these results, the hypothesis of this 
study was that protease inhibitors may induce insulin resistance via the NFκB 
pathway. 
3.5 Conclusion 
The protease inhibitors saquinavir and indinavir inhibited insulin-stimulated tyrosine 
phosphorylation of the insulin receptor β-subunit in CHO-IR cells and 3T3-L1 












salicylate may abrogate the effect of indinavir on tyrosine phosphorylation of the 
insulin receptor β-subunit, by decreasing phosphorylation of IRS-1 at serine 307.  
Therefore, in conclusion from these studies, HIV protease inhibitors appear to inhibit 
insulin receptor tyrosine phosphorylation indirectly via the NFκB pathway as a 
secondary effect involving a regulator of tyrosine phosphorylation, i.e. the level of 
phosphorylation of IRS-1 at serine 307. Salicylates may therefore provide a novel 
therapy for HIV protease inhibitor-induced insulin resistance and lipodystrophy. In 
addition, it was found that the other regulatory proteins investigated (PTP1B, SOCS-
1 and -3, SH2B1 and APS) in the insulin signalling pathway were not altered after 
indinavir treatment, indicating that changes in the expression of these proteins are 






























CHAPTER 4: METABOLOMIC ANALYSIS OF CELL CULTURE SUPERNATANTS 
FROM 3T3-L1 ADIPOCYTES TREATED WITH HIV PROTEASE INHIBITORS 
4.1 Introduction 
Metabolism is an essential process for all organisms. It is necessary for the 
acquisition and utilisation of free energy for carrying out various functions in the 
biological system of an organism using specific metabolic pathways. Metabolic 
pathways are a series of consecutive enzymatic reactions that produce specific 
products or metabolites, including amino acids, organic acids and free fatty acids 
(FFA). A metabolite is a small molecule that is one of the ultimate products of gene, 
mRNA, and protein activity. Metabolites may be synthesised from either a catabolic 
(degradation) or an anabolic (biosynthesis) pathway (Arakaki et al., 2008). 
Metabolomics is the study of metabolites (their characterisation, identification, and 
quantification) in a wide range of biochemical processes in living systems. It is 
beginning to emerge as a powerful tool for understanding the metabolic state of an 
organism (Arakaki et al., 2008; Koulman et al., 2009; Oresic, 2009). 
Adipose tissue functions as a fat storage depot. It also plays a pivotal role as an 
endocrine organ that regulates and maintains not only the tissue itself, but whole-
body metabolism, at the physiological level (Lee et al., 2009). Any dysfunctional 
alterations in metabolism in adipocytes may induce various side effects, such as 
insulin resistance and lipodystrophy. Insulin resistance may lead to type 2 diabetes. 
Thus, secreted metabolites from adipocytes act as biomarkers in indicating the 
metabolic state of adipocytes and potential disease conditions (Arakaki et al., 2008; 
Fonseca-Alaniz et al., 2007). 
Protease inhibitors have been reported to impair insulin-regulated metabolism in 
adipose tissue, resulting in metabolic abnormalities such as insulin resistance and 
lipodystrophy (Gougeon et al., 2004). Previous studies have shown that protease 
inhibitors induce insulin resistance by inhibiting insulin-regulated GLUT4 
translocation and glucose uptake (Murata et al., 2000; Rudich et al., 2001). Protease 
inhibitors have also been reported to inhibit lipogenesis, by impairing maturation of 
the sterol regulatory element-binding protein-1 (SREBP-1) and simultaneously 
inducing lipolysis in adipocytes (Carr, 2003; Lenhard et al., 2000). However, the 
precise molecular process by which protease inhibitors cause these effects is not 












In addition, protease inhibitor-treated patients with insulin resistance and 
lipodystrophy show increased FFA flux (Meininger et al., 2002). Since 40 years ago, 
FFAs (aka non-esterified fatty acids) have been known to play a role in glucose 
uptake (Randle et al., 1963). Increased FFA concentrations have been shown to lead 
directly to serine/threonine phosphorylation of IRS-1 and -2, thus reducing the ability 
of the IRS to activate PI3-K and GLUT4, and inducing insulin resistance (Lee et al., 
2009; Meininger et al., 2002). Moreover, increased FFA levels have a similar role to 
TNF-α. Both activate inflammatory pathways such as c-Jun NH2-terminal kinase 
(JNK) and IKKβ, which have been shown to inhibit insulin signalling in rodents (Lee 
et al., 2009). However, FFA levels in 3T3-L1 adipocytes treated with protease 
inhibitors have not been investigated.   
Previous studies (Carr, 2003; Garg, 2006; Lee et al., 2009; Meininger et al., 2002; 
Murata et al., 2000; Rudich et al., 2001) indicate that protease inhibitors interfere in 
the metabolism of adipose tissue at multiple levels, thereby inducing various side-
effects. We wanted to investigate the effects of antiretroviral protease inhibitors on 
adipocyte metabolism. Therefore, in this study, a metabolomic approach was used 
for the first time to investigate the effects of a protease inhibitor (indinavir) on 3T3-L1 
adipocytes. This was performed in an attempt to clarify some of the side-effects on 
adipose tissue. Specifically, amino acid and organic acid metabolism in 3T3-L1 
adipocytes was investigated by analysis of cell culture supernatants, using gas 
chromatography mass spectrometry (GC-MS). FFA levels in the supernatants of cells 
treated with the protease inhibitor were also analysed. 
4.2 Methods 
4.2.1 Sample preparation 
3T3-L1 pre-adipocyte fibroblasts were cultured using standard techniques, and 
differentiated as described in section 2.2.1 (Wilcox et al., 2004). Following 
differentiation, the cells were serum-starved for 16 h and stimulated with either or 
both of indinavir (50 µM) for 16 h and insulin (10 ng/ml) (1.7 nM) for 5 min. The four 
cell culture supernatants (i.e. untreated and treated with indinavir in a serum-free 
medium, with or without insulin stimulation) were harvested and stored at -80 °C for 
amino acid, organic acid and FFA analyses. Basal culture medium (serum-free 
medium) was used as a control, to compare the differences in the levels of amino 
acids, organic acids and FFAs in the untreated and treated cell culture supernatants, 
followed by insulin stimulation. For FFA analysis, 3T3-L1 adipocytes were also 












The two cell culture supernatants (i.e. untreated, and treated with indinavir in Medium 
4) were harvested and stored as above. Basal culture medium (adipocyte 
maintenance medium, viz. Medium 4) was used as a control in order to gauge the 
differences in the levels of FFAs in the untreated and treated cell culture 
supernatants. 
4.2.2 GC-MS analysis 
GC-MS analysis was perfomed at Red Cross Children’s Hospital, Rondebosch, 
South Africa. 
4.2.2.1 Amino acid analysis 
Amino acids were analysed in 100 µl of untreated and indinavir-treated cell culture 
supernatants, with or without insulin stimulation, using GC-MS on an Agilent 
7890A/5975C system (Agilent Technologies, CA, USA). The GC-MS detects amino 
acids at a minimum of 0.5 to 2 µM. Samples were prepared for analysis using a 
Phenomenex EZ-faast™ GC-MS kit (Phenomenex, CA, USA) (for cation exchange, 
extraction and derivation) to form a carbonyl hydrocarbon with the amino groups, and 
hydrocarbon esters with the carboxyl groups of amino acids. Amino acids in the basal 
culture medium were quantified as a control. After GC-MS analysis, the data were 
processed by Chemstation™ (Agilent Technologies, CA, USA) software. Amino acids 
were quantified using the nor-valine internal standard, and standard curves were 
generated from the kit calibrators. Amino acid concentrations in the cell culture 
supernatants were normalised to the total amount of cellular protein, assayed by 
protein assay, in each culture flask, as detailed in section 2.2.4.   
4.2.2.2 Organic acid analysis 
200 to 500 µl of cell culture supernatants (untreated and indinavir-treated, and then 
subjected to insulin stimulation) was analysed using GC-MS, to quantify organic 
acids. Organic acids in the basal culture medium were quantified as a control. The 
GC-MS detects organic acids at a minimum of 0.5 to 1 nM, to provide a detectable 
peak area to quantify. Organic acids are hydrocarbon carboxylic acids that are easily 
extracted from an aqueous medium by acidification and solvent extraction, using two 
different solvents (ethylacetate and diethyl-ether). Prior to extraction, a 
pentadecanoate (PDA) internal standard was added to each sample. The extracted 
acids were volatised by reaction with bis-(trimethylsilyl)trifluoroacetamide (BSTFA) to 












7890A/5975C system, and the chromatogram was analysed qualitatively and semi-
quantitatively. Initial analysis identified the chromatogram using Chemstation™ 
software. Then, semi-quantitation was performed by comparing the ratio of integrated 
peak areas of individual compounds to the internal standard between samples. 
Standardisation of the semi-quantitative analysis was done by correcting the amount 
of PDA internal standard to the total amount of cellular protein present in each flask.  
 
4.2.3 MetaboAnalyst web server 
Metabolomic analysis of the data was performed using the MetaboAnalyst web 
server (http://metaboanalyst.ca) (Xia et al., 2009). This web server was developed 
using Java Server Faces, and its operation is based on microarray analysis. Briefly, 
the process is divided into six steps: data upload, processing, normalisation, 
statistical analysis, annotation and final report. 
4.2.3.1 Data upload 
Data were converted to CSV (comma separated values) format before being loaded 
onto the web server, accessed through http://metaboanalyst.ca. A data integrity 
check was performed automatically, and the data details were reported for the next 
steps. 
4.2.3.2 Normalisation 
There are two normalisation procedures in the web server process. Row-wise 
normalisation was performed to normalise each concentration of amino acid or peak 
area of organic acid in cell culture supernatants (untreated and treated with indinavir, 
with or without insulin stimulation) from three to five independent experiments (a row) 
to ensure they are comparable to each other. In this study, amino acids were 
normalised according to protein concentration in each sample, and organic acids 
were normalised according to protein concentration and PDA internal standard in 
each sample.  
Column-wise normalisation (in the form of log normalisation) was performed to 
render all amino acids or organic acids (a column) in the untreated and drug-treated 
cell culture supernatants more comparable in magnitude to each other. 
Statistical analysis was performed on the data to identify the most significantly 
different amino acids and organic acids in all cell culture supernatants (untreated or 












included volcano plot, partial-least squares discriminant analysis (PLS-DA) and 
significance analysis of microarrays (and metabolites) (SAM).  
4.2.3.3 Volcano plot analysis 
The volcano plot is a simple statistical analysis that is used initially to obtain an 
overview of the data before applying more sophisticated data analysis tools. It 
examines each variable separately without including the effect of multiple 
comparisons. This statistical analysis is used to compare the size of the fold change 
(FC) to the p-value from the Student’s t-test. Fold change is a comparison of absolute 
value changes between mean concentrations of amino acids or peak areas of 
organic acids in untreated cell culture supernatants versus those treated with 
indinavir, with or without insulin stimulation. The Student’s t-test was conducted to 
detect whether the concentrations of amino acids or peak areas of organic acids are 
significantly different between the untreated and drug-treated cell culture 
supernatants. The threshold of FC is 1.8 and the significance level (threshold) of the 
t-test is 90% (α = 0.1). These values are suitable for the number of the samples in 
the study. The further away the amino acid position is (>75 %) from the origin (0.0) of 
the graph and the thresholds, the more significant is the change in the level of amino 
acid or organic acid in the untreated and drug-treated cell culture supernatants. 
4.2.3.4 PLS-DA analysis 
PLS-DA is a supervised method that can perform both classification and feature 
selection. The classification selection is a selection of amino acids or organic acids 
classified according to their samples or group, i.e. cell culture supernatants 
(untreated/treated with indinavir, followed by insulin stimulation). The feature 
selection is a selection of individual amino acids or organic acids in both the 
untreated and drug-treated cell culture supernatants, with or without insulin 
stimulation. This method uses a multiple linear regression technique to find the 
direction of maximum covariance between the individual amino acids or organic acids 
and the untreated and treated cell culture supernatants, with or without insulin 
stimulation.  
There are two variable importance measures in PSL-DA: variable importance in 
projection (VIP) and the coefficient-based importance measure (CIM). VIP is a 
weighted sum of the squares of the PLS loadings. The weights are based on the 












or the peak area of organic acids in each dimension, being the untreated and drug-
treated cell culture supernatants.  
CIM is based on the weighted sum of PLS-regression coefficients; i.e. the regression 
coefficient in concentration of amino acids or the peak area of organic acids, which is 
a function of the reduction of the sums of the squares across the full number of PLS 
components, being the total number of amino acids and organic acids in the 
untreated and drug-treated cell culture supernatants.  
The VIP scores tend to be 200 times larger than the CIM scores, but the relative 
ranking of significant metabolites is largely the same. After the VIP and CIM 
measurements, the identified amino acids and organic acids were used for further 
data analysis. 
4.2.3.5 SAM analysis 
SAM is designed to address False Discovery Rate (FDR) problems or errors when 
performing multiple tests on high-dimensional data. Firstly, it assigns a significance 
score to each variable of the amino acids or organic acids in cell culture supernatants 
(untreated/treated with indinavir, followed by insulin stimulation) based on its d-value, 
i.e. its change relative to the standard deviation of repeated measurements. Then, it 
chooses variables of amino acids and organic acids in the cell culture supernatants 
with scores below the lower (cutlow) threshold or greater than the upper (cutup) 
threshold and compares their relative difference to the distribution estimated by 
random permutations of the class labels (‘observed=expected’ line). For each 
threshold, a certain proportion of the variables in the permutation set will be found to 
be significant by chance. This number is used to calculate the FDR in the amino acid 
and organic acid analysis.  
In order to control the FDR, the Delta value or threshold of false positive in the 
validated dataset has been specified as 0.1 in the analysis. The Delta value (0.1) has 
an FDR of 12 % and identifies approximately 10 significant compounds above the 
adjustable threshold. It is a compromise between the FDR and the number of amino 
acids and organic acids detected. The Delta value in SAM analysis is showed as 
lower and upper thresholds (cutlow and cutup) in order to measure the most 













The cutlow is a lower or negative threshold where the significantly different amino 
acids or organic acids were measured, i.e. the mean concentration of amino acids or 
peak area of organic acids in ‘untreated higher than those in treated’ (negative) cell 
culture supernatants (untreated/treated with indinavir, followed by insulin 
stimulation). The cutup is an upper or positive threshold at which the significantly 
different amino acids or organic acids were measured, i.e. the mean concentration of 
amino acids (or peak area of organic acids) in the ‘treated higher than those in 
untreated’ (positive) cell culture supernatants. The lowest or greatest score of amino 
acid (or organic acid) from the thresholds (cutlow and cutup) indicates the most 
significantly different levels of amino acids (or organic acids) in the untreated-versus-
treated cell culture supernatants.  
In addition, the most significantly different amino acids (or organic acids) in the 
samples were also based on the lowest p-value (rawp), which was calculated 
automatically in the analysis. In this way, SAM is able to perform permutation testing 
which is not done in the t-test. The results of the SAM analysis are presented in the 
SAM graph and SAM results table for each of the significant compounds. 
The amino acids and organic acids from the above analysis that showed the most 
significant changes between untreated and indinavir-treated cell culture supernatants 
(followed by insulin stimulation) were further analysed to investigate whether the 
amino acids or organic acids were synthesised or utilised compared with the basal 
culture medium (control).  
The final reports are available to download in PDF format from the web server. 
4.2.4 Free fatty acid (FFA) analysis 
Levels of free fatty acids in untreated and indinavir-treated cell culture supernatants 
kept in a serum-free medium for 16 h (and then insulin-stimulated) were measured 
using a Free Fatty Acids Half-Micro Test Kit (Roche, Penzberg, Germany). The same 
analysis was performed on untreated and indinavir-treated cell culture supernatants 
in Medium 4 for 16 h, and on the basal culture media (serum-free medium and 
Medium 4) as controls.  
This kit allows a small volume (20 µl) of sample to be assayed readily. 20 µl of the 
cell culture supernatants and the basal culture medium was added to 400 µl 
potassium phosphate buffer, pH 7.8, containing adenosine triphosphate, coenzyme 












aminoantipyrine. 20 µl of N-ethyl-maleimide solution was added. Blanks with 
deionised water and controls with 0.35 mM palmitic acid were prepared in the same 
way. The absorbance without enzyme was first measured using a spectrophotometer 
(Beckman Coulter, Cape Town, South Africa) at 546 nm. Subsequently, 20 µl of 
enzyme acyl-CoA-oxidase was added to the mixture (final volume 460 μl) and 
incubated for 15 min at room temperature before the second reading was taken.  
The concentration of FFA in the untreated and indinavir-treated cell culture 
supernatants in the serum-free medium, Medium 4 and the basal culture media 
(serum-free medium and Medium 4) was measured after subtracting the absorbance 






V  = final volume (460 µl) 
v  = sample volume (20 µl) 
d  = light path (1 cm) 
ε  = absorbance coefficient of the dye at 546 nm: 19.3 (1 x mM-1 x cm-1) 
∆A = absorbance of sample after subtraction from the blank 
 
The kit uses Acyl CS and acyl-CoA-oxidase to convert FFA into enoyl-CoA and 
hydrogen peroxide. The hydrogen peroxide oxidises 4-amino-antipyrine, forming a 
red dye that absorbs at 546 nm. This method shows linearity up to a concentration of 
1.5 mM.  
4.3 Results  
Initially, the concentrations of amino acids and the peak areas under the curves of 
organic acids in untreated and indinavir-treated cell culture supernatants (followed by 
insulin stimulation) were compared to those in the basal culture medium (control). 





Concentration (mM/l) =        V       x ∆A 













4.3.1 Amino acid analysis 
A total of 27 amino acids and derivatives were detected in untreated and indinavir-
treated cell culture supernatants (followed by insulin stimulation), and in the basal 
culture medium (control). There were significant increases in the levels of four amino 
acids in the untreated supernatants and none in the drug-treated supernatants 
(without insulin stimulation) compared to the control (Figure 4.1). With insulin 
stimulation, there were significant increases in the levels of 19 amino acids in the 
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Figure 4.1: Amino acid analysis of untreated (    ) and drug-treated (     ) without insulin stimulation, and untreated (     ) and drug-treated (    ) with insulin-
stimulation of cell culture supernatants compared to the basal culture medium (control). (a) Concentration of amino acids 1-12: 0-4000 µmol/mg. (b) Concentration of 
amino acids 13-27: 0-4 x 105 µmol/mg. 3T3-L1 adipocytes were treated with indinavir (50 µM) for 16 h, followed by insulin stimulation. Cell culture supernatants were harvested 
for amino acid analysis using GC-MS. Concentrations of amino acids and derivatives in the untreated and treated cell culture supernatants were subtracted from those in the 
basal culture medium. Amino acid analysis is from three to five independent experiments. Data are shown as the mean and S.E.M. (n=3 to 5). *p < 0.05, using two-tailed 
Student’s t-test, untreated or treated cell culture supernatants versus basal culture medium. 1= Alpha-amino-butyrate, 2 = Beta-amino-isobutyrate, 3 = Asparagine, 4 = 
Aspartate, 5 = Cystathionine, 6 = Glutamate, 7 = OH-Proline, 8 = Hydroxylysine, 9 = Ornithine, 10 = Proline, 11 = Thioproline, 12 = Beta-alanine, 13 = Alanine, 14 = Cystine, 15 
= Glutamine, 16 = Glycine, 17 = Histidine, 18 = Isoleucine, 19 = Leucine, 20 = Lysine, 21 = Methionine, 22 = Phenylalanine, 23 = Serine, 24 = Threonine, 25 =  Tryptophan, 26 
= Tyrosine, 27 = Valine.  
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The MetaboAnalyst web server revealed two peaks (bimodal distribution) of amino 
acids revealed by normalisation, with or without stimulation with insulin (Figure 4.2, 




Figure 4.2: Box plots and kernel density plots of amino acids in the untreated and drug-treated 
cell culture supernatants (a) without and (b) with insulin stimulation after normalisation. 27 amino 
acids and derivatives were identified in supernatants of 3T3-L1 adipocytes before and after treatment 













These data indicate that there were two separate groups of amino acids, based on 
their relative abundance. In addition, at a glance, amino acids in the untreated and 
indinavir-treated supernatants without insulin stimulation showed no difference 
compared to those with insulin stimulation. Thus, statistical analyses using volcano 
plot, PLS-DA and SAM were performed to measure the most significantly different 
levels of amino acids between the two groups, with or without insulin stimulation. 
In the first analysis, statistical differences in amino acids in untreated and indinavir-
treated supernatants of 3T3-L1 adipocytes (followed by insulin stimulation) were 
analysed using a volcano plot. No significantly different amino acids in the untreated 
versus indinavir-treated cell culture supernatants with or without insulin stimulation 
were identified (see Figure 4.3). All 27 amino acids were < 75 % from the origin (0.0) 
of the graph.  
 
 
Figure 4.3: Volcano plot analysis of amino acids in the untreated and drug-treated cell culture 
supernatants a) without and b) with insulin stimulation. No significantly different amino acids in 
untreated cell culture supernatants versus those treated with indinavir (50 µM) for 16 h (followed by 
insulin stimulation) were identified in this plot. Circles represent 27 amino acids identified in the amino 
acid analysis using GC-MS. Both fold change and p-value were log-transformed to plot the amino acids 
in a symmetrical way. FC = fold change, p = p-value of Student’s t-test. 
 
In the PLS-DA analysis, VIP and CIM measurements were used to analyse the most 
significantly different amino acids between the untreated and drug-treated cell culture 
supernatants. In the cell culture supernatants tested without insulin stimulation, 
based on VIP (Figure 4.4(a)) and CIM (Figure 4.5(a)) measurements, glutamate, 
aspartate and hydroxylysine were the amino acids ranked as having the most 
significantly different levels between the two groups. For these amino acids, the VIP 
and CIM measurements were > 1.2 and 0.006, respectively.  












According to VIP measurement, beta-amino-isobutyrate, hydroxylysine, thioproline 
and glutamate were ranked as the amino acids having the most significantly different 
levels between the two groups with insulin stimulation (Figure 4.4(b)). For these 
amino acids, the VIP measurements were > 1.5. Using the CIM measurement, 
hydroxylysine and thioproline were ranked as the amino acids with the most 
significantly different levels between the untreated and treated cell culture 




Figure 4.4: Partial-least squares discriminant analysis of amino acids in the untreated and drug-
treated cell culture supernatants a) without and b) with insulin stimulation according to VIP 
















                              
Figure 4.5: Partial-least squares discriminant analysis of amino acids in the untreated and drug-
treated cell culture supernatants a) without and b) with insulin stimulation according to CIM 
(coefficient-based importance measure) score.  
 
In the final analysis, the differences in amino acids in untreated cell culture 
supernatants and those treated with indinavir (followed by insulin stimulation) were 
analysed using SAM analysis. Using a Delta value of 0.1, in the cell culture 
supernatants analysed without the insulin stimulation, the cutup was 0.574, while the 
cutlow of the graph was infinity (Figure 4.6). In total, there were significant 
differences in the levels of 14 amino acids in the drug-treated versus untreated 
supernatants located above the cutup threshold. Data from Table 4.1 indicated that 
aspartate had the greatest d-value (0.880) at the threshold, and the lowest p-value 













significantly different level in the untreated versus drug-treated cell culture 
supernatants without insulin stimulation. 
 
Figure 4.6: Significance analysis of microarrays (and metabolites) (SAM) of amino acids in the 
untreated and drug-treated cell culture supernatants without insulin stimulation. 27 amino acids 
in untreated cell culture supernatants versus those treated with indinavir (50 µM) for 16 h at the basal 
level were plotted on the graph based on the d-value (Table 4.1). The green circles represent significant 
differences in the levels of 14 amino acids (see Table 4.1) between the two groups (i.e. the levels of the 
amino acids were increased). FDR = false discovery rate.  
 
Table 4.1: Significantly different amino acids in the untreated and drug-treated cell culture 
supernatants without insulin stimulation identified by SAM (from Figure 4.6). d-value = a ‘score’, 
i.e. concentration of amino acids which is changed relative to the standard deviation (stdev) of repeated 
measurements, stdev = standard deviation, rawp = raw p-value from Student’s t-test. 
 
In the cell culture supernatants analysed with insulin stimulation, the cutup was 
infinity, while the cutlow of the graph was -0.517 (Figure 4.7). In total, there were 
significant differences in the levels of 16 amino acids in indinavir-treated versus 
Amino acids d-value stdev rawp Relative 
fold-effect 
Changes 
1. Aspartate 0.880 1.027 0.426 1.871  Increase 
2. Histidine 0.682 1.175 0.481 1.743 Increase 
3. Ornithine 0.667 1.059 0.493 1.632 Increase 
4. Serine 0.661 1.200 0.504 1.733 Increase 
5. Lysine 0.645 1.196 0.519 1.707 Increase 
6. Glutamate 0.638 1.461 0.522 1.909 Increase 
7. Leucine 0.625 1.136 0.533 1.635 Increase 
8. Alpha-amino-butyrate 0.609 1.207 0.556 1.665 Increase 
9. Isoleucine 0.607 1.124 0.563 1.605 Increase 
10. Tyrosine 0.597 1.188 0.570 1.634 Increase 
11. Threonine 0.583 1.178 0.581 1.609 Increase 
12. Glutamine 0.576 1.215 0.593 1.625 Increase 
13. Hydroxylysine 0.574 1.479 0.596 1.802 Increase 
14. Valine 0.574 1.149 0.600 1.580 Increase 
 
Cutlow = infinity 
Cutup = 0.574 
Significant = 14 















untreated supernatants located below the cutlow threshold. Data from Table 4.2 
indicate that hydroxylysine had the greatest d-value (-1.454) at the threshold, with the 
lowest p-value (rawp) of 0.185. Thus, hydroxylysine was identified as the amino acid 
having the most significantly different levels in the untreated versus drug-treated cell 
culture supernatants with insulin stimulation. 
 
Figure 4.7: Significance analysis of microarrays (and metabolites) (SAM) of amino acids in the 
untreated and drug-treated cell culture supernatants with insulin stimulation. 27 amino acids in 
untreated cell culture supernatants versus those treated with indinavir (50 µM) for 16 h (followed by 
insulin stimulation) were plotted on the graph based on the d-value (Table 4.2). The green circles 
represent significant differences in the levels of 16 amino acids (see Table 4.2) between the two groups 
(i.e. the levels of the amino acids were decreased). FDR = false discovery rate.   
Table 4.2: Significantly different amino acids in the untreated and drug-treated cell culture 
supernatants with insulin stimulation identified by SAM (from Figure 4.7). d-value = a score i.e. 
concentration of amino acid which is changed relative to the standard deviation (stdev) of repeated 
measurements, stdev = standard deviation, rawp = raw p-value from Student’s t-test. 
Amino acids d-value stdev rawp Relative 
fold-effect 
Changes 
1. Hydroxylysine -1.454 0.662 0.185 0.513 Decrease 
2. Proline -1.365 0.378 0.227 0.699 Decrease 
3. Beta-amino-isobutyrate -1.288 0.811 0.258 0.485 Decrease 
4. Tryptophan  -1.023 0.497 0.344 0.703 Decrease 
5.  Beta-alanine -0.995 0.307 0.355 0.809 Decrease 
6.  Hydroxyproline -0.841 0.661 0.404 0.680 Decrease 
7.  Glycine -0.830 0.413 0.408 0.789 Decrease 
8. Phenylalanine -0.795 0.486 0.418 0.765 Decrease 
9. Tyrosine -0.733 0.484 0.456 0.782 Decrease 
10. Methionine -0.713 0.428 0.468 0.81 Decrease 
11. Histidine -0.700 0.486 0.477 0.790 Decrease 
12. Cystathionine -0.696 0.816 0.479 0.674 Decrease 
13. Cysteine -0.562 0.449 0.577 0.839 Decrease 
14. Ornithine -0.548 0.619 0.590 0.791 Decrease 
15. Alpha-amino-butyrate -0.520 0.554 0.618 0.819 Decrease 
16. Leucine -0.517 0.494 0.620 0.838 Decrease 
 
Cutlow = -0.517  
Cutup = infinity 
Significant = 16 















Without insulin stimulation, aspartate was noted to be significantly increased (i.e. 
synthesised more) in untreated cell culture supernatants, compared to the basal 
culture medium (control) (Figure 4.1). Results from PLS-DA and SAM analyses 
indicated that aspartate was the amino acid having the most significantly different 
level between the untreated versus indinavir-treated cell culture supernatants. In 
particular, in this study, synthesis of aspartate was found to be significantly increased 































Figure 4.8: Synthesis of aspartate in the drug-treated cell culture supernatants without insulin 
stimulation based on PLS-DA and SAM analyses. 3T3-L1 adipocytes were untreated (    ) and 
treated (    ) with indinavir (50 µM) for 16 h at the basal level. Cell culture supernatants were harvested 
for amino acid analysis using GC-MS. Basal (    ) culture medium was used as a control. Data are 
shown as the mean ± S.E.M. (n=3). *p < 0.05 versus basal culture medium (control). 
 
With insulin stimulation, hydroxylysine was established to be significantly increased 
(i.e. synthesised more) in cell culture supernatants treated with indinavir, compared 
to the basal culture medium (control) (Figure 4.1). Results from PLS-DA and SAM 
analyses indicated that hydroxylysine was the amino acid having the most 
significantly different level between the drug-treated versus untreated cell culture 
supernatants. In particular, in this study, synthesis of hydroxylysine was found to be 
significantly decreased in the drug-treated versus untreated cell culture supernatants 


















































Figure 4.9: Synthesis of hydroxylysine in the drug-treated cell culture supernatants with insulin 
stimulation based on PLS-DA and SAM analyses. 3T3-L1 adipocytes were treated (    ) with indinavir 
(50 µM) or untreated (     ) for 16 h, followed by insulin stimulation. Cell culture supernatants were 
harvested for amino acid analysis using GC-MS. Basal (     ) culture medium was used as a control. 
Data are shown as the mean ± S.E.M. (n=5). p < 0.05 versus basal culture medium (control). 
 
4.3.2 Organic acid analysis 
A total of 60 organic acids and derivatives were identified in untreated cell culture 
supernatants and those treated with indinavir (followed by insulin stimulation), and in 
the basal culture medium (control). There were significant increases in the levels of 
10 organic acids in the untreated supernatants (and of eight in the drug-treated 
supernatants) without insulin stimulation, compared to the control (Figure 4.10). With 
insulin stimulation, there were significant increases in the levels of 14 organic acids in 
the untreated supernatants (and 12 in the treated supernatants) compared to the 


































See detail on pages 74 and 75. 


















































































































Figure 4.10: Organic acid analysis of untreated (     ) and drug-treated (     ) without insulin stimulation, and untreated (     ) and drug-treated (     ) with insulin 
stimulation of cell culture supernatants compared to the basal culture medium (control). (a) Concentration of organic acids 1-18: 0-20 pear area (ratio). (b) 
Concentration of organic acids 19-38:  -20 - 60 peak area (ratio). (c) Concentration of organic acids 39-50: 0-200 peak area (ratio). (d) Concentration of organic acids 51-60: 0 - 
1200 peak area (ratio). 3T3-L1 adipocytes were treated with indinavir (50 µM) for 16 h followed by insulin stimulation. Cell culture supernatants were harvested for organic acid 
analysis using GC-MS. Peak areas of organic acids and derivatives in the untreated and treated cell culture supernatants were subtracted from those in the basal culture 
medium. Organic acid analysis is from five independent experiments. Data are shown as the mean and S.E.M. (n=5). *p < 0.05, using two-tailed Student’s t-test, untreated or 
treated cell culture supernatants versus basal culture medium. For details of organic acids (1-60), please see Table 4.3. 
    


























Table 4.3: Organic acids identified in the drug-treated or untreated cell culture supernatants 
using GC-MS. 3T3-L1 adipocytes were left untreated or treated with indinavir (50 µM) for 16 h, followed 
by insulin stimulation. 
No. Organic acids No. Organic acids 
1 Azelaic acid 31 Nonanoic acid 
2 N-phenylacetylglycine 32 2-deoxytetronate 
3 Myristate  33 (R*,S*)-3,4-dihydroxybutanoic acid  
4 Pantothenic acid 34 2-methyl-1,3-bis(trimethylsilyloxy)butane 
5 Palmitelaidic acid 35 L-proline 




8 Benzoic acid  38 Dodecanoic acid 
9 Pentasiloxane,dodecamethyl 39 1,2,3-propanetricarboxylic acid 
10 2-ethylhydracrylic acid  40 Palmitate  
11 N,O-bis(trismethylsilyl)-L-phenylalanine  41 Sulphate  
12 Homovanillate 42 Isovalerate 
13 Oxacyclotetradec-5-yn 43 Propylene glycol 
14 4-hydroxyphenyllactate  44 Phenyl acetic acid 
15 Oleate  45 Phenylacetylglycine 
16 Oleic acid 46 Citrate  
17 Oleanitrile 47 Stearate 
18 Dehydroabietic acid 48 Hexadecanoic acid 
19 1,2-bis(trimethylsiloxy)ethane 49 Heptadecanoic acid 
20 Acetamide  50 Octadecanoic acid 
21 3-hydroxybutyrate    51 Butanoic acid, 3-(trimethylsiloxy)-
,ethylester     
22 Lactate 52 Trifluoromethyl-bis-
(trimethyl)methylketone 
23 Phosphorous acid  53 Carbamic acid 
24 2-propanedioic acid  54 Benzene 
25 2-ketoisocaproic acid  55 Butane 
26 1-pentanethyldisilyloxybutane 56 Propanoic acid 
27 Glycerol  57 Acetic acid 
28 Butanedioic acid 58 Ethanedioic acid 
29 Succinate 59 Butanoic acid, 4-(trimethylsiloxy)-
,ethylester 
30 Cyclohexasilaxane  60 D-erythro-pentonic acid 
 
In addition, only one organic acid was exclusively identified in indinavir-treated 
supernatants without insulin stimulation, and eight in the drug-treated supernatants 
















Table 4.4: Organic acids that were exclusively identified in cell culture supernatants treated with 
indinavir with or without insulin stimulation using GC-MS. 3T3-L1 adipocytes were left untreated or 
treated with indinavir (50 µM) for 16 h, followed by insulin stimulation. 
Without insulin stimulation With insulin stimulation 
1. Pentanedioicaid 1. 3-hydroxybutyrate 









Two peaks (bimodal distribution) of organic acids emerged after normalisation 
(Figure 4.11(a) and (b)) by the MetaboAnalyst web server.  
These data indicate that there are two separate groups of organic acids, based on 
their relative abundance. In addition, organic acids in the untreated and indinavir-
treated supernatants without insulin stimulation showed changes compared to those 
with insulin stimulation. Thus, statistical analyses using volcano plot, PLS-DA and 
SAM were performed to measure the most significantly different levels of organic 















Figure 4.11: Box plots and kernel density plots of organic acids in the untreated and drug-treated cell 
culture supernatants (a) without and (b) with insulin stimulation after normalisation. 60 organic acids and 
derivatives were identified in supernatants of 3T3-L1 adipocytes before and after treatment with indinavir (50 µM) 
for 16 h, followed by insulin stimulation using GC-MS.  
 
In the first analysis, a volcano plot was used to obtain an overview of statistical differences 
of organic acids in untreated supernatants of 3T3-L1 adipocytes and those treated with 
indinavir (followed by insulin stimulation). 1,2,3-propanetricarboxylic acid (FC = 2.021, p = 
0.078) (Figure 4.12(a)) was shown to be significantly different between the untreated and 













drug-treated supernatants without insulin stimulation. With insulin stimulation, succinate (FC 
= 5.283, p = 0.016), butanoic acid 3-(trimethylsiloxy)-ethylester (FC = 0.221, p = 0.060) and 
isovalerate (FC = 0.026, p = 0.071) were shown to be significantly different between the 
untreated and drug-treated supernatants using the volcano plot analysis (Figure 4.12(b). 
 
 
     
 
Figure 4.12: Volcano plot analysis of organic acids in the untreated and drug-treated cell culture 
supernatants a) without and b) with insulin stimulation. The red circles represent significantly different 
organic acids in untreated cell culture supernatants versus those treated with indinavir (50 µM) for 16 h (followed 
by insulin stimulation) that were identified in this plot. Circles represent 60 organic acids identified in the organic 
acid analysis using GC-MS. Both fold change and p-value were log-transformed to plot the organic acids in a 
symmetrical way. FC = fold change, p = p-value of Student’s t-test.  
 
Subsequently, organic acids were analysed using the PLS-DA analysis. In the case of cell 
culture supernatants without insulin stimulation, based on VIP (Figure 4.13(a)) and CIM 
(Figure 4.14(a)) measurements, carbamic acid and butane were ranked as having the most 
significantly different organic acid levels between the two groups. For these organic acids, 
the VIP and CIM measurements were > 2.0 and 0.02, respectively.  
With insulin stimulation, according to VIP (Figure 4.13(b)) and CIM (Figure 4.14(b)) 
measurements, isovalerate, butanoic acid 3-(trimethylsiloxy)-ethylester and succinate were 
ranked as the most significantly different organic acid levels between the two groups. For 



















   
 
Figure 4.13: Partial-least squares discriminant analysis of organic acids in the untreated and drug-treated 
cell culture supernatants a) without and b) with insulin stimulation according to VIP (variable importance 




















                      
Figure 4.14: Partial-least squares discriminant analysis of organic acids in the untreated and drug-treated 
cell culture supernatants a) without and b) with insulin stimulation according to CIM (coefficient-based 
importance measure) score.  
 
In the final analysis using SAM, there were significant changes in the levels of 15 organic 
acids in untreated cell culture supernatants and those treated with indinavir, without insulin 
stimulation (Figure 4.15 and Table 4.5). Using a Delta value of 0.1, the cutlow was -0.753, 
while the cutup of the graph was infinity (Figure 4.15). Data from Table 4.5 indicate that 
butane, 1,2,3-propanetricarboxylic acid and propanoic acid have the greatest d-value (< -2) 














identified as the organic acids with the most significantly different levels between the 
untreated and drug-treated cell culture supernatants without insulin stimulation. 
 
Figure 4.15: Significance analysis of microarrays (and metabolites) (SAM) of organic acids in the 
untreated and drug-treated cell culture supernatants without insulin stimulation. 60 organic acids in 
untreated cell culture supernatants versus those treated with indinavir (50 µM) for 16 h at the basal level were 
plotted on the graph based on the d-value (Table 4.5). The green circles represent significant differences in the 
levels of 15 organic acids (see Table 4.5) between the two groups (i.e. the levels of the organic acids were 
decreased). FDR = false discovery rate.  
Table 4.5: Significantly different organic acids in the untreated and drug-treated cell culture supernatants 
without insulin stimulation, identified by SAM (from Figure 4.15). d-value = a score i.e. peak area of organic 
acids which is changed relative to the standard deviation (stdev) of repeated measurements, stdev = standard 
deviation, rawp = raw p-value from Student’s t-test. 
Organic acids d-value stdev rawp Relative 
fold-effect 
Changes 
1. Butane -2.516 1.620 0.057 0.059 Decrease 
2. 1,2,3-propanetricarboxylic acid -2.359 0.433 0.067 0.493 Decrease 
3. Propanoic acid -2.073 0.431 0.097 0.538 Decrease 
4. Carbamic acid -2.015 2.934 0.100 0.017 Decrease 
5. Benzene -1.997 1.416 0.103 0.141 Decrease 
6. Pantothenic acid -1.692 1.288 0.200 0.221 Decrease 
7. L-proline -1.523 1.296 0.220 0.255 Decrease 
8. (R*,S*)-3,4-dihydroxybutanoic acid -1.432 0.720 0.237 0.489 Decrease 
9. Butanoic acid, 4-(trimethylsiloxy)-
ethylester 
-1.294 1.694 0.267 0.219 Decrease 
10. Heptadecanoic acid -1.248 0.592 0.273 0.599 Decrease 
11. Butanoic acid, 3-(trimethylsiloxy)-
ethylester 
-1.244 0.476 0.277 0.663 Decrease 
12. Azelaic acid -1.224 1.205 0.287 0.360 Decrease 
13. Octadecanoic acid -1.090 1.874 0.343 0.243 Decrease 
14. Nonanoic acid -0.981 1.252 0.387 0.427 Decrease 
15. 1-pentanethyldisilyloxybutane -0.753 1.911 0.500 0.369 Decrease 
 
Cutlow = -0.753  
Cutup = infinity 
Significant = 15 
















In the cell culture supernatants analysed with insulin stimulation, the cutup was 0.335, while 
the cutlow of the graph was -3.200 (Figure 4.16). In total, there were significant differences 
in the levels of 18 organic acids in the drug-treated versus untreated supernatants (Figure 
4.16 and Table 4.6). Data from Table 4.6 indicate that succinate, isovalerate and butanoic 
acid 3-(trimethylsiloxy)-ethylester had the lowest d-value (>-3.200) at the threshold, with the 
lowest p-value (rawp) of <0.1. Thus, succinate, isovalerate and butanoic acid 3-
(trimethylsiloxy)-ethylester were identified as the organic acids having the most significantly 
different levels in the untreated versus drug-treated cell culture supernatants with insulin 
stimulation.  
 
Figure 4.16: Significance analysis of microarrays (and metabolites) (SAM) of organic acids in the 
untreated and drug-treated cell culture supernatants with insulin stimulation. 60 organic acids in untreated 
cell culture supernatants versus those treated with indinavir (50 µM) for 16 h at the basal level were plotted on 
the graph based on the d-value (Table 4.6). The green circles represent significant differences in the levels of 18 
organic acids (see Table 4.6) between the two groups (i.e. the levels of the organic acids were increased). FDR = 
false discovery rate.  
 
Without insulin stimulation, butane was observed not to be statistically different in indinavir-
treated supernatants versus the basal culture medium (control) (Figure 4.10). Results from 
PLS-DA and SAM analyses indicated that butane was the organic acid with the most 
significantly different levels between the drug-treated versus untreated cell culture 
supernatants. In particular, in this study, synthesis of butane was found to be significantly 
decreased in the drug-treated cell culture supernatants (Figure 4.17). 
 
 
Cutlow = -3.200  
Cutup = 0.335 
Significant = 18 

















Table 4.6: Significantly different organic acids in the untreated and drug-treated cell culture supernatants 
with insulin stimulation identified by SAM (from Figure 4.16). d-value = a score i.e. peak area of organic 
acids, which is changed relative to the standard deviation (stdev) of repeated measurements, stdev = standard 



























Figure 4.17: Synthesis of butane in the drug-treated cell culture supernatants without insulin stimulation 
based on PLS-DA and SAM analyses. 3T3-L1 adipocytes were left untreated (     ) and treated (    ) with 
indinavir (50 µM) for 16 h at the basal level. Cell culture supernatants were harvested for organic acid analysis 
using GC-MS. Basal (     ) culture medium was used as a control. Data are shown as the mean ± S.E.M. (n=3). p 






Organic acids d-value stdev rawp Relative 
fold-effect 
Changes 
1. Succinate -3.200 0.978 0.006 0.114 Decrease 
2. Isovalerate 2.443 1.470 0.022 12.047 Increase 
3. Butanoic acid, 3-(trimethylsiloxy),-ethylester 2.194 1.404 0.035 8.461 Increase 
4. Pentasiloxane, dodecamethyl 1.599 1.049 0.105 3.199 Increase 
5. 2-ethylhydracrylic acid 1.596 0.897 0.12 2.697 Increase 
6. Glycerol 1.591 0.612 0.138 1.963 Increase 
7. D-erythro-pentonic acid 1.057 1.759 0.253 3.628 Increase 
8. 2,4,6(1H,3H,5H)-pyrimidinetrione,5-(1-
methylpopyl) 
1.000 0.662 0.271 1.582 Increase 
9. Oxacyclotetradec-5-yn 1.000 0.609 0.373 1.525 Increase 
10. Trifluoromethyl-bis-(trimethyl)methylketone 1.000 0.526 0.373 1.440 Increase 
11. 4-hydroxyphenyllactate 1.000 0.737 0.470 1.667 Increase 
12. Phosphorous acid 1.000 0.481 0.470 1.396 Increase 
13. 3-hydroxybutyrate 1.000 1.499 0.527 2.826 Increase 
14. Homovanillate 0.909 1.315 0.551 2.290 Increase 
15. Phenyl acetic acid 0.675 0.944 0.639 1.556 Increase 
16. Benzoic acid 0.484 1.108 0.735 1.450 Increase 
17. Pyroglutamate 0.362 0.669 0.792 1.183 Increase 


















With insulin stimulation, butanoic acid 3-(trimethylsiloxy)-ethylester was revealed to be 
significantly increased (i.e. synthesised more) in cell culture supernatants treated with 
indinavir, followed by insulin stimulation, versus the basal culture medium (control) (Figure 
4.10). Based on volcano plot, PLS-DA and SAM analyses, butanoic acid 3-(trimethylsiloxy)-
ethylester was identified as among the most significantly different organic acids between 
untreated cell culture supernatants versus those treated with indinavir, followed by insulin 
stimulation. In particular, synthesis of butanoic acid 3-(trimethylsiloxy)-ethylester was 



























Figure 4.18: Synthesis of butanoic acid 3-(trimethylsiloxy)-ethylester in the drug-treated cell culture 
supernatants with insulin stimulation, based on PLS-DA and SAM analyses. 3T3-L1 adipocytes were left 
untreated (     ) or treated (     ) with indinavir (50 µM) for 16 h with or without insulin stimulation. Cell culture 
supernatants were harvested for organic acid analysis using GC-MS. Basal (      ) culture medium was used as a 
control. Data are shown as the mean ± S.E.M. (n=5). p < 0.05 versus basal culture medium (control). 
 
 
Levels of succinate were not statistically different in untreated cell culture supernatants or 
those treated with indinavir (followed by insulin stimulation) versus the basal culture medium 
(control) (Figure 4.10). However, in the context of biology, the difference in succinate may be 
significant between the groups and the control. Volcano plot, PLS-DA and SAM analyses 
indicated that succinate was among the organic acids with most significantly different levels 
between untreated cell culture supernatants versus those treated with indinavir, followed by 
insulin stimulation. In particular, synthesis of succinate was significantly reduced in the drug-

















Isovalerate was identified as exclusively significant, i.e. synthesised only in cell culture 
supernatants treated with indinavir, followed by insulin stimulation, using volcano plot, PLS-
























Figure 4.19: Synthesis of succinate in the drug-treated cell culture supernatants (with insulin stimulation) 
based on PLS-DA and SAM analyses. 3T3-L1 adipocytes were left untreated (     ) and treated (     ) with 
indinavir (50 µM) for 16 h followed by insulin stimulation. Cell culture supernatants were harvested for organic 
acid analysis using GC-MS. Basal (      ) culture medium was used as a control. Data are shown as the mean ± 
S.E.M. (n=5). p < 0.05 versus untreated cell culture supernatants. 
 
4.3.3 Free fatty acid analysis 
FFA analysis was performed in untreated cell culture supernatants and those treated with 
indinavir for 16 h in a serum-free medium followed by insulin stimulation, and in Medium 4, 
using the Free Fatty Acids Half-Micro Test Kit. Results from the analysis indicate that there 
were no differences in the levels of FFAs in the untreated and drug-treated cell culture 
supernatants in the serum-free medium without (Figure 4.20(a)) and with (Figure 4.20(b)) 





















































Figure 4.20: FFA analysis using the Free Fatty Acids Half-Micro Test Kit (Roche). 3T3-L1 adipocytes were 
serum-starved and treated with indinavir (50 µM) (      ) or left untreated (     ) for 16 h without (a) and with (b) 





















There was a significant decrease (p = 0.02) in the levels of FFAs in Medium 4 exposed to 
cells when compared to basal cell culture. However, this significant decrease in the levels of 





























Figure 4.21: FFA analysis using the Free Fatty Acids Half-Micro Test Kit (Roche). 3T3-L1 adipocytes were 
cultured, and left untreated (     ) and treated (     ) with indinavir (50 µM) in Medium 4 for 16 h. Data are shown as 
the mean and S.E.M. (n=3). *p < 0.05, using Student’s t-test versus basal culture medium (control). 
Basal (     ) = Medium 4 (control). 
 
4.4 Discussion 
Adipocyte metabolism is critical for the biological functions of multicellular organisms. Any 
alteration in adipocyte metabolism induced by protease inhibitors is likely to affect insulin 
action. For the first time the effect of indinavir on amino acid and organic acid metabolism in 
3T3-L1 adipocytes was investigated using metabolomic analysis, by GC-MS. This is 
advantageous, as secreted metabolites from the cell culture supernatants are easier to 
measure than a complex cell lysate. Any perturbation in adipocyte metabolome may be 
easier to detect. Moreover, to date the number of systematic studies of metabolites from 
adipocytes treated with HIV protease inhibitors using these approaches has been limited. 
Generally, the synthesis of amino acids without insulin stimulation was found to be higher in 
cell culture supernatants treated with indinavir versus untreated supernatants. However, with 
insulin stimulation, synthesis of amino acids was lower in the drug-treated than in the 
untreated supernatants. These findings show that antiretroviral drugs may interfere in 
insulin-mediated amino acid metabolism in the cells. 
In the context of organic acids in untreated cell culture supernatants and in those treated 
with indinavir, several organic acids were exclusively synthesised at the basal level, while 

















both levels. Most interestingly, there were several organic acids that were exclusively 
synthesised in drug-treated supernatants, with or without insulin stimulation. They may act 
as biomarkers in the study of insulin resistance induced by protease inhibitors.  
The organic acids in untreated and drug-treated cell culture supernatants appeared higher 
with insulin stimulation. However, in general, with insulin stimulation the organic acid levels 
in the untreated supernatants were higher than in the drug-treated supernatants. It appears 
that HIV protease inhibitors alter the insulin-mediated metabolism of organic acids. 
In order to find the most significantly different amino acid and organic acid levels in the cell 
culture supernatants, the data were analysed using the MetaboAnalyst web server (Xia et 
al., 2009). Access to this web server is free; it is easy to use; it is able to characterise a large 
number of metabolites; and it accepts a variety of input data, such as nuclear magnetic 
resonance peak list, binned spectra, mass spectrometry peak list, compound or 
concentration data, in a wide variety of formats, from GC-MS to liquid chromatography mass 
spectrometry (Xia et al., 2009). Thus, the web server is very useful, and suited to analysing 
the data from the present study. 
In amino acid analysis, without insulin stimulation, aspartate was the amino acid found to 
have the most significantly different level between the untreated and indinavir-treated cell 
culture supernatants. This amino acid is the carboxylic acid analogue of asparagine. 
Aspartate is a nonessential amino acid which is made from glutamic acid by enzymes, using 
vitamin B6 (http://www.hmdb.ca/). It has important roles in the urea cycle and in DNA 
metabolism (http://www.hmdb.ca/). In addition, aspartate is a major excitatory 
neurotransmitter, which is sometimes found to be increased in epileptic and stroke patients 
(Rainesalo et al., 2004). However, the function of aspartate in insulin resistance is still 
unclear. In the present study, aspartate was found to have significantly higher levels in the 
drug-treated versus untreated cell culture supernatants. This result shows that the 
antiretroviral drug may alter aspartate metabolism in the cells and then induce insulin 
resistance.  
Synthesis of hydroxylysine was significantly reduced in cell culture supernatants treated with 
indinavir versus untreated supernatants, with insulin stimulation. This amino acid derivative 
is hydroxylated from lysine and is involved in collagen synthesis (Rautavuoma et al., 2002). 
Adiponectin, an adipokine released by adipocytes, contains a collagenous domain with four 
lysine residues (68, 71, 80 and 104) (Fonseca-Alaniz et al., 2007). These four lysines have 
been reported to be hydroxylated to hydroxylysine, and subsequently glycosylated to 
modulate the insulin sensitivity of cells (Wang et al., 2002). A previous study noted that 













induced by protease inhibitors (Gougeon et al., 2004). The low level of hydroxylysine 
synthesis observed in the present study may be correlated with a low level of adiponectin, 
which has induced insulin insensitivity in the cells. 
Organic acid analysis of indinavir-treated cells revealed a significantly decreased level of 
butane in the treated versus untreated cell culture supernatants, without insulin stimulation. 
The significance of this  finding, however, is unclear and requires further investigation.   
With insulin stimulation, synthesis of succinate was significantly reduced in cell culture 
supernatants treated with indinavir versus untreated supernatants. Succinate is a Krebs 
cycle intermediate (http://www.hmdb.ca/) and has been observed at higher levels during 
differentiation of 3T3-F442A adipocytes (Lai and Goldman, 1992). A low level of succinate in 
the treated cell culture supernatants may indicate low activity of the Krebs cycle. In addition, 
extracellular glucose uptake, which is essential for the Krebs cycle, is inhibited during insulin 
resistance (Murata et al., 2002; Rudich et al., 2001). Therefore, it is possible that inhibition of 
glucose uptake decreased activity of the Krebs cycle and reduced synthesis of succinate.  
Isovalerate was exclusively identified in cell culture supernatants treated with indinavir with 
insulin stimulation. This organic acid is derived from leucine catabolism 
(http://www.hmdb.ca/). Utilisation of leucine was higher in the treated cell culture 
supernatants, although this increase was not statistically different compared to the untreated 
cell culture supernatants. A high utilisation of leucine suggests an increase in synthesis of 
isovalerate in the treated cell culture supernatants. Though the function of isovalerate is still 
unclear, increased isovalerate has been observed to be associated with certain diseases 
such as Reye’s syndrome (Trauner et al., 1975).  
Synthesis of butanoic acid 3-(trimethylsiloxy)-ethylester was significantly increased in cell 
culture supernatants treated with indinavir versus untreated supernatants, followed by insulin 
stimulation. Butanoic acid 3-(trimethylsiloxy)-ethylester (aka butyric acid) is a fatty acid and a 
normal urinary metabolite (http://www.hmdb.ca/). Overproduction of this organic acid will 
produce ketone bodies and may induce ketosis and ketoacidosis. Overproduction of ketone 
bodies is associated with insulin deficiency in type 1 diabetes mellitus (Laffel, 1999). In this 
study, 3-hydroxybutyrate, a ketone body, was synthesised only in the treated cell culture 
supernatants, but the results were not statistically different compared to those of the 
untreated supernatants, based on volcano plot, PLS-DA and SAM analyses. Thus, butanoic 
acid 3-(trimethylsiloxy)-ethylester and ketone bodies are probably involved in the insulin 













The levels of FFAs in untreated supernatants of 3T3-L1 adipocytes and those treated with 
HIV protease inhibitors were investigated for the first time. The levels of FFAs established 
were not statistically different in untreated cell culture supernatants and those treated with 
indinavir in a serum-free medium for 16 h (with or without insulin stimulation) to those of the 
control (basal serum-free medium).  
The levels of FFAs were significantly increased in the basal culture Medium 4 (DMEM with 
10 % FCS, 2 mM L- glutamine, 1 % of 100 x antibiotic/antimycotic and 0.1 % gentamicin) 
versus cell culture supernatants untreated with indinavir left in the medium for 16 h. The 
presence of FFAs probably reflects the contribution of serum.  
The levels of FFAs were significantly decreased in the untreated cell culture supernatants 
versus the basal Medium 4. In particular, 3T3-L1 adipocytes untreated with indinavir utilised 
FFAs which were supplied in the medium. However, the levels of FFAs were not significantly 
decreased in the drug-treated cell culture supernatants versus the basal Medium 4. This 
finding indicates that the drug-treated cells used smaller amounts of FFAs in the culture 
medium than the cells untreated with indinavir. It appears that indinavir decreased the ability 
of the cells to utilise the FFAs in the medium. Thus, the levels of FFAs were higher (i.e. they 
had accumulated) in the drug-treated versus untreated cell culture supernatants. The high 
levels of FFAs may induce insulin resistance. 
FFAs have been reported to play a role similar to TNF-α, which activates the inflammatory 
pathway of IKKβ and NFκB, and then phosphorylates serine 307 of IRS-1, thus inhibiting 
insulin signalling in rodent (Lee et al., 2009). This finding parallels the Western blot analysis 
(see Chapter 3), showing that the NFκB pathway may be involved in inducing insulin 
resistance in 3T3-L1 adipocytes treated with protease inhibitors. However, these findings are 
still unclear, as the levels of FFAs observed in the basal serum-free medium, and in the 
untreated cells and those treated with indinavir in serum-free medium followed by insulin 
stimulation, were not statistically different. 
4.5 Conclusion 
Metabolomic analysis is emerging as a powerful tool for analysing disease conditions. The 
results from this study suggest that HIV protease inhibitors induce alterations in the 
metabolism of adipocytes. FFAs may play a role in inducing insulin resistance in 3T3-L1 
adipocytes treated with protease inhibitors via the NFκB pathway. The alterations in the 
levels of aspartate, hydroxylysine, succinate, isovalerate and butanoic acid 3-
(trimethylsiloxy)-ethylester may be a secondary effect and a marker of insulin insensitivity 













findings. An understanding of the effects of protease inhibitors on adipocyte metabolism, 
particularly regarding the levels of amino acids, organic acids and FFAs, may shed new light 





































CHAPTER 5: EFFECT OF HIV PROTEASE INHIBITORS ON LIPOPROTEIN LIPASE 
ACTIVITY IN ADIPOCYTES 
5.1 Introduction 
 
Lipoprotein lipase (LPL) is an enzyme expressed in cardiac muscle, skeletal muscle and 
adipose tissue, and is located in the endothelial cells lining the capillaries. This insulin-
regulated enzyme hydrolyses the lipids in lipoprotein to three free fatty acids and one 
glycerol molecule, and therefore has a function in the anabolic actions of insulin. 
Abnormalities in LPL function have been reported to be associated with a number of 
pathophysiological conditions, including atherosclerosis, chylomicronaemia, Alzheimer’s 
disease and cancer, as well as lipodystrophy associated with insulin resistance and diabetes 
mellitus (Mead et al., 2002). 
More than 60 % of HIV-positive patients treated with protease inhibitors develop 
lipodystrophy associated with insulin resistance (Barbaro and Barbarini, 2006; Gan et al., 
2001). Lipodystrophy is a result of the abnormal hydrolysis and remobilisation of adipose 
tissue. It appears that protease inhibitors are the major antiretroviral drugs causing these 
abnormalities. However, the mechanisms responsible for these side effects have not been 
positively established. As alluded to above, LPL is known to play a role in lipid storage in 
adipose tissue, in response to insulin. Therefore, it is important to assess LPL activity in 
adipocytes after exposure to protease inhibitors.  
LPL activity has been measured in 3T3-L1 adipocytes using several methods (Dousset et 
al., 1988; Nilsson-Ehle and Schotz, 1976; Shirai and Jackson, 1982; Trost et al., 2009; Vilaro 
et al., 1986). Traditional methods for LPL activity assay include: measurement of the 
hydrolysis of a radioactive substrate emulsion ([3H]triolein (glycerol tri-[9,10(N)-3H]oleate) 
(Nilsson-Ehle and Schotz, 1976), fluorescently labelled triacylglycerol as a substrate 
(Dousset et al., 1988), and a method which measures the clearing of Intralipid (Vilaro et al., 
1986). A fluorescent LPL activity assay kit (Roar, NY, USA) has recently been developed to 
measure the activity of the enzyme (Yokota et al., 2009). This method uses a ready-made 
non-fluorescent substrate emulsion (propriety substrate) which becomes intensely 
fluorescent when it is hydrolysed by LPL.  
However, these methods are either expensive, or laborious and cumbersome. By contrast, 
an earlier method for assaying LPL in milk established that LPL-catalysed hydrolysis of p-
nitrophenyl butyrate (pNPB) could be measured relatively easily and cheaply using the 
appearance of p-nitrophenyl phosphate as an endproduct (Shirai and Jackson, 1982). This 













The objective of this study was to establish a rapid and robust method for analysing LPL 
activity in supernatants from 3T3-L1 adipocytes, such that the effects of various protease 
inhibitors on LPL activity could be assessed. 
5.2 Methods 
 
5.2.1 Preparation of 3T3-L1 adipocytes for the assay of released LPL  
 
3T3-L1 adipocytes were differentiated and serum-starved as described in sections 2.2.1 and 
2.2.2 (Wilcox et al., 2004). The cells were rinsed with PBS (1 ml) twice, and bathed in an 
additional aliquot of fresh PBS (500 µl) containing insulin (100 ng/ml) (17 nM) for 1 h at 37 
°C in an incubator, to stimulate LPL activity. After 1 h, heparin sodium-fresenius (final 
concentration 100 U/ml) was added for a further 20 min to release the enzyme from the cell 
surface (Knutson, 2000; Ong et al., 1988; Ranganathan and Kern, 2002; Stewart and 
Schotz, 1974). The cell culture supernatants were then harvested in order to assay LPL 
activity. The cells that remained were lysed with lysis buffer to measure protein 
concentration, as described in section 2.2.3. 
5.2.2 Linearity tests 
 
Part of the validation of the assay required assessment of the linearity of the assay 
methodology using pNPB as a substrate for the measurement of LPL activity. Linearity was 
assessed as a function of both time (measured in duplicate in six independent experiments) 
and LPL concentration (measured in duplicate in two independent experiments). For the 
former, LPL activity in 100 µl of the 500 µl cell culture supernatants harvested was measured 
continuously at specific time points (after 5, 10, 15, 30, 60, 120, 180 and 240 min) of 
incubation at 37 °C in a waterbath. The linearity of the assay in response to LPL 
concentration was measured using 100 µl cell culture supernatants diluted serially twofold 
stepwise in PBS.  
The standard for the experiment was prepared from LPL derived from Pseudomonas sp. in a 
range of concentrations from 2.13 µU/mg to 213 U/mg. Enzyme activity was also measured 
after the addition of phenylmethylsulphonyl fluoride (PMSF) (1 mM) (measured in duplicate 
in two independent experiments), to confirm that the assessed enzyme activity belonged to 
the LPL, as PMSF is known to inhibit LPL activity (Quinn et al., 1983). PMSF (10 mM) was 














5.2.3 LPL activity assay  
 
The assay of LPL activity in supernatants from 3T3-L1 adipocytes was designed as follows 






Cell culture supernatants (100 µl) were mixed with 900 µl buffer (0.1 M sodium phosphate, 
monobasic, anhydrous, pH 7.2; 0.9 % sodium chloride; 0.5 % (v/v) Triton X-100 (900 µl)) 
(Quinn et al., 1982; Shirai and Jackson, 1982). pNPB (10 µl of 50 mM in acetonitrile at 1 % 
(v/v) final concentration) was then added. The reactions were incubated in cuvettes at 37 °C 
in a waterbath (Shirai and Jackson, 1982) for specific periods of time. Absorbance was then 
measured using spectrophotometry at 400 nm. 






1.01   = volume (in ml) of incubation mixture 
df   = dilution factor (0.1) 
0.0148   = µM extinction coefficient of p-nitrophenol at 400 nm 
0.1   = volume (in ml) of enzyme used 
Units/mg protein  =      units/ml supernatant 
     mg protein/ml supernatant 
Unit definition: 
One unit will release 1.0 nmole of p-nitrophenol phosphate per minute at pH 7.2 and 37° C, 
when using p-nitrophenyl butyrate as substrate. 
 
Units/ml enzyme = (∆A400nm/min test - (∆A400nm/min substrate blank)) (1.01) (df) 
 
     (0.0148)(0.1) 
 
900 µl buffer + 100 µl supernatants from 3T3-L1 adipocytes + 10 µl pNPB in 
acetonitrile 
 













5.2.4 Effect of HIV protease inhibitors on LPL activity  
 
3T3-L1 adipocytes were serum-starved and treated with HIV protease inhibitors for 16 h. 
The protease inhibitors used were at plasma concentrations determined in vivo or at 
experimental concentration as measured in Chapter 3. Plasma concentrations of darunavir 
(2 µM) and tipranavir (15 µM) have previously been reported (Martin et al., 2009). The 
experimental concentration of indinavir (50 µM) was previously determined (see Chapter 3). 
The cells were then stimulated with insulin to increase LPL activity and treated with heparin 
to release LPL, as described in section 5.2.1. The LPL activity in 100 µl of the cell culture 
supernatants was measured as described in section 5.2.3, after 10 min incubation in a 
waterbath at 37 °C and measured in duplicate in two independent experiments.  
In addition to measuring whether these drugs interfere directly with LPL activity, quantities of 
the drugs (darunavir (2 µM), tipranavir (15 µM) and indinavir (50 µM)) were added directly to 
the assay reaction after recovering the untreated (no drug) cell culture supernatants from 
cells stimulated with both insulin and heparin. These were then incubated at 37 °C in a 
waterbath for 10 min. This experiment was also designed to reveal whether the drugs 
affected the spectral absorbance of the assay reaction. This experiment was conducted 
once.   
5.3 Results 
 
5.3.1 Optimisation procedures 
 
The LPL-catalysed hydrolysis of pNPB was successfully measured in supernatants of 3T3-
L1 adipocytes stimulated with both insulin and heparin (Figure 5.1). Cells which were 
stimulated with both insulin and heparin had significantly increased LPL activity, with 
detectable enzyme release from the cell surface from 5 min (p = 0.0005) up to 120 min (p = 
0.03) incubation. The cells which were stimulated with heparin only also released LPL from 
the cell surface, and showed significantly increased LPL activity after 5 min (p = 0.04) up to 
120 min (p = 0.03) incubation. However, the LPL activity in cell culture supernatants 
stimulated with heparin only was significantly lower after 5 min (p = 0.002) up to 60 min (p = 















 In 3T3-L1 adipocytes stimulated with both insulin and heparin, LPL activity reached a 
plateau at 60 min. However, in cells stimulated with heparin only, LPL activity reached a 
plateau at a later time point. This result indicates that LPL activity was higher (i.e. the total 
enzyme activity was higher) in the cell culture supernatants stimulated with both insulin and 
heparin, compared to the cell culture supernatants stimulated with heparin only. Thus, insulin 
significantly increased the level of enzyme activity. 
LPL activity in 3T3-L1 adipocytes stimulated with insulin, but not heparin-treated, was not 
significantly different from the LPL activity of the cells in PBS (Figure 5.1). No LPL was 
released from unstimulated cells in PBS, or from cells stimulated with insulin without the 
addition of heparin. 
The release of p-nitrophenol from supernatants of 3T3-L1 adipocytes stimulated with both 
insulin and heparin was linear for 15 min (Figure 5.1). Thus, 10 min of incubation was 
considered appropriate for future experimentation. 

























Figure 5.1: Time course of LPL activity in supernatants of 3T3-L1 adipocytes stimulated with insulin and 
heparin. 3T3-L1 adipocytes were stimulated with insulin for 1 h followed by the addition of heparin. Cell culture 
supernatants were harvested to measure LPL activity at indicated incubation periods using spectrophotometry 
(400 nm). LPL activity was measured in duplicate in six independent experiments. Data are shown as the mean 
and S.E.M. (n=6). * = PBS+I+H or PBS+H versus PBS, # = PBS+H versus PBS+I+H, p<0.05, using Student’s t-
test. PBS = phosphate buffered saline, H = heparin, I = insulin. 
 
In the assessment of linearity with respect to LPL concentration, 100 µl and twofold serial 
dilutions of LPL from supernatants of 3T3-L1 adipocytes stimulated with both insulin and 
heparin were prepared in the assay reaction, and incubated for 10 min. The absorbance of 
















































Figure 5.2: LPL activity in supernatants of 3T3-L1 adipocytes stimulated with both insulin and heparin, at 
different dilutions after 10 min incubation. 3T3-L1 adipocytes were stimulated with insulin for 1 h followed by 
the addition of heparin. Cell culture supernatants were harvested to measure LPL activity at different 
concentrations after 10 min incubation using spectrophotometry (400 nm). LPL activity was measured in 
duplicate in two independent experiments. Data are shown as the mean and S.E.M. (n=2). 
 
LPL was assayed after the addition of PMSF for the different times indicated. The results 
showed significantly decreased LPL activity in 3T3-L1 adipocytes stimulated with both insulin 
and heparin after 10 min (p = 0.04) to 240 min (p = 0.01) incubation (Figure 5.3). The activity 
of LPL in cell culture supernatants in PBS with or without PMSF addition was not 
significantly different. These data indicate that PMSF inhibited enzyme activity, suggesting 
that the enzyme activity noted belonged to the LPL. 























Figure 5.3: LPL activity terminated by PMSF. 3T3-L1 adipocytes were stimulated with insulin for 1 h followed 
by the addition of heparin. Cell culture supernatants were harvested and PMSF was then added prior to the 
indicated incubation periods to measure LPL activity using spectrophotometry (400 nm). LPL activity was 
measured in duplicate in two independent experiments. Data are shown as the mean and S.E.M. (n=2). * = 
PBS+I+H versus PBS+I+H+PMSF, p<0.05, using Student’s t-test (Lord test). PBS = phosphate buffered saline, H 





















5.3.2 Effect of HIV protease inhibitors on LPL activity  
 
LPL activity was measured in 3T3-L1 adipocytes treated with darunavir, tipranavir and 
indinavir for 16 h using the optimised assay conditions. As observed previously, LPL activity 
was significantly increased (p = 0.002) when cells were exposed to both insulin and heparin, 
compared to the unstimulated cell culture supernatants (Figure 5.4). In addition, the results 
showed darunavir (p = 0.002) and indinavir (p = 0.002) significantly decreased LPL activity 
(Figure 5.4) compared to the enzyme activity in the untreated cells exposed to both insulin 
































Figure 5.4: LPL activity in supernatants of 3T3-L1 adipocytes treated with darunavir, tipranavir and 
indinavir. 3T3-L1 adipocytes were treated with the protease inhibitors for 16 h in a serum-free medium, followed 
by exposure to both insulin and heparin. LPL activity was measured in duplicate in two independent experiments. 
Data are shown as the mean and S.E.M. (n=2). * = PBS versus PBS+I+H, # = PBS+I+H+Dvr or PBS+I+H+Idv 
versus PBS+I+H, p < 0.05, using Student’s t-test (Lord test). PBS = phosphate buffered saline, H = heparin, I = 
insulin, Dvr = darunavir, Tpr = tipranavir, Idv = indinavir. 
 
Protease inhibitors that were added directly to the assay reaction prior to incubation in a 
waterbath for 10 min did not decrease LPL activity (Figure 5.5). In contrast, LPL activity from 
cells treated with the protease inhibitors darunavir and indinavir showed decreased enzyme 
activity as observed above (Figure 5.4). In addition, it was found that the drugs did not 
interfere with the spectral absorbance of the assay reaction at the wavelength used. 
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Figure 5.5: Effect of protease inhibitors on the catalytic activity of  LPL as measured in the supernatant of 
adipocytes after prior exposure to protease inhibitors. 3T3-L1 adipocytes were treated with the protease 
inhibitors or left untreated for 16 h in a serum-free medium, followed by exposure to both insulin and heparin. LPL 
activity was measured singularly Thus, no statistical analysis was done for this experiment. PBS = phosphate 
buffered saline, H = heparin, I = insulin, Dvr = darunavir, Tpr = tipranavir, Idv = indinavir, Dvr*, Tpr* and Idv* = 
protease inhibitors were added directly to the assay reaction prior to 10 min incubation to determine if the 




This study shows that LPL release from 3T3-L1 adipocytes can be measured successfully in 
a colourimetric assay, using pNPB as substrate. pNPB was chosen as a substrate because 
LPL has been shown to catalyse the hydrolysis of short-chain fatty acyl esters such as 
tributyrin, p-nitrophenylacetate and pNPB in vivo (Shirai and Jackson, 1982). This substrate 
is more convenient to use than lipid-soluble substrates, as the product of LPL-catalysed 
hydrolysis of pNPB, p-nitrophenol, absorbs light strongly at 400 nm. It also allows the 
continuous monitoring of the reaction in the assay (Quinn et al., 1982).  
In this study, 3T3-L1 adipocytes were incubated in 500 µl PBS, which was assessed to be 
the smallest volume that could cover the cells adequately and yet still obtain the highest 
concentration of enzyme from the cells. The results of the study revealed that 100 ng/ml (17 
nM) insulin significantly stimulated LPL activity in the cells, while 100 U/ml heparin 
significantly released the enzyme from the cell surface. Heparin (100 U/ml) has been found 
to release 97 % of the enzyme from the cell surface (Knutson, 2000; Ong et al., 1988; 
Ranganathan and Kern, 2002; Stewart and Schotz, 1974). Thus, in this study, LPL activity in 













LPL is a heparin-releasable enzyme. This enzyme binds to heparan sulphate-proteoglycans 
at the endothelial surface in vivo by ionic interactions (Mead et al., 2002). Heparin, a 
heparan sulphate, releases LPL from the cell surface and stabilises the purified enzyme 
(Jackson et al., 1980). In this study, supernatants of 3T3-L1 adipocytes treated with heparin 
showed measurable LPL activity. However, the activity was significantly lower than in cells 
stimulated with both heparin and insulin. These results showed that insulin stimulated LPL 
activity in the cells. Insulin stimulates LPL activity by increasing LPL mRNA, which leads to 
an increase in the synthetic rate of the LPL protein (Ong et al., 1988). However, insulin does 
not cause the release of LPL from the cell surface. Thus, cells stimulated with insulin only 
showed no increase in LPL activity in this study.  
LPL activity was significantly inhibited by PMSF. This result suggested that the assessed 
enzyme activity belonged to the LPL. PMSF, a serine protease inhibitor, is one of the 
inhibitors known to inhibit LPL activity by binding to the active site of the enzyme (Mamputu 
et al., 2000; Quinn et al., 1983; Van Heusden, 1993). Other protease inhibitors such as 
phenyl-n-butylborinic acid also inhibit LPL activity (Van Heusden, 1993). However, this 
current study was focussed only on examining of the role of heparin-induced activity on 
pNPB hydrolysis. The effect of heparin is a characteristic property of LPL and therefore the 
heparin-induced hydrolysis of pNPB can be assumed to be directly due to LPL activity, 
rather than any other lipase. 
Darunavir and tipranavir are relatively new protease inhibitor drugs. LPL activity of 3T3-L1 
adipocytes treated with darunavir and tipranavir (at plasma concentrations) and indinavir (at 
experimental concentrations) have not been investigated previously. In the present study, it 
was shown for the first time that LPL activity in the cells was significantly decreased after 
treatment with darunavir and indinavir. This concurs with a previous study using a different 
method (Ranganathan and Kern, 2002). It was found that indinavir (11 µM) at 
therapeutically-measured plasma concentrations did not result in significant reduction of LPL 
activity in 3T3-F442A cell lines, assayed using an emulsified [3H]-triolein substrate 
(Ranganathan and Kern, 2002). Tipranavir also reduced enzyme activity, but this was not 
statistically significant at the concentrations used. This finding suggests that protease 
inhibitors may play a role in inhibiting lipoprotein lipase activity in vivo, and may thereby 
induce metabolic disorders in HIV-positive patients being treated with protease inhibitors.  
 
In addition, protease inhibitors were not found to decrease LPL activity directly when added 
to the assay reaction in vitro. This indicates that the drugs act intracellularly. The drugs may 













enzyme, or through the prevention of transport of LPL from the cytoplasm to the cell surface. 
It was also found that the drugs did not cause any spectral interference with the absorbance 
of the assay reaction.  
Alteration of LPL activity affects lipid metabolism and induces metabolic disorders such as 
chylomicronaemia, atherosclerosis, cancer, and lipodystrophy associated with insulin 
resistance and diabetes mellitus. The hydrolysis and release of lipids for storage from 
triglyceride-rich lipoproteins such as chylomicrons and very low density lipoproteins, and 
their subsequent storage in adipose tissue, cannot take place without lipoprotein lipase. 
Therefore, inhibition of these activities could potentially lead to hypertriglyceridaemia, 
lipodystrophy and increased coronary artery disease (Mead et al., 2002).  
5.5 Conclusion 
 
This study revealed that LPL activity can be readily assayed in adipocytes using pNPB as a 
substrate. Furthermore, the assay can be used to assay the effects of drugs on adipocytes. 
This is the first study to report that darunavir and indinavir significantly decrease LPL activiy. 
Alteration of LPL activity in HIV-positive patients treated with protease inhibitors could 
potentially lead to hypertriglyceridaemia, and subsequent aberrant mobilisation and 


























CHAPTER 6: GENERAL DISCUSSION AND CONCLUSION  
6.1 General discussion 
Protease inhibitors have been observed to play a leading role in inducing insulin resistance 
in HIV-positive patients (Ismail et al., 2009). However, details of the mechanistic basis of 
insulin resistance induced by protease inhibitors are largely unknown, and may be related to 
the general insulin resistance found in type 2 diabetes and obesity.  
Previous studies have shown that protease inhibitors inhibit insulin-stimulated glucose 
uptake in the insulin signalling pathway (Murata et al., 2002; Rudich et al., 2005). Most of the 
early studies focused on the distal steps of the insulin signalling pathway; but the inhibition of 
glucose uptake may occur at a proximal step, which has been observed in cases of insulin 
resistance in type 2 diabetes and obesity (Arner et al., 1987; Caro et al., 1987; Meyer et al., 
2002; Nolan et al., 1994). However, only a few studies have shown that protease inhibitors 
decrease insulin-stimulated tyrosine phosphorylation of IRS-1 (Cammalleri and Germinario, 
2003; Schutt et al., 2000). The effect of protease inhibitors on tyrosine phosphorylation of the 
insulin receptor β-subunit has previously been unclear, and this study reveals new insights.  
Using cells transfected with high levels of insulin receptor, CHO-IR cells, and 3T3-L1 
adipocytes, the effects of protease inhibitors on insulin-stimulated tyrosine phosphorylation 
of insulin receptor β-subunit and tyrosine kinase activation were investigated. CHO-IR cells 
were used for the first time to study the effects of protease inhibitors on the insulin signalling 
pathways. These cells have a high level of insulin receptor expression, which facilitates more 
sensitive detection of changes in signalling proteins than is the case in 3T3-L1 adipocytes. 
This may have facilitated easier analysis of changes in the insulin receptor β-subunit than 
has been possible previously. 
In both CHO-IR cells and 3T3-L1 adipocytes, treatment with the protease inhibitor indinavir 
significantly decreased insulin-stimulated tyrosine phosphorylation of the insulin receptor β-
subunit and IRS-1. The treatment also significantly increased phosphorylation of serine 307 
on IRS-1. However, pre-treatment with sodium salicylate blocked the effects of indinavir, i.e. 
decreased serine 307 phosphorylation of IRS-1 and increased insulin-stimulated tyrosine 
phosphorylation of the insulin receptor β-subunit and IRS-1. These findings suggest that 
protease inhibitors induce insulin resistance via the NFκB pathway, similar to salicylate 
action in reducing blood glucose concentrations in diabetic patients (Yuan et al., 2001). 
Using the metabolomic approach, amino acids, organic acids and FFA in supernatants of 













amino acids, it was found that aspartate and hydroxylysine were significantly decreased in 
cell culture supernatants treated with indinavir versus untreated supernatants, with or without 
insulin stimulation, respectively. A high level of aspartate was noted in the drug-treated 
supernatants without insulin stimulation. It has been reported that a high level of aspartate 
may be associated with several diseases (Rainesalo et al., 2004). However, the function of 
the amino acid in insulin resistance has not yet been established and may merely be a 
function of the general disturbance of metabolism in the adipocytes.  
A low level of hydroxylysine was established in the drug-treated supernatants in cells 
stimulated with insulin. This may be correlated with a low level of adiponectin secreted by 
the adipocytes. A decrease in adiponectin will cause insulin resistance. This finding of 
decreased hydroxylysine is worthy of further investigation.   
Organic acid analysis of drug-treated cells revealed significantly less butane in the treated 
cell culture supernatants without insulin stimulation. High levels of butane may be a result of 
exposure to serum-free medium. Succinate synthesis was decreased in indinavir-treated cell 
culture supernatants compared to untreated cells (insulin-stimulated), indicating low activity 
of the Krebs cycle. Succinate is usually found in high levels in differentiated adipocytes (Lai 
and Goldman, 1992). The decreased level of succinate found may be a result of the 
decreased tyrosine phosphorylation in the insulin receptor β-subunit and IRS-1, as observed 
above. This decreased activity of the tyrosine kinase may decrease glucose uptake (which is 
essential for the Krebs cycle) and therefore less succinate may be produced in the treated 
supernatants. However, further investigation is required. 
In contrast, butanoic acid 3-(trimethylsiloxy)-ethylester was synthesised significantly more in 
the treated versus untreated cell culture supernatants with insulin stimulation. 
Overproduction of this organic acid may relate to the production of ketone bodies 
concomitant with the low activity of the Krebs cycle. Ketone bodies are known to be 
associated with insulin deficiency, for example in type 1 diabetes mellitus (Laffel, 1999).  
In addition, isovalerate was synthesised exclusively in the treated cell culture supernatants 
with insulin stimulation. A high level of isovalerate is also associated with several diseases 
(Trauner et al., 1975). However, the effects of this synthesis of isovalerate, and its 
relationship to insulin resistance induced by protease inhibitors, are still unclear. 
 The levels of FFAs were high in the cell culture supernatants treated with indinavir. This 
suggests that the drug inhibits the utilisation of FFAs via FFA uptake. This could potentially 
result in high levels of circulating FFAs. FFAs may play a role in inducing insulin resistance. 













induce insulin resistance via the NFκB pathway (Lee et al., 2009). This finding parallels the 
results of indinavir treatment, which significantly increased phosphorylation of serine 307 on 
IRS-1 in the present study. It is important to compare the effects of other HIV protease 
inhibitors on the release of FFAs from adipocytes. 
Treatment with protease inhibitors also reduced LPL activity in 3T3-L1 adipocytes. Low LPL 
activity may affect lipid metabolism which could potentially lead to insulin resistance, 
hypertriglyceridaemia, lipodystrophy and increased coronary artery disease (Mead et al., 
2002). There were differences in the effects of the individual protease inhibitors on LPL 
activity. Thus, this assay could potentially be used to evaluate protease inhibitors for effects 
on LPL, and this could provide information on the propensity of the drug to cause increased 
FFA levels in vivo. The availability of this novel high-throughput method would facilitate the 
analysis of newly developed protease inhibitors, other novel antiretroviral drugs and for 
clinical studies. Although other lipases act on pNPB, only LPL is released by heparin 
indication that the activity measured after heparin is specific for LPL. 
6.2 Future work 
Sodium salicylate may provide a novel therapy for HIV protease inhibitor-induced insulin 
resistance and lipodystrophy. However, it has been reported to inhibit NFκB and induce 
apoptosis in rats (Kiss et al., 2004). Therefore, observation of the effects of sodium salicylate 
on apoptosis via the caspase-3 protein in CHO-IR cells and 3T3-L1 adipocytes treated with 
protease inhibitors is suggested for future study. In addition, signals obtained with 
phosphospecific antibodies tend to be of low intensity and significant optimisation is required 
before higher intensity signals can be obtained.  
The present study suggests that protease inhibitors induce insulin resistance via the NFκB 
pathway. In order to confirm this finding, the effects of protease inhibitors should be 
investigated in NFκB-knockout cells.  
In addition, as the present study showed, it would be useful to perform metabolomic analysis 
of other protease inhibitors such as ritonavir and liponavir for the purposes of a comparison 
study. The results may shed new light on drug development in insulin resistance induced by 
protease inhibitors. 
Furthermore, it would be interesting to expand the established method of LPL assay from 















In conclusion, this study suggests that treatment of CHO-IR cells and 3T3-L1 adipocytes 
with protease inhibitors inhibits LPL activity and increases FFA. The high levels of FFAs 
stimulate the NFκB pathway, which increases serine 307 phosphorylation of IRS-1, and then 
decreases insulin-stimulated tyrosine phosphorylation of IRS-1 and the insulin receptor β-
subunit to induce insulin resistance. Low levels of hydroxylysine and succinate, and high 
levels of aspartate, butanoic acid 3-(trimethylsiloxy)-ethylester and isovalerate may be a 
secondary effect of insulin resistance induced by protease inhibitors. 
In the context of adipocytes, NFκB induced by TNF-α has been observed to inhibit 
adipogenesis (Berg et al., 2004). Protease inhibitors may activate TNF-α or other 
inflammatory cytokines to induce the NFκB pathway of adipocytes in HIV-positive patients. 
This mechanism may affect the insulin signalling pathway, FFA, amino acids, organic acids 
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Appendix 1: Materials 
 
1) Antibodies        Supplier 
Actin goat polyclonal IgG (SC1615)6 Santa Cruz Biotechnology, CA, USA  
APS rabbit polyclonal IgG ((#4832)   Cell Signaling, MA, USA 
Goat anti-mouse horseradish  
peroxidase-conjugated (HRP) (#31430)  Pierce, IL, USA  
Goat anti-rabbit HRP (SC2004) Santa Cruz Biotechnology, CA, USA 
IR β-subunit rabbit polyclonal IgG (SC711) Santa Cruz Biotechnology, CA, USA  
Total IRS-1 rabbit polyclonal IgG (#2382)  Cell Signaling, MA, USA 
Mouse anti-goat HRP (#314000)   Pierce, IL, USA  
pS307 rabbit polyclonal IgG (#2381S)  Cell Signaling, MA, USA 
PTP1B rabbit polyclonal IgG (SC4021) Santa Cruz Biotechnology, CA, USA  
Mouse monoclonal IgG of PY20 (610000) BD Transduction Laboratories, NJ, USA 
SH2B rabbit polyclonal IgG    (Kotani et al., 1998)  
SOCS-1 rabbit polyclonal IgG (SC9021) Santa Cruz Biotechnology, CA, USA 
SOCS-3 rabbit polyclonal IgG (SC9023) Santa Cruz Biotechnology, CA, USA 
 
2) Cell lines 
CHO-IR cells Dr. Gus Gustafson, University of 
Maryland, USA (Wilcox et al., 2004) 
3T3-L1 murine adipocytes Prof. Peter Shepherd, University College 
London, UK (Wilcox et al., 2004) 
3) Chemicals/Reagents     
Acetic acid (2789)     Merck, Darmstadt, Germany 
Acetonitrile (2567064)     Merck, Darmstadt, Germany  
Acrylamide/bis (A3449)    Sigma, MO, USA 
Antibiotic/antimycotic solution (A5955)  Sigma, MO, USA  
Ammonium persulphate (APS) (A9164)  Sigma, MO, USA 
                                                            













Bromophenol blue (B5525)    Sigma, MO, USA  
Bovine serum albumin (BSA) (A3059)  Sigma, MO, USA  
Chemiluminescent reagent (34080)   Pierce, IL, USA 
Dexamethasone (D1756)    Sigma, MO, USA  
Dulbecco’s modified Eagle’s medium  
(DMEM) (D5671)     Sigma, MO, USA  
Dimethyl sulphoxide (DMSO) (D2650)  Sigma, MO, USA  
Ethanol      Kimix, Cape Town, South Africa  
Foetal calf serum (FCS) (DE14-801FI)  Lonza, MA, USA 
Film developer (83052-50)    Ilford, Cheshire, UK 
Film fixer (83060-10)     Ilford, Cheshire, UK 
Free fatty acid (FFA) kit (11383175001)  Roche, Basel, Switzerland 
G418-sulphate (11811-03)    Gibco, CA, USA 
Gas chromatography mass  
spectrometry (GC-MS) kit (KGO-7165)   Phenomenex, CA, USA  
Gentamicin (G1272)     Sigma, MO, USA  
Glycerol (G8773)     Sigma, MO, USA  
Glycine       Kimix, Cape Town, South Africa 
Ham’s F12 medium (12-615F)   Lonza, MA, USA 
Heparin sodium-fresenius 5000 i.u/ml Bodene, Port Elizabeth, South Africa 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
(HEPES) (H3375)     Sigma, MO, USA 
3-isobutyl-1-methyl-xanthine (IBMX) (I7018)  Sigma, MO, USA  
Insulin from bovine pancreas (I5500)   Sigma, MO, USA  
Isopropanol (1219)     Merck, Darmstadt, Germany 
L-glutamine (17-605E)    Lonza, MA, USA  
Lipoprotein lipase (LPL) from  
Pseudomonas sp. (62336)    Fluka, Buschs, Switzerland 
Methanol       Kimix, Cape Town, South Africa 
Newborn calf serum (NCS) (N4762)   Lonza, MA, USA  













Phenoxylpolyethoxylethanol (Tergitol) (NP40) Sigma, MO, USA 
Phosphatase inhibitors for cell culture  
(04906837001)     Roche, Basel, Switzerland 
Protein assay (500-0006)    Bio-Rad, CA, USA  
Protease inhibitors (indinavir, darunavir, tipranavir) Merck, Darmstadt, Germany and NIH, 
MD, USA 
Ponceau S (27195)     Sigma, MO, USA  
Precision plus protein dual colour standard  
(marker) (161-0374)      Bio-Rad, CA, USA 
Protease inhibitors for cell culture (04693124001) Roche, Basel, Switzerland 
Skimmed milk powder (92964)   Marvel, London, UK  
Sodium dodecyl sulphate (SDS) (161-0301)  Bio-Rad, California, USA 
Sodium chloride (71378)    Fluka, Buschs, Switzerland 
Sodium phosphate, monobasic, anhydrous (6346) Merck, Darmstadt, Germany 
Sodium salicylate (S2679)    Sigma, MO, USA 
N, N, N’, N’,-tetra-methyl-ethylenediamine  
(TEMED) (161-0801)     Bio-Rad, CA, USA 
Tris base       Kimix, Cape Town, South Africa 
Tris-HCl       Promega, WI, USA  
Triton x-100 (T8787)     Sigma, MO, USA 
Trypsin-ethylenediaminetetraacetic acid  
(trypsin-EDTA) (T3924)    Sigma, MO, USA  
Tween 20 (P1379)     Sigma, MO, USA  
2-mercaptoethanol (805740)    Merck, Darmstadt, Germany 
p-nitrophenyl butyrate (pNPB) (N9876)  Sigma, MO, USA  
4) Consumables  
6-well plate (140675)     Amersham Biosciences, NJ, USA 
20 ml universal bottle (128B)    Sterilin, London, UK  
25 cm2 flask (430639)     Corning, NY, USA 
3.5 cm dish (150318)      Amersham Biosciences, NJ, USA 
50 ml centrifuge tube      Corning, NY, USA 













Cryotube       Nalgene, NY, USA   
Disposable counting chamber    ISL, Paignton, UK  
Disposable cuvette     Lasec, Cape Town, South Africa 
Filter paper (3030-861)    Whatman, Kent, UK  
Medical X-ray film (LEEBN000)   Agfa, Mortsel, Belgium 
Mirocentrifuge tubes and tips    QSP, CA, USA 
Nitrocellulose membrane (RPN303P) Amersham Biosciences, NJ, USA 
Syringe       Pall, NY, USA  
Syringe filter (0.2 μm)      Pall, NY, USA 
5) Software and web server 
ChemiImager (Fluorchem 5500 Programme) Alpha Innotech Corporation, CA, USA 
Chemstation       Agilent Technologies, CA, USA  
GraphPad Prism      GraphPad Software, CA, USA  
MetaboAnalyst  University of Alberta, Alberta, Canada  
Statistica 8       StatSoft, OK, USA  




























Appendix 2: Cell culture reagent 
 
1) Ham’s F12 mixture culture medium 
 
0.4 g G418-sulphate powder was dissolved in 1 ml dH2O and filtered using a 0.2 µM syringe 
filter.  
2) Medium 1 
 
3) Medium 2 
 
0.125 mM dexamethasone was prepared in ethanol and 0.25 M IBMX was prepared in 1 M 
NaOH. Insulin (1mg/ml) (0.17 mM) was prepared in 1 % acetic acid. The solutions were 




Reagents Volume (ml) Final 
concentration 
a) Ham’s F12 medium 500  
b) Foetal calf serum (FCS) 50 10 % 
c) 200 mM Glutamine 5 2 mM 
d) 100 x Antibiotic/antimycotic solution 5 1% 
e) Gentamicin 2.5 0.5 % 
f) G418 0.5 400 µg/ml 
Total volume 563  
Reagents Volume (ml) Final 
concentration 
a) Dulbecco’s modified Eagle’s medium (DMEM)  500  
b) Newborn calf serum 50 10 % 
c) 200 mM Glutamine 5 2 mM 
d) 100 x Antibiotic/antimycotic solution 5 1 % 
e) Gentamicin 2.5 0.5 % 
Total volume 562.5  
Reagents Volume (ml) Final 
concentration 
a) DMEM 500  
b) FCS 50 10 % 
c) 200 mM Glutamine 5 2 mM 
d) 100 x Antibiotic/antimycotic solution 5 1 % 
e) Gentamicin 2.5 0.5 % 
f)  0.125 mM Dexamethasone 1 0.25  µM 
g) 0.25 M IBMX  1 0.5 mM 
h) 1 mg/ml Insulin  0.5  166 nM 













4) Medium 3 
 
5) Medium 4 
 
6) Serum-free medium 
 
7) 10 x Lysis buffer stock solution 
 
8) 1 x Lysis buffer solution 
The lysis buffer was prepared with 1 tablet of protease inhibitor and 1 tablet of phosphatase 




Reagents Volume (ml)  Final 
concentration 
a) DMEM 500   
b) FCS 50 10 % 
c) 200 mM Glutamine 5  2 mM 
d) 100 x Antibiotic/antimycotic solution 5  1 % 
e) Gentamicin 2.5  0.5 % 
f) 1 mg/ml Insulin 0.5 166 nM 
Total volume 563   
Reagents Volume (ml) Final 
concentration 
a) DMEM  500  
b) FCS 50  10 % 
c) 200 mM Glutamine 5 2 mM 
d) 100 x Antibiotic/antimycotic solution 5  1 % 
e) Gentamicin 2.5  0.5 % 
Total volume 562.5   
Reagents Volume (ml) Final 
concentration 
a) DMEM 500  
c) 200 mM Glutamine 5 2 mM 
d) 100 x Antibiotic/antimycotic solution 5  1 % 
e) Gentamicin 2.5  0.5 % 
Total volume 512.5  
Reagents Volume Final 
concentration 
a) 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), pH 7.5 
445 ml 50 mM 
b) Phenoxylpolyethoxyethanol (NP40) 5 ml 1 % 
c) Glycerol 50 ml 10 % 
d) Sodium chloride (NaCl) 1.461 g 50 mM 













9) 5 x Laemmli buffer 
 
10) Freezing solution for CHO-IR cells 
 
11) Freezing solution for 3T3-L1 pre-adipocytes 
 
12) Phosphate buffered saline (PBS) 
1 tablet of PBS was dissolved in 100 ml dH2O and the mixture was filtered sterile with a 
syringe filter. 
13) Insulin stimulation 
Insulin was prepared in 100 mM acetic acid + 0.1% bovine serum albumin (BSA) 
i. 100 mM acetic acid 
a. 0.294 ml 17 M acetic acid + 49.706 ml dH2O 
ii. 0.1% BSA 
a. Add 0.05 g BSA into 50 ml acetic acid to become 0.1% BSA 
5 mg insulin was dissolved in 5 ml of 100 mM acetic acid + 0.1% BSA = 1 mg/ml 
100 ng/ml (17 nM) insulin = 10 µl + 990 µl PBS 





Reagents Volume Final 
concentration 
a) 1 M Tris, pH 6.8 1.25 ml 25 nM 
b)  Sodium dodecyl sulphate (SDS) 1 g  2 % 
c) 1 % Bromophenol blue 0.33 ml 0.002 % 
d) Glycerol 5 ml 10 % 
e) 2-Mercaptoethanol 2.5 ml 5 % 
f)  Water 1.25 ml  
Total volume 10.33 ml  
Reagents Volume (ml) Final 
concentration 
a) Dimethyl sulphoxide (DMSO) 10 10 % 
b) FCS 40  
Total volume 50  
Reagents Volume (ml) Final 
concentration 
a) DMSO 10 10 % 
b) Newborn calf serum 40  













14) Drugs stock solutions 
Drugs were prepared using a standard formula: 
Mass drug (g) = concentration (M) x molecular weight (MW) x volume (L) 
a) 5 mM indinavir, MW = 711.88 
b) 5 mM saquinavir, MW = 670.85 
c) 0.2 mM darunavir, MW = 593.73 
d) 1.5 mM tipranavir, MW = 602.70 
e) 50 mM sodium salicylate, MW = 160.10 
15) Calculation of cell number 
CHO-IR cells were counted using a haemocytometer to determine the total number of cells 
in the original flask. Then, 10 µl cell medium solution was loaded into the haemocytometer. 
The number of cells in 5 of 10 of the 0.1 mm3 blocks was counted as follows: 
 
Cells cm-3 =    Number of cells counted      x conversion factor (1000) 
          Number of squares counted  





























Appendix 3: Electrophoresis and Western blot analysis 
1) 1.5 M Tris-HCl, pH 8.8, for 500 ml 
 
Using an Henderson–Hasselbalch equation: 
 
pH = pHa + log (Base) B 
  
                          (Acid) A 
Tris-HCl (A) = 0.113 g 
 
Tris-Base (B) = 0.276 g 
 
 
2) 0.5 M Tris-HCl, pH 6.8, for 500 ml 
 
Tris-HCl (A) = 0.153 g 
 
Tris-Base (B) = 0.004 g 
 
 
3) 10 % Ammonium persulphate (APS) 
 
0.1 g APS was dissolved in 1 ml dH2O 
 
4) 10 % SDS  
 
5 g SDS was dissolved in 50 ml dH2O 
 















Reagents Volume (ml) Final 
concentration 
a) 0.5 M Tris-HCl, pH 6.8 1.260 0.126 M 
b) 30 % Acrylamide/bis  (19:1) 0.660 4 % 
c)  dH2O 3.000  
d) 10 % SDS 0.500 0.1 % 
e) 10 % APS 0.250 0.05 % 
f) TEMED  0.005 0.1 % 
Total volume 5.675  
Reagents Volume (ml) Final 
concentration 
a) 1.5 M Tris-HCl, pH 8.8  2.500 0.375 M 
b) 30 % Acrylamide/bis  (19:1) 2.500 7.5 % 
c)  dH2O 4.850  
d) 10 % SDS 0.100 0.1 % 
e) 10 % APS 0.050 0.05 % 
f) TEMED  0.005 0.05 % 




















8) 1 x Running buffer  
100 ml 10 x stock solution was added to 900 ml deionised water. 
 






10) 1 x Transfer buffer 
80 ml 10 x stock solution was added to 720 ml deionised water and 200 ml methanol. 
 







11) 0.1 % Ponceau S solution  
0.1 g Ponceau was dissolved in 100 ml of 5 % acetic acid. 
 
12) 3 % BSA 
1.5 g BSA was dissolved in 50 ml TBST. 
 
13) 5 % Milk solution 
2.5 g skimmed milk powder was dissolved in 50 ml TBST. 
 
 
Reagents Volume Final 
concentration 
a) Tris base  14.41 g 0.025 M 
b) Glycine 3 g 0.192 M 
c) SDS  1 g 0.1 % 
d) dH2O 1 l  
Total volume 1 l  
Reagents Volume Final 
concentration 
a) Tris base  30.28 g 0.025 M 
b) glycine 144.13g 0.192 M 
c) dH2O  800 ml  
Total volume 800 l  
Reagents Volume Final 
concentration 
a) Tris-HCl  6.8 g 0.05 M  
b) Tris base 0.82 g   
c)  NaCl 8.77 g  0.150 M 
d) Tween 20 5 ml 0.1 % 
e)  dH2O 1 l  











































Reagents Volume (ml) Final 
concentration 
a) 1 M Tris-HCl, pH 6.8 1.56 0.063M 
b) 10 % SDS 5 2 % 
c)  2-mercaptoethanol 0.175 0.1 M 
d)  dH2O 18.27  













Appendix 4: Metabolomic analysis 
 
1) Amino acid analysis (summarised from Phenomenex EZ-faast™ kit: user’s manual) 
a) 100 µl of nor-valine internal standard (Reagent 1) was pipetted into tubes. 
b) 100 µl of sample was added to each tube and mixed. 
c) The mixture was slowly drawn up into a sorbent tip. Avoid air-bubble. 
d) The sorbent tip was left in a new tube and washed with washing solution (Reagent 2) 
(200 µl). 
e) Elution fluid (Reagent 3) (200 µl) was then pipetted into the tube. 
f) The elution fluid was drawn up and expelled twice until all the resin in the sorbent tip 
had been removed from the tip. 
g) Reagent 4 (50 µl) was added into each tube using a glass Hamilton syringe.   
h) The mixture was vortexed for 5 sec and let stand for 1 min, twice. 
i) Reagent 5 (100 µl) was added to each tube using a glass Hamilton syringe and 
vortexed for 5 sec. 
j) The mixture was centrifuged at 2300 rpm for 1 min. 
k) Top layer of the mixture was transferred into a vial using a glass Pasteur pipette. 
l) The top layer was dried down under nitrogen for 10 min. 
m) The dried sample was then resuspended with reagent 6 (100 µl) and vortexed for 5 
sec. 
n) The entire sample was transferred into an insert using a glass Pasteur pipette prior to 

























2) Organic acid analysis (Procedure of organic acid extraction) 
a) Samples (200-500 µl) were pipetted into tubes (Tube 1) and were made up to 2 ml with 
dH2O. 
b) Six drops of 5 M HCl were added to each tube (pH < 2). 
c) 5 µl of pentadecanoate (PDA) was added to each tube. 
d) Approximately 1 g of NaCl was added to saturate the samples, and the mixture was 
vortexed. 
e) The mixture was transferred to a tube (Tube 2) in a fume cupboard. 
f) 2 ml ethyl acetate was added to each tube. 
g) The tubes were capped and placed on a mixer for 2 min. 
h) The mixture was centrifuged for 3 min at 1000 rpm using Mistral 6L Centrifuge. The 
temperature was set to 10 °C. 
i) Top layer was transferred to another tube using a glass Pasteur pipette. 
j) Steps f) to i) were repeated. 
k) Steps f) to i) were repeated using 2 ml diethyl ether. 
l) The extract was dried by adding approximately 2 g anhydrous sodium sulphate. 
m) The dry extract was transferred to another tube (Tube 3). 
n) The dry extract was evaporated under nitrogen at 37 °C using a heating block. 
o) Bis-(trimethylsilyl)trifluoroacetamide (BSTFA) (75 µl) and pyridine (20 µl) were added to 
each tube in a fume cupboard. The tubes were capped and vortexed. 
p) The tubes were placed in a heating block at 80 °C for 30 min. 





























































4) Normalisation  
 
 
   
 
Box plots and kernel density plots of amino acids in the untreated and drug-treated cell culture 
supernatants (a) without and (b) with insulin stimulation: before normalisation. 27 amino acids and 
derivatives were identified in supernatants of 3T3-L1 adipocytes before and after treatment with indinavir (50 µM) 





















Box plots and kernel density plots of organic acids in the untreated and drug-treated cell culture 
supernatants (a) without and (b) with insulin stimulation: before normalisation. 60 organic acids and 
derivatives were identified in supernatants of 3T3-L1 adipocytes before and after treatment with indinavir (50 µM) 



















Organic acids that were exclusively identified in cell culture supernatants (drug-treated, untreated or both) with or without insulin stimulation using GC-MS. 3T3-L1 
adipocytes were left untreated or treated with indinavir (50 µM) for 16 h, followed by insulin stimulation. 
Before insulin stimulation After insulin stimulation Untreated and drug-
treated supernatants with 
or without insulin 
simulation 
Untreated supernatants Drug-treated supernatants Untreated supernatants Drug-treated supernatants 
1. Carbamic acid 1. Carbamic acid 1. Succinate 1. Succinate 1. Butanoic acid,3-
(trimethylsilyloxy)-ethylester 
2. Butane 2. Butane 2. Sulphate 2. Sulphate 2. Benzene 
3. 2-ketoisocaproic acid 3. 2-ketoisocaproic acid 3. Pyroglumate 3. Pyroglumate 3. Propanoic acid 
4. 1-pentanethyldisilyloxybutane 4. 1-pentanethyldisilyloxybutane 4. Palmitate 4. Palmitate 4. Ethanedioic acid 
5. Butanedioic acid 5. Butanedioic acid 5. Stearate 5. Stearate 5. (RxSx)-3,4-
dihydroxybutanoic acid 
6. Cyclohexasilaxane 6. Cyclohexasilaxane 6. Benzoic acid 6. Benzoic acid 6. Butanoic acid,4-
(trimethylsilyloxy)-,ethylester 





8. Phenylacetylglycine 8. Phenylacetylglycine 8. Hexanedoic acid 




9. Acetic acid 
10. Dodecanoic acid 10. Dodecanoic acid 10. Homovanillate 10. Homovanillate  





12. Oleate 12. Oleate  
13. Pantothenic acid 13. Pantothenic acid 13. Phenyl acetic acid 13. Phenyl acetic acid  
14. Palmitelaidic acid 14. Palmitelaidic acid 14. 1,2-
bis(trimethylsiloxy)ethane 
14. 3-hydroxybutyrate  
15. Glucopyranose 15. Glucopyranose 15. Oleanitrile 15. Phosphorous acid  




17. Octadecanoic acid 17. Octadecanoic acid  17. Isovalerate  
 18. Pentanedioicaid  18. Pentasiloxane,dodecamethyl  
   19. 2-ethylhydracrylic acid  
   19. Oxacyclotetradec-5-yn  













Appendix 5: Lipoprotein lipase assay 
 
1) Measurement of protein concentration using Bradford protein assay 
















Bovine serum albumin 
(µg/ml) 

































2) Absorbance of assay reagent of LPL activity assay in cuvettes at 400 nm after 10 min 
incubation at 37 ºC in a waterbath 
 
No. Assays Absorbance (nm) 
at 400nm 
1 Buffer + (PBS) + pNPB 0.12 
2 Buffer + (PBS + H) + pNPB 0.12 
3 Buffer + (PBS + I) + pNPB 0.13 
4 Buffer + (PBS + I + H) + pNPB 0.12 
5 Buffer + (PBS) + acetonitrile 0 
6 Buffer + (PBS + H) + acetonitrile 0 
7 Buffer + (PBS + I) + acetonitrile 0 
8 Buffer + (PBS + I + H) + acetonitrile 0 
9 Buffer + (Cell culture supernatants in PBS) + acetonitrile 0 
10 
Buffer + (Cell culture supernatants in PBS + H) + 
acetonitrile 0 
11 
Buffer + (Cell culture supernatants in PBS + I) + 
acetonitrile 0 
12 
Buffer + (Cell culture supernatants in PBS + I + H) + 
acetonitrile 0 
13 Buffer + (Cell culture supernatants in PBS) + pNPB 0.14 
14 Buffer + (Cell culture supernatants in PBS + H) + pNPB 0.18 
15 Buffer + (Cell culture supernatants in PBS+I) + pNPB 0.16 
16 Buffer + (Cell culture supernatants in PBS+I+H) + pNPB 0.58 
17 Buffer + (PBS) + pNPB 0.12 
18 
Standard LPL enzyme from Pseudomonas sp. (E)1 (213 
U/mg) 3.04 
19 E1/100 (2.13 U/mg) 2.46 
20 E1/100000 (2.13 mU/mg) 1.48 
21 E1/1000000000 (2.13 µU/mg) 0.45 
 
Buffer = 0.1 M sodium phosphate, monobasic, anhydrous, pH 7.2; 0.9 % sodium 
chloride; 0.5 % (v/v) Triton X-100 
PBS = phosphate buffered saline 
pNPB = para-nitrophenyl butyrate was prepared in acetonitrile 
I = insulin (100 ng/ml) (17 nM)  
H = heparin (100 U/ml) 
LPL = lipoprotein lipase 








































































Abstract 1: 1st Medical Research Centre (MRC) Research Day, Cape Town, South Africa 
(18th October 2007) 
 
Inhibition of the insulin receptor kinase by antiretroviral protease inhibitors 
Wan Iryani Wan Ismail and Tahir S. Pillay 
Division of Chemical Pathology, Department of Clinical Laboratory Sciences, Faculty of 
Health Sciences, University of Cape Town, South Africa 
 
Human immunodeficiency virus (HIV) protease inhibitors (HPIs) are potent antiretroviral 
agents. Recently, a substantial number of clinical and epidemiological studies have 
shown that HPIs play a major role in inducing insulin resistance and lipodystrophy in 
highly active antiretroviral therapy (HAART)-treated patients. In this study, we assessed 
the effect of saquinavir on the insulin signalling pathway in Chinese Hamster Ovary 
(CHO) cells and differentiated 3T3-L1 adipocytes. A 17-h exposure to saquinavir resulted 
in impaired phosphorylation of the insulin receptor (IR) and insulin receptor substrate 1 
(IRS-1) in CHO cells and 3T3-L1 adipocytes. A dose-dependent decrease in the 
phosphorylation of the IR and IRS-1 in CHO cells and 3T3-L1 adipocytes was observed 
with saquinavir (0.5-50 µM) following immunoblotting analysis using anti-phosphotyrosine 
antibody. In time-course studies, IR and IRS-1 phosphorylation in both cell lines declined 
slowly with increasing exposure to 50 µM of saquinavir over 17 hours. This study 
demonstrates that saquinavir induces insulin resistance in both CHO cells and 3T3-L1 
adipocytes by inhibiting the early steps of the insulin signalling cascade. 




























Abstract 2: 9th Annual Astra Zeneca Medical Research Day, University of Cape Town 
(UCT), Cape Town, South Africa (14th February 2008) 
 
Effects of antiretroviral protease Inhibitors on the insulin receptor kinase in vitro  
Wan Iryani Wan Ismail and Tahir S. Pillay 
Division of Chemical Pathology, Department of Clinical Laboratory Sciences, Faculty of 
Health Sciences, University of Cape Town, South Africa 
Human immunodeficiency virus (HIV) therapy using anti-retroviral protease inhibitors can 
increase lifetime of HIV infected patients. Unfortunately, the treatment has been reported 
to cause metabolic abnormalities such as insulin resistance, lipodystrohy, hyperglycemia, 
and type 2 diabetes. The molecular mechanisms of these side effects are still unknown 
and only small studies have been conducted to understand this pathway. In order to 
analyse the complications, cell culture study using Chinese Hamster Ovary transfected 
with high level of human insulin receptor (CHO-IR) cells and differentiated 3T3-L1 murine 
adipocytes were treated with various dose responses of saquinavir and indinavir for 16-h 
following immunoblotting analysis using anti-phosphotyrosine antibody. Saquinavir 
appeared to impair phosphorylation of the insulin receptor (IR) and insulin receptor 
substrate 1 (IRS-1) in CHO-IR cells and 3T3-L1 adipocytes at the basal level and insulin 
stimulation level. While indinavir inhibited the phosphorylation of the IR and IRS in CHO 
cells and 3T3-L1 adipocytes only at the basal level with the similar concentration. 






























Abstract 3: 43rd Society for Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA) Meeting, Cape Town, South Africa (12-15th April 2008) 
INHIBITION OF THE INSULIN RECEPTOR KINASE BY ANTIRETROVIRAL PROTEASE 
INHIBITORS  
W. I. W. Ismail and T. S. Pillay 
Division of Chemical Pathology, Department of Clinical Laboratory Sciences, Faculty of 
Health Sciences, University of Cape Town, Private Bag X3, Observatory, Cape Town, 
7935 
Human immunodeficiency virus protease inhibitors (HPIs) are potent antiretroviral agents. 
Unfortunately, prolonged use of the drugs has caused many complications among 
patients, including insulin resistance, lipodystrophy, hyperglycaemia, and type 2 diabetes 
mellitus. The molecular basis for these drug-induced metabolic syndromes is still 
unknown. Few studies have addressed the molecular pathways involved. Thus, this study 
was designed to elucidate how HPIs may affect the insulin signalling pathway in Chinese 
Hamster Ovary cells transfected with high levels of human insulin receptor (CHO-IR cells) 
and in differentiated 3T3-L1 murine adipocytes. We have also examined the effects of 
these drugs on lipoprotein lipase in the adipocytes. Cells were treated with a range of 
doses of HPIs (saquinavir and indinavir) for 16 h and then stimulated with insulin. Insulin-
stimulated tyrosine phosphorylation was analyzed by immunoblotting with anti-
phosphotyrosine antibody. Saquinavir (30-40 µM) displayed potent inhibition of the 
tyrosine phosphorylation of th -subunit and IRS proteins in both cell 
types. In contrast, indinavir (60 µM) had mild effects on insulin signalling. Thus both drugs 
display differences in their effects on insulin signalling and this may influence the 
propensity to cause the side effect of insulin resistance seen in patients on the drugs. We 
postulate that the inhibition of the insulin receptor kinase may occur because of direct 




























Abstract 4: 3rd Faculty of Health Sciences Research Day, UCT, Cape Town, South 
Africa (3rd September 2008) 
INHIBITION OF THE INSULIN RECEPTOR KINASE BY ANTIRETROVIRAL 
PROTEASE INHIBITORS 
Wan Iryani Wan Ismail, Tahir Pillay 
Division of Chemical Pathology, Department of Clinical Laboratory Sciences, Faculty 
of Health Sciences, University of Cape Town. 
 
Human immunodeficiency virus protease inhibitors (HPIs) are potent antiretroviral 
agents. Unfortunately, prolonged use of these drugs causes many complications among 
patients, including insulin resistance, lipodystrophy, hyperglycaemia, and type 2 
diabetes mellitus and the incidence of these is increasing as patients with HIV infection 
and on treatment experience prolonged lifespans. The molecular basis for these drug-
induced metabolic syndromes is still unknown and few studies have attempted to 
address this. In this study we have sought  to elucidate how HPIs may affect the insulin 
signalling pathway in Chinese Hamster Ovary cells transfected with high levels of 
human insulin receptor (CHO-IR cells) and in differentiated 3T3-L1 murine adipocytes. 
We have also examined the effects of these drugs on lipoprotein lipase (LPL) in the 
adipocytes as LPL levels have been found altered in patients treated with HPIs who 
later develop lipodystrophy. We investigated the effects of HPIs on cells were treated 
with saquinavir and indinavir for 16 h and then stimulated with insulin. Insulin-stimulated 
tyrosine phosphorylation was analyzed by immunoblotting with anti-phosphotyrosine 
antibody. We found that saquinavir (30-40 µM) displayed potent inhibition of the 
tyrosine phosphorylation of the insulin re -subunit and IRS proteins in both cell 
types. Indinavir (50 µM) had similar effects on insulin signalling but with a different 
dose-response profile. Thus both drugs display potency differences in their effects on 
insulin signalling and this may influence the propensity to cause the side effect of insulin 
resistance seen in patients. The inhibition of insulin signalling appears to be at a 
proximal level and involves a direct effect on the insulin receptor.  We postulated that 
the inhibition of the insulin receptor kinase may occur because of changes in the level 
or activity of tyrosine phosphatases and suppressor of cytokine signaling 1 (SOCS-1). 
However, we found that PTP1B and anti-SOCS-1 levels were not altered. We conclude 
that the effects of HPIs to cause insulin resistance does not involve PTP1B or SOCS-1 























Abstract 5: 2nd MRC Research Day, Cape Town, South Africa (16-17th October 2008) 
MOLECULAR BASIS OF INSULIN RESISTANCE INDUCED BY 
ANTIRETROVIRAL PROTEASE INHIBITORS 
WIW Ismail, TS Pillay 
Division of Chemical Pathology, Department of Clinical Laboratory Sciences, Faculty 
of Health Sciences, University of Cape Town, South Africa 
 
BACKGROUND 
Prolonged use of human immunodeficiency virus protease inhibitors (HPIs) has been 
reported to cause insulin resistance which is accompanied by dyslipidaemia, 
lipodystrophy, and atherosclerosis in patients. The incidence of these complications is 
increasing in patients as antiretroviral treatment is used increasingly. The mechanism of 
these adverse effects is not fully understood. Therefore, this study has attempted to 
identify possible mechanisms. 
METHODS 
Chinese hamster ovary cells transfected with high levels of human insulin receptor 
(CHO-IR cells) and differentiated 3T3-L1 murine adipocytes were serum-starved and 
treated with several concentrations of saquinavir or indinavir for 16 h followed by insulin 
stimulation for 5 min. The cells were lysed for immunoblotting using anti-
phosphotyrosine antibody, anti-insulin receptor antibody, anti-protein tyrosine 
phosphatase 1B (PTP1B), and anti-suppressor of cytokine signaling 1 antibody (SOCS-
1). 
RESULTS 
We found that saquinavir (30-40 µM) displayed potent inhibition of the tyrosine 
phosphorylation of the insulin receptor β-subunit and IRS proteins in both cell types. 
Indinavir (50 µM) had similar effects on insulin signalling but with a different dose-
response profile. Thus both drugs display potency differences in their effects on insulin 
signalling and this may influence the propensity to cause the side effect of insulin 
resistance seen in patients. The inhibition of insulin signalling appears to be at a 
proximal level and involves a direct effect on the insulin receptor.  We postulated that 
the inhibition of the insulin receptor kinase may occur because of changes in the level 
or activity of tyrosine phosphatases and SOCS-1. However, we found that PTP1B and 
anti-SOCS-1 levels were not altered.  
CONCLUSION 
We conclude that the effects of HPIs to cause insulin resistance do not involve PTP1B 
or SOCS-1 protein but may involve other regulatory proteins in the insulin signalling 
pathway.  
Key words: CHO-IR cells, 3T3-L1 adipocytes, saquinavir, indinavir, phosphorylation, 
















Abstract 6: 10th International Workshop Adverse Drug Reactions and Lipodystrophy 
in HIV, London, United Kingdom (6-8th November 2008) 
Inhibition of the Insulin Receptor Kinase by Antiretroviral Protease Inhibitors 
WIW Ismail, TS Pillay 
Division of Chemical Pathology, Department of Clinical Laboratory Sciences, Faculty 
of Health Sciences, University of Cape Town, South Africa 
Human immunodeficiency virus protease inhibitors (HPIs) are potent antiretroviral 
agents. Unfortunately, prolonged use of these drugs causes many complications among 
patients, including insulin resistance, lipodystrophy, hyperglycaemia, and type 2 
diabetes mellitus and the incidence of these is increasing as patients with HIV infection 
and on treatment experience prolonged lifespans. The molecular basis for these drug-
induced metabolic syndromes is still unknown and few studies have attempted to 
address this.  
Objectives: In this study we have sought to elucidate how HPIs may affect the insulin 
signalling pathway in Chinese Hamster Ovary cells transfected with high levels of 
human insulin receptor (CHO-IR cells) and in differentiated 3T3-L1 murine adipocytes. 
We have also examined the effects of these drugs on lipoprotein lipase (LPL) in the 
adipocytes as LPL levels have been found altered in patients treated with HPIs who 
later develop lipodystrophy.  
Methods: We investigated the effects of HPIs on cells were treated with saquinavir and 
indinavir for 16 h and then stimulated with insulin. Insulin-stimulated tyrosine 
phosphorylation was analyzed by immunoblotting with anti-phosphotyrosine antibody.  
Results: We found that saquinavir (30-40 µM) displayed potent inhibition of the tyrosine 
phosphorylation of the insulin receptor β-subunit and IRS proteins in both cell types. 
Indinavir (50 µM) had similar effects on insulin signalling but with a different dose-
response profile. Thus both drugs display potency differences in their effects on insulin 
signalling and this may influence the propensity to cause the side effect of insulin 
resistance seen in patients. The inhibition of insulin signalling appears to be at a 
proximal level and involves a direct effect on the insulin receptor.  We postulated that 
the inhibition of the insulin receptor kinase may occur because of changes in the level 
or activity of tyrosine phosphatases and suppressor of cytokine signaling 1 (SOCS-1). 
However, we found that PTP1B and anti-SOCS-1 levels were not altered.  
Conclusion: We conclude that the effects of HPIs to cause insulin resistance does not 





















Abstract 7: 2nd Pfizer-College of Health Sciences National Young Health Scientists 
Research Symposium, University of Kwazulu-Natal, Durban, South Africa (21st October 
2009) 
HIV PROTEASE INHIBITORS INDUCE INSULIN RESISTANCE VIA THE NFκB 
PATHWAY  
Ismail W.I.W., King J.A. and Pillay T.S. 
Division of Chemical Pathology, University of Cape Town and National Health Laboratory 
Service, Groote Schuur Hospital, Cape Town, 7925, South Africa 
Aim 
The aim of this study was to elucidate the molecular basis of insulin resistance induced 
by HIV protease inhibitors (HPIs) using Chinese hamster ovary cells transfected with high 
levels of human insulin receptor (CHO-IR). 
Methods 
CHO-IR cells were treated with indinavir for 16 h followed by insulin stimulation for 5 min, 
and then lysed and analysed by immunoblotting using antibodies against 
phosphotyrosine, insulin receptor β-subunit, protein tyrosine phosphatase 1B (PTP1B), 
suppressor of cytokines signalling-1,-3 (SOCS-1,-3), insulin receptor substrate 1 (IRS-1), 
phosphoIRS-1 serine residue 307 (S307), Src homology 2B (SH2B) and actin. Cells were 
also pre-treated with sodium salicylate (NaSal) (5mM) for 1h to inhibit nuclear factor 
kappa B (NFκB).   
Results 
Indinavir inhibited tyrosine phosphorylation of the insulin receptor β-subunit and 
increased phosphorylation of IRS-1 on S307. PTP1B, SOCS-1,3 and SH2B levels were 
not altered.  NaSal treatment blocked the effects of indinavir on the tyrosine 
phosphorylation of the insulin receptor and phosphorylation of IRS-1 at S307.  
Discussion and Conclusion 
Sodium salicylate inhibits the upstream activator of NFκB, the IκB kinase β (IKKβ), 
resulting in decreased phosphorylation of IRS-1 on S307. Serine phosphorylated IRS-1 
acts to inhibit phosphorylation of the insulin receptor. We show for the first time that 
blockade of IKKβ by NaSal abrogates the effect of indinavir on the tyrosine 
phosphorylation of the insulin receptor by decreasing phosphoIRS-1 S307. We conclude, 
therefore, that protease inhibitors act via the NFκB pathway to induce insulin resistance in 
vivo. Salicylates may provide a novel therapy for HIV protease inhibitor-induced 
lipodystrophy. 
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